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ABSTRACT OF DISSERTATION 
USING THE QBEST EQUATION TO EVALUATE ELLAGIC ACID SAFETY DATA: 
GENERATING A QNOAEL WITH CONFIDENCE LEVELS FROM DISPARATE 
LITERATURE  
QBEST, a novel statistical method, can be applied to the problem of estimating the No               
Observed Adverse Effect Level (NOAEL or QNOAEL) of a New Molecular Entity (NME)             
in order to anticipate a safe starting dose for beginning clinical trials. The NOAEL from               
QBEST (called the QNOAEL) can be calculated using multiple disparate studies in the             
literature and/or from the lab. The QNOAEL is similar in some ways to the Benchmark               
Dose Method (BMD) used widely in toxicological research, but is superior to the BMD in               
some ways. The QNOAEL simulation generates an intuitive curve that is comparable to             
the dose-response curve. The NOAEL of ellagic acid (EA) is calculated for clinical trials              
as a component therapeutic agent (in BSN476) for treating Chikungunya infections.           
Results are used in a simulation based on nonparametric cluster analysis methods to             
calculate confidence levels on the difference between the Effect and the No Effect             
studies. In order to evaluate the statistical power of the algorithm, simulated data             
clusters with known parameters are fed into the algorithm in a separate study, testing the               
algorithm’s accuracy and precision “Around the Compass Rose” at known coordinates           
along the circumference of a multidimensional data cluster. The specific aims of the             
proposed study are to evaluate the accuracy and precision of the QBEST Simulation and              
QNOAEL compared to the Benchmark Dose Method, and to calculate the QNOAEL of             
EA for BSN476 Drug Development. 
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CHAPTER 1: INTRODUCTION 
 
What is the Quantile Bootstrap Error Statistical Test? 
The Quantile Bootstrap Error-adjusted Statistical Test (QBEST) is a novel statistical 
method for the nonparametric analysis of multivariate data.  It is similar in many ways to 
the Mahalanobis test, but represents an important mathematical improvement over the 
Mahalanobis methodology, as the QBEST is not forced to use a symmetric standard 
deviation (SD) to analyze a data cluster even when the data cluster is skewed.  Instead, 
QBEST measures a distance in asymmetric nonparametric central 68% confidence 
intervals (equivalent to SDs for a normal distribution) from the center point of a cluster 
out to the test sample point 1, 3-9 .  In other words, the QBEST metric represents an 
asymmetric nonparametric central 68% confidence interval for the mean.  This property 
allows QBEST to competently handle abnormally-shaped clusters of data for which the 
standard deviation along opposite vectors of an axis from the center ought to vary 3,5-9 . 
Furthermore, QBEST relies on simple mathematical calculations of Euclidean distance; 
its calculation is fairly simple, and requires far less memory than the Mahalanobis test for 
large matrix problems 3,5-9 .  QBEST makes calculations that are currently technologically 
impossible to complete on supercomputers using the Mahalanobis equation possible to 
be run at home on a standard PC laptop.  QBEST is the multivariate analysis equation of 
the future and will allow for the processing of ever-increasing stores of complex Big 
Data. 
 
What is Multivariate Variation, in Layman’s Terms? 
Data are considered to be multivariate when two or more independent variables describe 
a single data point.  For example, a person can be described by his height and weight, 
which can affect blood pressure.  So a set of data containing people, characterized by 
height and weight to predict blood pressure, is multivariate.  Any data that can be plotted 
in a 3-dimensional space (2 independent variables and 1 dependent variable) is 
multivariate by definition.  
 
Furthermore, complex samples that seem on the surface to be a single continuous 
measurement can also be treated as multivariate data sets.  Consider, for example, an 
infrared spectrum that represents the absorbance of light across a range of wavelengths:  
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 Figure 1: Sample Spectrum 
(Note: In chemistry, “wavelength” is denoted by the Greek letter ƛ.) 
 
While these data may not seem to be multivariate at first glance, in reality, the 
absorbance at each individual wavelength of light used in the test may be considered a 
variable.  This entire spectrum could be graphed as a single point in a large multivariate 
space.  One would start by assigning each wavelength to an axis.  For simplicity, let us 
first assume that we are only interested in ƛ 1  and ƛ 2  (labelled on the graph).  We can 
assign absorbance at ƛ 1  to the x-axis and absorbance at ƛ 2  to the y-axis.  Then, we can 
use the values derived from the original spectrum to graph a point reflecting these data.  
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Figure 2: Graphing a Sample Spectrum  
On the left, see the original infrared 
spectrum.  Two wavelengths of interest 
are labeled ƛ 1  and ƛ 2 . 
On the right, see the entire spectrum 
graphed as a single point in 
two-dimensional space.  The x-coordinate 
is the absorbance at ƛ 1  and the 
y-coordinate is the absorbance at ƛ 2 . 
 
We can use this method to graph any complex data, utilizing any number of axes. 
Pictured below are a standard x-y chart (a 2-dimensional graph) and a 3-dimensional 
graph.  A graph can have any finite number of axes, though they become difficult to draw 
on paper and even more difficult to imagine.  Though this is certainly difficult for a 
human, machines are incredibly capable at handling this kind of data.  For this reason, it 
is important to be able to simplify complex data into a series of coordinate points that a 
computer can manipulate, and from the resulting clusters, determine statistical trends. 
 
2-Dimensional Graph 3-Dimensional Graph 4-Dimensional Graph 
 
 
In this image, the x- and y- 
axes hold the two 
variables. 
Adding a third dimension 
means adding a third axis. 
A fourth dimension has to 
be graphically represented 
as an array of graphs. 
Figure 3: Graphing Increasingly Multivariate Data 
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Finally, we can use a single graph to keep track of large numbers of different multivariate 
samples.  Imagine that we had run an infrared spectral analysis on the same chemical a 
number of  times, and each time we found slightly different results.  We could graph all of 
the individual spectra on the same axis, as follows.  When we look at the data, it 
becomes apparent that similar samples cluster together when represented as data 
points. These groups of points are referred to as clusters of data.  These clusters have 
unique properties; the points may be very closely clustered along one axis, and more 
spread out along another.  The significance of this will be discussed shortly. 
 
 
  
Figure 4: Clusters Spatially Separated Figure 5:   An Irregular Cluster 
 
Pharmaceutical Applications of Multivariate Data Analysis 
Pharmaceutical applications of multivariate data analysis include the determination of the 
toxicity of novel pharmaceuticals.  Toxicity determinations can be performed by 
experimentally determining the subject’s current blood levels of a pharmaceutical and 
the dosage that subject was administered, and noting whether the pharmaceutical then 
produced an adverse effect in the subject.  QBEST and discriminant cluster analysis can 
be applied to determine the safe dosage of the novel pharmaceutical agent.  QBEST can 
be applied to the problem of calculating No-Observed Adverse Effect Levels (NOAELs) 
from published animal studies and clinical trials in a similar manner.  The dosage and 
some numerical outcome variable (a minimum of one outcome variable) can be 
analyzed.  Chapter 4 of this work addresses the generation of QNOAELs from the 
literature. 
 
Additionally, QBEST can be used in the future to manage the increasingly vast amounts 
of health data generated in clinical trials and post marketing studies.  The Mahalanobis 
equation is incapable of calculating a Mahalanobis distance in multidimensional SDs for 
all the data generated by many clinical trials.  This is because the Mahalanobis requires 
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more data observations (e.g., subjects) than dimensions or independent variables (e.g., 
blood chemistry values, pathology measurements, etc.) in order to be calculated. 
Additionally, clinical studies observe a great number of other characteristics ranging from 
blood pressure and heart rate to weight and food intake.  A single clinical study may 
record 50 or 100 data values for each patient.  Unfortunately, because clinical trials are 
expensive, a phase 1 or phase 2 trial can easily have more data variables than subjects. 
Furthermore, in meta-analyses, it is unlikely that more than 50 or 100 clinical trials would 
be reported in the literature for a given pharmaceutical, again in large part because of 
cost.  This means that all 50 or 100 variables measured could not be used as data in a 
Mahalanobis distance calculated by the Mahalanobis equation.  QBEST, however, can 
be used even when the number of variables measured far exceeds the number of 
samples (subjects or clinical trials) measured.  Data supporting this (situations where 
number of dimensions is far higher than number of training points) can be found in 
Chapter 5. For this reason, QBEST offers the best solution to solving clinical trial data 
problems and using all of the data generated in one single statistical test. 
 
Even personal health monitoring systems could be improved by the implementation of 
QBEST.  Numerous personal fitness systems currently monitor consumers’ vitals almost 
continuously.  Smartwatches, FitBits™, phones, and similar devices store information 
about heart rate, activity level, and even sleep quality.  These devices generally establish 
a baseline for the person’s vitals and note if an abnormal event happens.  QBEST could 
easily be implemented in these device algorithms to detect the significance of deviation 
from normal, and to identify the nature of the aberration.  For example, a test heart rate 
and pulse pattern could be compared to the patient’s baseline training set as well as to a 
stored library of heart attack patterns and arrhythmias.  Using QBEST, even a simple 
smartwatch could serve as an early detection system for heart conditions.   Of course, if 
QBEST could be implemented in consumer devices, it could be put to even better use in 
medical devices such as continuous glucose monitoring insulin pumps. 
Why a Statistical Method is Needed Beyond Simple Standard Deviation: 
Most individuals involved in the sciences are familiar with the standard deviation.  A 
standard deviation is a measure of variation around a central value.  Distance in 
standard deviations often serves as a sort of limit by which we measure the 
reproducibility of data. (A limit of 3 SDs or 6 SDs is commonly used to denote class 
membership, for example.)  I could state that I am 5’5” tall.  Does that make me typical 
for a human being?  Or am I gigantic, or perhaps diminutive?  Answering that question is 
simple enough; One could estimate the average height of a human being with a good 
sampling of human beings, and then calculate the standard deviation of height.  68% of 
the height data should fall within one standard deviation of average if the heights follow 
the normal (Gaussian) distribution.  By comparing my height to the average human 
height plus or minus one standard deviation, it becomes apparent that I fall within the +/- 
34% of most people.  So 5’5” tall is not an abnormal height. 
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But standard deviation is a mathematical parameter that is defined only in regard to a 
single variable.  While it is possible to answer simple questions with standard deviation, 
such as “Is my height typical?”, more complicated questions cannot be answered using 
standard deviation alone.  For instance, take the question, “Is my height and weight 
typical for a human?”  It becomes readily apparent that adding a second variable 
(weight), thus making the problem multivariate, complicates the question considerably. 
To know whether my height and weight are typical, I need to know four things: 
1) What is the average height and weight of all humans? 
2) How much does height vary from person to person? (What is the standard 
deviation of height?) 
3) How much does weight vary from person to person? (What is the standard 
deviation of weight?)  
-and- 
4) How do height and weight vary with regard to each other? 
A covariance matrix is required to answer that last question.  The covariance matrix is 
part of the Mahalanobis distance Equation. Specifically, the Mahalanobis equation 
represents the first statistical method capable of determining the difference between a 
test data point and a known cluster of multivariate data. 
 
What is the Mahalanobis distance Equation? 
The Mahalanobis metric has been described as “a rubber ruler.” 2,3   The rubber ruler 
analogy can be explained as follows, by graphing a data sample of coordinate points. 2,3 
 
1. The Mahalanobis equation starts with the center of a data sample.  Along any 
line drawn in coordinate space that passes through the center of the data 
distribution, the Mahalanobis equation can be used to determine the scalar size 
of a standard deviation unit.  In this way, the scalar standard deviation units are 
the markings along the ruler. The ruler stretches to different lengths in different 
directions to maintain 1 SD as a central 68% confidence interval for normally 
distributed data.  In the figure below, the distribution is wider than it is high, so the 
ruler must stretch in the horizontal direction compared to the vertical direction. 
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 Figure 6.1: A Sample Distribution with Known Center 
 
2. Rubber rulers can be thought of as being laid from end to end across the 
distribution to make the initial measurement to a new sample point (a point not in 
the original training set).  Imagine laying a blank ruler one SD long across the 
data in a line through the center. Then, like a tailor flipping a ruler end-over-end 
to measure a bolt of cloth, we can extend that measurement infinitely out into 
hyperspace in the direction of each new sample point.  
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 Figure 6.2:  Centering the Rubber Ruler; Flipping the Ruler Out into 
Hyperspace 
 
3. The markings on a “rubber ruler” indicate the number of standard deviation units 
a new sample point is from center.  This is the “ruler” part of the rubber ruler 
analogy (with more than 1 SD marked on it). 
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 Figure 6.3: Determining Standard Deviation Unit Size Along the First Axis 
 
4. The “rubber” part of the analogy is illustrated when you measure in a new 
direction.  The same Mahalanobis equation can be used then to determine the 
standard deviation across any other line passing through the center of the 
distribution. Imagine picking up the ruler that you just made and rotating it 90 
degrees to find the standard deviation units across the orthogonal direction of the 
data cluster.  You center the ruler on the center of the cluster, but what do you 
find?  The ruler is too short to cover the span of the data in this direction!  So, you 
pinch both ends of the ruler and stretch it out until it extends to both ends of the 
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distribution.  Now you know the standard deviation units of points along this axis 
as well. 
 
 
Figure 6.4:  Stretching the Rubber Ruler to Fit the Second Axis 
 
5. In statistical terms, what this “rubber ruler” means is that SD is not equivalent 
along all directions; and to determine the confidence with which a single 
datapoint fits a distribution, your statistical test must be able to take into account 
the differing variation along any direction in a cluster, a major axis, a minor one, 
or a line falling anywhere in between. 
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 Figure 6.5: Determining Standard Deviation Unit Size Along the Second 
Axis 
 
6. By laying the “rubber ruler” over our cluster, we can see that one unit of spatial 
distance can be very big along one axis, while it is not so in another.  The 
Mahalanobis equation allows us to quantify this change. 
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 Figure 6.6: The Standard Deviation Unit Size is Reflective of the Spread of 
the Data Along Each Axis 
 
 
Why is the Mahalanobis distance Insufficient? 
The Mahalanobis equation is Inaccurate When Handling Asymmetrical and Irregular 
Data Clusters  
Because the Mahalanobis equation is a rubber ruler whose length is determined by the 
span of a data cluster on a line passing through the center, the Mahalanobis equation is 
inherently prone to error when asymmetrical or irregular clusters of data are involved. 
Consider the following theoretical data clusters: 
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Figure 7: Three Asymmetrically-Distributed Data Clusters with Mahalanobis Rubber 
Ruler Drawn 
 
Do the proposed rubber rulers really fit?  Visually, it is apparent that it is ridiculous to 
measure the left and right-hand sides of these distributions with the same units of 
standard deviation.  All of the pictured distributions have unequal dispersion along the 
left-hand or right-hand directional vector.  This is where the QBEST is better, as will be 
explained later, because QBEST independently determines the right-hand and left-hand 
standard deviation units, that is the standard deviations along a line in opposite 
directions. 
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The Mahalanobis equation is Mathematically Incapable of Calculating Distances For 
Datasets with More Variables Than Observations  
The Mahalanobis equation involves several matrix math operations that cannot be 
performed when there are fewer rows than columns of the matrices.  In terms of 
pharmaceutical science, the Mahalanobis equation cannot be computed when the 
number of observations is less than the number of variables that describe those 
observations.  Moreover, even when the number of samples exceeds the number of data 
observations, as the number of variables approaches the number of samples observed 
(the number of rows approaches the number of columns), the Mahalanobis equation 
loses accuracy and precision.   However, QBEST is able to calculate a distance in SDs 
under those conditions with accuracy and precision. 
What This Means in a Pharmaceutical Context 
This capability of QBEST is particularly important in applications of multivariate data 
processing such as the meta-analysis of clinical trials.  In such instances, a very few 
clinical studies may have been performed (clinical studies are expensive), but each 
study collected perhaps 100 endpoints.   Even animal studies are very expensive to 
perform, both in terms of money and time resources, but human studies are even more 
so.  As a result, studies tend to be fairly limited in quantity, and the researchers who 
have performed them use their subjects to the maximum extent possible. Animal studies 
and human subjects trials tend to have a lot of clinical endpoints (variables) monitored 
and reported at the end of the study. 
 
Clinical monitoring is a multivariate by nature. All of the many biological factors noted 
about an organism are variables that could give some insight into the organisms 
well-being or condition. Until now, it has not been possible, mathematically speaking, to 
process all of the data provided by handful of clinical studies using a single 
comprehensive statistical test.  The QBEST is the first statistical method following the 
form of the Mahalanobis equation that is able to comprehensively test all data as a single 
multivariate data points comparable to other multivariate data point clusters, and is also 
able mathematically to process a matrix with a greater number of columns than rows.  
In more practical terms, what this means is that QBEST is capable of analyzing, for 
instance, six clinical trials that each assayed the same 60 clinical end points. That feat is 
mathematically impossible using the Mahalanobis equation.  
The Mahalanobis Requires Too Much Computing Power 
The Mahalanobis equation is an order of d 3  equation, which means that for every d 
increase in the number of dimensions or variables describing the data, the equation 
takes d 3  more computing power to process.  QBEST is an order of d equation, which 
means that for every d increase in the number of dimensions or variables describing the 
data, the equation takes d more  computing power to process (a d 2  advantage in running 
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time) .  This allows QBEST to quickly calculate the solution to Big Data problems with 
run times that would be prohibitively long for Mahalanobis equation calculation. 
What is the Quantile Bootstrap Error Statistical Test in Detail? 
The Quantile Bootstrap Error Statistical Test (QBEST) is a novel statistical method for 
the determination of the degree of difference between a test point and a training set of 
data points.  
 
QBEST functions first by taking bootstrap replicates from a sample of data (called the 
training set). Then QBEST determines the center of the training set. QBEST relies on the 
Euclidean metric to determine the spatial distance between the two points along a 
straight line. (These straight lines are the hyperline between the center of the training set 
and each new sample test point, and the hyperline connecting the center of the training 
set to each bootstrap replicate point.  The word “hyperline” is used because this line 
ordinarily exists in a hyperspace of many dimensions.)  While it would be ideal to be able 
to consider just bootstrap replicate points that fall on this hyperline in making 
measurements of standard deviation in that direction, a line is infinitely thin, so the 
likelihood that any other given bootstrap replicate point will fall directly upon the 
hyperline is incredibly low.  
 
If the hyperline used to measure the distance between the training set center and a test 
point is infinitely thin and no bootstrap replicates in the distribution fall on it, how do we 
measure the distribution of bootstrap replicate points along that hyperline in the direction 
of the new sample point?  Instead of using an infinitely thin line, we instead use a 
hypercylinder in hyperspace. The radius of the hyper cylinder is increased until at least 
50 bootstrap replicate points are captured within it.  Replicate points in the direction of 
the test point will be engulfed by the growing hypercylinder. The QBEST equation 
requires that the user specify a “radfrac” or fraction of the training point spectra that 
should be included in this hypercylinder. Basically, the radfrac determines how big the 
radius of the hypercylinder should be - fat or thin depending on what proportion of the 
points should be included. The computer sets the radius based off of the radfrac input by 
the user.  
 
 
Why is QBEST Superior to the Mahalanobis equation? 
The Mahalanobis equation is limited in two very simple but very critical ways.  First, the 
Mahalanobis equation is incapable of calculating a Mahalanobis distance when the 
number of variables comprising the data exceed the number of samples. 3   That is to say, 
the Mahalanobis equation requires that the number of observations must far exceed the 
number of variables of the multivariate data In order to produce results with accuracy 
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and precision.  Secondly, the Mahalanobis equation is very costly calculation to run in 
terms of computation. 3   This means that for a given calculation, the Mahalanobis 
equation needs significantly more time and computational power than the QBEST does 
(more on that later). 3 
 
Observations vs. Variables 
What This Means for Pharmaceutical Studies 
Clinical trials and animal studies are incredibly expensive.  This naturally limits the 
number of such studies that are conducted and published in the literature. Imagine that a 
dozen or so clinical trials are performed for a given therapeutic agent with roughly the 
same endpoints being measured.  In these studies, blood concentrations of the drug are 
measured at many time points.  Continuous blood pressure and heart rate monitoring 
are performed.  Additionally, metabolic panels, lipid panels, and a number of 
drug-specific tests are done and the outcomes reported.  Remember that continuous 
data can be broken down into a series of variables, so that where time is important, each 
time point at which blood pressure (for example) was measured becomes an additional 
variable. It is reasonable to expect that perhaps one hundred variables are measured in 
the course of a single clinical trial.  
 
In this example, it is mathematically impossible to calculate a Mahalanobis distance 
using the Mahalanobis equation.  There are simply too few clinical trials in relation to the 
number of variables measured for each trial.  QBEST, however, can handle the given 
problem with statistical accuracy and precision. 
Computational Cost 
The Mahalanobis equation is order of d 3  in computational complexity, which is to say that 
for every d increase in variables (or dimensions), the computation cost increases by d 3 . 3 
In practical application, this causes the computer running the Mahalanobis equation to 
very quickly become “bogged down” as more variables are collected.  
 
QBEST is an order of d equation, which means that for every d increase in the number 
of dimensions of the data, QBEST requires only d more memory and computational 
power to complete the calculation.  The same problem that would cause a 
supercomputer running the Mahalanobis equation to freeze or take hundreds of years to 
run can easily be completed using the QBEST method on a cheap personal laptop 
computer. 3   QBEST makes advanced computation possible for individuals, researchers, 
and small corporations using the most meager of resources; QBEST allows researchers 
using advanced supercomputers to attempt multivariate data problems not yet dreamed 
of. 
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What is the QBEST? 
“A Rubber Ruler with a Nail in the Center” 
If the Mahalanobis equation is a rubber ruler, then the QBEST equation is a rubber ruler 
with a nail in the center.  The QBEST ruler can be stretched longer or shorter 
independently on opposite sides of a data cluster.  In this way, it is capable of 
independently calculating different-sized standard deviation units for opposite halves of 
an asymmetric data cluster 1,3-9 . 
 
 
Figure 8: QBEST is a “Rubber Ruler with a Nail” 
Shown in green is the left-hand QBEST rubber ruler with a small standard deviation. 
Shown in blue is the right-hand QBEST rubber ruler  with a larger standard deviation. 
The standard deviation units for each side are calculated independently by QBEST, 
which is reflective of the skew of the data. 
 
 
How Does QBEST Work? 
QBEST is a multivariate nonparametric statistical method.  First, the original training set 
is replicated using a Monte Carlo integration of the bootstrap distribution function.  The 
replicates allow for the approximation of traditional parametric statistics like bias, 
variance, confidence intervals and prediction error. 5-9  
 
The QBEST calculates the number of standard deviation units between a test point and 
the center of the training set.  It does this by calculating the Euclidean distance between 
the two points and scaling that distance with the Euclidean distance of one SD of the 
training set points.  A hypercylinder is used for the selection of comparable training 
spectrum points. 5-9  
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The equation for determining two-dimensional Euclidean distance is defined as the 
following:  
dist((x,y),(a,b))=  √(x ) y ) − a 2 + ( − b 2
 
The equation for determining multidimensional Euclidean distance is defined as follows: 
 (x  ) D 2ij = ∑
d
v=1
vi − x vj
2  
What is Discriminant Cluster Analysis? 
Simply put, discriminant cluster analysis is the process of determining whether a given 
point belongs to one cluster of data points or another.  
How Can Discriminant Cluster Analysis be Applied to Drug Development? 
Detecting Contamination 
Suppose there are two clusters of data, one describing safe dosages of a 
pharmaceutical and one describing adulterated drug. Given a new unknown test article, 
analysis via QBEST would determine the likelihood that the test point belonged to one 
category (safe) or the other (adulterated).  This method has been used to differentiate 
between the near infrared spectra of pharmaceutical capsules contaminated with 
cyanide and normal capsules. 4,5 
 
No Observed Adverse Effect Limits 
Alternatively, suppose that the two clusters of data represent drug studies done on a 
novel pharmaceutical agent.  Each point represents one dosage given in a study along 
with any number of multivariate factors on different spatial dimensions, including 
pharmacokinetic information like Cmax, or a measure of physiological changes induced 
by the medication, such as a measure of the increase in heart rate after dosage.  One 
cluster represents dosages that produced no adverse effects in the patient; the other 
represents dosages that caused some adverse effect.  From the existing literature 
available on this novel therapeutic, we want to determine the maximum “safe” dose of 
the agent to aid us in powering our clinical studies.  To do this, we would like to 
determine the No Observed Adverse Effect Limit (NOAEL).  This metric represents the 
highest dose of an agent that can be administered to a patient that will cause no adverse 
effects.  (Any higher dose is likely to cause some negative effect.) 
 
Traditionally, NOAELs and No Observed Effect Levels (NOELs) have been 
experimentally determined in a single experiment by administering increasingly high 
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doses of an agent to patients and determining which of the doses was the highest given 
that produced no adverse effect.  The scientific problems with this methodology are fairly 
obvious: it is impossible to determine a NOAEL or NOEL value for any dose other than 
an exact dosage that was administered, leaving much room for error because the levels 
are usually spaced an order of magnitude or more apart.  NOAEL studies cannot be 
easily meta-analyzed or pooled, as methodology of the study protocol can greatly 
influence the outcome of the study.  It is costly to repeat NOAEL studies to increase 
precision and requires the use of new human or animal subjects. 
 
Discriminant cluster analysis using QBEST can be used for meta-analysis in place of a 
traditional NOAEL study or the Benchmark Dose Method .  QBEST provides greater 
accuracy and reproducibility than a traditional NOAEL and yields more intuitively 
comprehensible results than a BMD (Benchmark Dose) analysis.  Furthermore, 
performing a discriminant cluster meta-analysis re-utilizes data that has already been 
generated and published in the literature and prevents the waste of resources and 
research animals in redundant studies.  Finally, QBEST can provide an estimate of an 
effect level that can be used to power additional preclinical and clinical trials. QNOAEL 
and QNOEL determination are described in detail in Chapter 2 and Chapter 4. 
 
What is new about QBEST? 
Nonparametric Method 
QBEST represents a novel means to analyze data in several ways.  First, QBEST is a 
nonparametric statistical method, which means that it is capable of treating data that 
does not follow a known statistical distribution (such as a normal distribution). 
Parametric methods require an assumption that the data follows a certain distribution.  If 
these assumptions are not met, the results of the analysis are inaccurate and it is 
inappropriate to apply the method in question.  QBEST is unique in that it makes no 
assumptions about the distribution of the data.  As such, QBEST can also be applied to 
parametric data. 
Unique Handling of Skewed Data 
QBEST is novel in that it treats opposite sides of a data cluster separately when 
determining standard deviation units from center.  QBEST does not assume that the left- 
and right-hand sides of a cluster are equally distributed.  This allows QBEST to 
accurately determine the significance of the distance of a test point from the center of a 
cluster even when the cluster is abnormally-shaped.  The most widely used method, the 
Mahalanobis method, does not account for skewed clusters.  The QBEST distance is 
considerably more accurate than the Mahalanobis distance for irregular and skewed 
data clusters. 
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Discriminant Cluster Analysis Applied Non-Traditionally 
Discriminant cluster analysis, the method of determining whether a test point belongs to 
one or the other possibly overlapping classified clusters of data points, has never been 
applied to the determination of toxicology studies 11 .  This method is primarily used in 
analytical chemistry for the classification of substances and the determination of 
impurities.  The method has been used in other applications, but is not used as widely as 
perhaps it should be.  Some current applications include analysis in the tourism industry 
and data analysis in banking 10, 11 .  Discriminant cluster analysis is an incredibly powerful 
statistical technique with many possible applications from business to science to artificial 
intelligence and machine learning.  The application of discriminant cluster analysis to 
toxicology data is a novel aspect of this work that lays the ground for future medical 
applications of discriminant cluster analysis.  
How do you use QBEST? 
The Variables 
The Training Set 
The training set is the set of data points of known outcomes used to test a new 
(unknown) “test point”. Training sets are common in calibrating neural networks, for 
example.  In a pharmaceutical context, the training sets could be groups of points 
representing preclinical or clinical studies of medication that caused no adverse effects 
and groups of points representing studies of medication that caused adverse effects.  A 
test point could be an individual study.  
 
The training points input into the QBEST are critical to obtaining valid results. The old 
maxim, "garbage in, garbage out" holds for all training sets, not just QBEST, but the 
Mahalanobis equation and neural networks as well. As with all data analysis, first and 
foremost it is important that quality data representative of the population are used. 
Precautions such as Cochrane Review of data can ensure that appropriate data are 
chosen in the first place.  
 
After quality data have been selected, it is the task of the researcher to inspect the data. 
The size of the training set and the distribution of training points determine the value of 
other parameters that should be set when using the QBEST equation. Guidelines for 
setting these parameters can be found in Chapter 4. 
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 Radfrac 
The radfrac is the fraction of bootstrap replicate points used to generate the 
hypercylinder.  Points within the hypercylinder form the basis of statistical comparison to 
the test point. 
When is it appropriate to use a large/small radfrac? 
Radfrac is important because it determines how bootstrap replicate points are 
determined to be relevant to the test point. When the number of bootstrap replicate 
points is very large, one can decrease the radfrac because the large number of points 
provides more in the hypercylinder, and narrowing the radius of the hypercylinder 
increases accuracy in this case for clusters that contain a concavity. Furthermore, when 
the cluster is highly irregular, it is important to decrease the radfrac in order to avoid 
including points that do not fit a concave surface for that part of the cluster.  
 
Number of Bootstrap Replicates 
The number of bootstrap replicate points made for a new training set is important 
because having more points increases precision, albeit at a small cost of increased 
memory and computation time. 
 
 
Number of Variables or Dimensions 
The number of variables or dimensions of the multivariate data affects the accuracy of 
the algorithm.  The algorithm is more accurate when largely multivariate data also has a 
large training set size. 
 
 
When Is QBEST Insufficient? 
QBEST is meant for the analysis of multivariate data.  It can be used effectively for 
numerical response variables.  QBEST can also theoretically be used to compare ordinal 
or binary response variables (given that the variable is assigned a numerical score) 
alone or in combination with numerical response variables.  However, at present, no 
testing has been done on ordinal or binary response data. 
 
As with any meta-analysis method, the accuracy of QBEST is most negatively impacted 
when the quality of the training set of data is poor.  Increasing the quality of the training 
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set and the quantity of the training set observations increases the accuracy and 
reproducibility of QBEST.  When a very few training set observations are supplied, the 
reproducibility of QBEST’s output is decreased.  These trends are discussed in detail in 
Chapter 5.  
 
As with any other statistical method, the researcher should always visually inspect all 
combinations of two variables of the data graphed against one another to ensure that 
there are no problems (like nonlinearities) that would complicate discriminant cluster 
analysis.  QBEST takes into account the typical variation in points.  So, for example, for 
ultrasonic resonance spectral data that follow a Lissajous function, QBEST may 
generate a less accurate probability measurement.  
 
Many irregular clusters can be evaluated with accuracy if the radfrac is set to be 
appropriately high or low after the data are inspected.  The danger of setting radfrac 
without visually inspecting the data on all axes is that too high of a radfrac could include 
points that are not indicative of the trend along a given vector, while too low of a radfrac 
would exclude points that ought to be included.  This principle is especially important for 
data clusters that include concavities, which could otherwise be handled poorly by the 
algorithm.  (See the Conclusion for an explanation of data with concavities.)  The 
selection of an appropriate radfrac for the shape of an irregular cluster of data very 
strongly affects the accuracy of the algorithm and great care should be taken in 
assigning this value. 
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CHAPTER 2: A NOVEL STATISTICAL APPROACH TO NOAEL: QBEST 
APPLIED TO DOSING OF ELLAGIC ACID AND THE QNOAEL VS. BMD FOR 
POINT OF DEPARTURE 
 
Purpose: This article describes the research strategy and goals for this thesis.  This 
chapter was  published as “The QNOAEL vs. BMD for Point of Departure” on BioRxiv.  It 
is the preprint of a later paper, published as “A Novel Statistical Approach to NOAEL: 
QBEST Applied to Dosing of Ellagic Acid,” on Webmedcentral.com. 
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The QNOAEL vs. BMD for Point of Departure 
Abstract 
Quantile bootstrap (QB) methods can be applied to the problem of estimating the No 
Observed Adverse Effect Level (NOAEL) of a New Molecular Entity (NME) to anticipate 
a safe starting dose for beginning clinical trials. An estimate of the NOAEL from the 
extended QB method (called the QNOAEL) can be calculated using multiple disparate 
studies in the literature and/or from laboratory experiments. The QNOAEL is similar in 
some ways to the Benchmark Dose (BMD) and is superior to the BMD in others. The 
Benchmark Dose method is currently widely used in toxicological research. 
Results are used in a simulation based on nonparametric cluster analysis methods to 
calculate confidence levels on the difference between the Effect and the No Effect 
studies. The QNOAEL simulation generates an intuitive curve that is comparable to the 
dose-response curve. 
 
The QNOAEL of ellagic acid (EA) will be calculated for clinical trials of its use as a 
component therapeutic agent (in BSN476) for treating Chikungunya infections. This will 
be the first application of QB to the problem of NOAEL estimation for a drug. The specific 
aims of the proposed study are to evaluate the accuracy and precision of the QB 
Simulation and QNOAEL compared to the Benchmark Dose Method, and to calculate 
the QNOAEL of EA for BSN476 Drug Development. 
 
Specific Aims 
Nonparametric statistics are statistics that are not based on parameterized families of 
probability distributions, like the normal distribution. They are important because data 
frequently follow a distribution other than a known one, like the normal distribution. 
The NOAEL is an important part of the non-clinical risk assessment for new drugs like 
BSN476, a drug for treating Chikungunya. The NOAEL is a professional opinion based 
on the design of the study, indication of the drug, expected pharmacology, and spectrum 
of off-target effects. It is the highest dose at which there was not an observed toxic or 
adverse effect 11 . There are important theoretical limitations to the traditional NOAEL 
calculation, which led to the newer Benchmark Dose method, which also has a number 
of problems. In brief, the traditional NOAEL is determined by administering a few 
different doses of drug to a group of subjects, observing those subjects for physiological 
change, and assigning the dosages to the categories of “having an adverse effect” and 
“not having an adverse effect”. The highest dosage resulting in no adverse effect is 
determined to be the NOAEL. 
 
The NOAEL method is problematic because (1) dose levels are often an order of 
magnitude apart, and it is highly unlikely that the exact NOAEL dosage will be 
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administered in any particular study; (2) determination of what constitutes an “effect” can 
be difficult when negative effects are of a highly subjective nature (for example, when 
mood is affected) 4 . A nonparametric simulation using extended QB (Quantile Bootstrap) 
methods can solve the problems associated with the use of the traditional NOAEL or the 
Benchmark Dose (BMD) and enable accurate toxicological estimates to be made. 
Evaluate the accuracy and precision of the QB Simulation and QNOAEL compared to 
the Benchmark Dose Method 
Utilizing synthetic data with known characteristics, the BMD and QNOAEL will be 
calculated. The QNOAEL will then be compared to the BMD to determine which is 
closest to be known answer for the synthetic data. 
Calculate the QNOAEL of Ellagic Acid for BSN476 Drug Development 
Chikungunya is a rapidly spreading mosquito-borne disease that now infects over 3 
million people worldwide 12 . BSN476, a drug for treating chikungunya infections, contains 
in part EA. QB will estimate a safe level of EA for the first-in-human study in order to 
develop a treatment for Chikungunya. An EA toxicity meta-analysis using food 
consumption will be completed as part of the Investigational New Drug (IND) application 
to the FDA. Studies will be selected from the literature and analyzed according to the 
Cochrane protocols, and the QNOAEL of EA will be calculated along with the NOAEL 
and BMD. These results will serve as the basis for the first-in-human study of EA. 
Strategy 
Significance 
Method Significance 
The NOAEL depends strongly on the dose selection, dose spacing, and sample size of a 
single study from which the critical effect has been identified. The primary goal of BMD 
modeling is to define a point of departure that is largely independent of study design. But 
while the BMD effectively enables multiple studies to be pooled to increase accuracy, it 
does not handle studies with conflicting results gracefully, as will be seen below 3 . 
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Table 1: Advantages and Disadvantages of the NOAEL, BMD, and QNOAEL 
NOAEL Benchmark Dose QNOAEL 
Advantages ● Very simple, early
method of deriving
a POD that has
been utilized for
years
● Defined as the
highest dose which
generates no effect
in the studied
population
● Can be used
when data will not
work with BMD
mode
● Calculation is not
limited to specific
experimental
doses, but can
calculate a BMD
within the tested
range
● Multiple studies
may be pooled to
increase accuracy
● Allows for
weighting of results
based on study
quality
● Accounts for
dose-response
curve and
pharmacokinetic
modeling
● Benchmark Dose
is defined as the
dose which
generates a
specific benchmark
effect
The advantages of 
BMD, plus: 
● Calculates
statistical measures
of certainty to
gracefully handle
conflicting input
study results
● Generates an
intuitive correlation
vs. dose curve that
shows the
statistical likelihood
of effect at a given
dose
● Able to account
for publication bias
in the literature
● Bootstrapping
algorithm is robust
and nonparametric
(and thus able to
solve problems in
which the
underlying
distribution is
unknown )
● Can extrapolate
to lower doses than
dosing range
studied/reported in
the literature.
● Computed
quickly(an order of
n1 algorithm)
Limitations ● Limited to doses
studied/reported in
the literature
● Lowest Observed
Average Effect
Level (LOAEL)
● More complicated
and
time-consuming
process than
simple NOAEL
● Limited strongly
● More complicated
and
time-consuming
process than
simple NOAEL
● Limited
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Table 1 Continued 
cannot be used to 
generate NOAEL  
● Not designed for
pooling of multiple
studies
● Does not take
into account the
statistical likelihood
of effect across a
large population
● Does not
represent the
population as a
whole; is limited to
the population
studied
by the quality of 
information and the 
inclusion criteria 
chosen by the 
researcher  
● Unable to
account well for
conflicting study
results
● Generates a
non-intuitive mean
response x dose
line which is
ambiguous for
doses which
sometimes cause
an effect, or which
cause an effect in a
certain percentage
of the population
● Results do not
well indicate the
response of a large
population to a drug
● Parametric test.
● “Effect” vs. “No
Effect” classification
can be difficult
when studies
examined different
endpoints; ex:
effect on heart rate
vs. mood alteration
somewhat by the 
quality of 
information and the 
study inclusion 
criteria chosen by 
the researcher  
The BMDL (the statistical lower confidence limit on the benchmark dose, or BMD) is 
used as the point of departure (POD) for most non-cancer and cancer risk estimates 
derived by the U.S. EPA. The initial step in the risk assessment process is hazard 
identification, which is defined as the identification of effects on health noted as the result 
of exposure to a specified chemical. Hazard identification is followed by determination of 
the critical effect on which to construct NOAELs (No Adverse Effect Levels) or BMDs 
and BMDLs. 
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Both the NOAEL and BMD approach require some common considerations of the 
general quality of a particular study. A few of these considerations include: 
a. Sample Size. Were the sample sizes used large enough to properly detect treatment
effects?
b. Exposure. Were the exposure durations adequate? Were relevant routes of exposure
employed in the study?
c. Endpoints. Did the study measure endpoints of interest?
d. Quality. Did the study employ standard quality control procedures like good laboratory
practice (GLP)?
In addition to these common data quality considerations that affect both the NOAEL and 
BMD estimates, there are added BMD-specific points to consider in the identification of 
datasets that are appropriate for BMD modeling. For example, when sample size 
decreases, which results in decreased power to detect treatment effects, the NOAEL 
procedure produces POD estimates while the BMD approach produces lower (extra 
precautionary) PODs. To maintain consistency and reproducibility, most scientists 
employ a six-step process for BMD analysis. The six steps involved in the BMD analysis 
are (1) choice of a BMR, (2) selecting a set of models, (3) assessing model fit, (4) model 
selection when BMDLs are divergent, (5) model selection when BMDLs are not 
divergent, and (6) data reporting. 
The new QB nonparametric meta-analysis of multiple studies so far appears to be 
superior to BMD modeling. Unlike BMD, the QNOAEL estimate is not limited by the 
format of the data presented. The QNOAEL is no more time-consuming to calculate than 
the BMD, and provides a simpler decision-making process. For example, the graphs 
below show the BMD and QB simulations for THC in hemp seed. Note that the same 
clinical studies were used for both analyses. QB not only more clearly demonstrates the 
trend of data, but also produces a correlation curve which is intuitively noncontradictory. 
(It is to be expected that different studies may reach contradictory results on the effects 
of a given dosage, as study methods and populations vary.) 
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Figure 9: Linear BMD Model for THC in Hemp Seed  
The BMD method attempts to fit a model to studies at different THC doses (green 
circles) that sometimes show an effect, and sometimes do not. This fitting process can 
seem to make little sense considering the data. Note that two different studies at 10 
mg THC show opposite effects. (Dosages falling on the 0 line of “Mean Response” are 
no-effect dosages in this figure.) 
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 Figure 10: THC Doses Showing Effect or No Effect Graphed in Multivariate 
Space  
On the other hand, in multivariate space the doses show no discontinuities. Red 
circles are test set study results (showed effect on heart rate HR and blood pressure 
BP). Blue squares are training set study results (no effect on HR or BP, sometimes an 
effect on Cmax). Orange circles are test set after recentering on the training set. 
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 Figure 11: Determining 98% Confidence Levels 
In the new nonparametric method, 98% confidence limits are set on the No Effect Set 
(or Training Set) by correlating integrals of bootstrap replicates of the training set with 
themselves. The simulation then projects the Effect Set (or Test Set) into the same 
space as the No Effect Set, and then translates the Effect Set toward/away from the 
center of the No Effect Set to determine when the correlations between the No Effect 
and Effect replicate integrals become significantly different. 
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 Figure 12: Determining the QNOEL of THC  
The gradual approach of the line to the 98% confidence limit reveals that the scale of 
the test set is larger than the scale of the training set. The horizontal blue line 
represents the 98% confidence limit on the training set (the no effect on HR/BP set). 
The 98% confidence limit on the training set was 9.1 mg orally (which is the NOEL for 
heart rate) with a Cmax = 2.8 ng/ml. 
 
 
Application Significance 
Chikungunya is a rapidly spreading mosquito-borne disease that now infects over 3 
million people worldwide 12 . The disease originated in Africa around 1700 A.D., and until 
recent years, reported infections were limited to the African continent and Southeast 
Asia 1 . The disease was first identified in 1952 during an outbreak so serious that 
infections were clinically indistinguishable from dengue fever 19 . Throughout the 1960s 
and 1970’s, outbreaks were reported in Southeast Asia 19 . After decades without another 
Southeast Asian outbreak, a 1999 outbreak in Indonesia led to a massive outbreak 
reported in India in 2006, the strain responsible for this resurgence bearing 99% 
similarity to the strain responsible for a 1989 outbreak in Uganda 3,19 . In December, 2013, 
the disease made its debut in the Americas, with its first local transmission occurring on 
the island of St. Martin; local transmission in French Guiana on the South American 
continent occurred later that month 15,17,18 . After only two years, local transmission had 
been documented in 19 Caribbean countries, including Puerto Rico, as well as in nearly 
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every country on the South American continent 15-18 . The WHO has currently issued a 
level-1 watch for travelers visiting South America and the Caribbean and expects 
Chikungunya to spread 15,18 . 
 
BSN476 contains in part EA. EA is a polyphenolic compound with antiproliferative and 
antiviral properties 6 . EA at 10 uM produces 99.6% inhibition of Chikungunya virus in 
vitro 6 . EA is found in a number of plant extracts, usually in the form of hydrolyzable 
ellagitannins which are complex esters of EA with glucose 5,14 . Ellagitannins are broken 
down in the intestine to eventually release EA 5,14 . To develop BSN476 as a treatment for 
Chikungunya, the PK of the drug must be studied in a first-in-human (FIH) trial, and a 
safe range of exposure must be determined for that trial. 
 
 
Figure 13: Map of Chikungunya Outbreaks  
Yellow dots mark the locations of chikungunya outbreaks, while the green areas mark 
the ranges of the mosquitoes able to propagate the outbreaks. This map was shows 
data only from June, 2015 and earlier. 12 
 
 
QB is applied within the Cochrane framework for meta-analysis (the Cochrane 
framework provides a “Garbage-In-Garbage-Out” standard for data inputs - generally 
clinical studies) to determine doses for the first in human study 2 . The QNOAEL of EA will 
be estimated from previously published food consumption studies. Bootstrap replication 
and manipulation of data clusters will reveal the QNOAEL of EA with 98% confidence. 
This project will use the QNOAEL to estimate a safe range of exposure to EA for the FIH 
study on the way to developing a treatment for Chikungunya. QB is a robust O(n) 
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algorithm that is designed for massively parallel computers, and is a very powerful 
meta-analysis tool (most algorithms use matrix factorization and are O(n 3 ) in execution 
time). The QB algorithm will be translated from MATLAB into Python to make it more 
accessible to the scientific community. Very large sample datasets will be used to test 
the memory usage and reproducibility of the results of the algorithm, as well as minimum 
parameters for its usage. These data have permitted estimation of the maximum 
analysis capability of cloud computing services and the National Science Foundation 
XSEDE supercomputer (Comet). 
Innovation 
This proposed study utilizes a Quantile Bootstrap statistical method designed for Big 
Data problems, SOB, inside a new simulation to estimate the QNOAEL for a drug with 
98% confidence from a set of small studies 7-10 . SOB is a form of cluster analysis, which 
is a common analytical technique for determining chemical identity and purity 7-10 . So far, 
the QNOAEL appears to be superior to the NOAEL and the BMD. 
Figure 14: QBEST Distance to a Test Point for Various Clusters  
Distances in BEST SDs depend not only on the direction in space, but also on the 
cluster selected to develop the metric. 
QB is applied within the Cochrane framework for meta-analysis. QB works by analyzing 
clusters of studies that found an effect, and clusters of studies that found no effect (the 
studies can use different dose levels). By analyzing the quantiles of each cluster and 
adjusting for cluster skew, QB can measure the distance between clusters in probability 
space, until it finds the dose that yields no adverse effects for the entire human 
population at a specified level of statistical significance (see Figure 21, 98% level set by 
default). 
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Approach 
 
 
 
Figure 15: The V-model for the Systems Engineering Process 13  
 
This is a software development project undertaken as part of a larger drug development 
project. Good Engineering Practice, Standard Operating Procedures (SOPs) and 
working practice guidelines have been implemented for project design as well as 
execution (see Figure 22). A robust change control system must be implemented in this 
project. 
 
The Design SOPs and Configuration Management system will be applied to the system 
designed to resolve each specific aim in this project. Each specific aim will begin with a 
Needs Analysis to determine what the new system needs to be able to do. A 
requirements analysis will also be conducted to determine what is required to fill those 
needs. A System Requirements Review (SRR) will demonstrate understanding of the 
requirements documents (scope, specifications, schedule, validation plans, and budget). 
SRR will determine the initial design direction and describe preliminary data and 
progress, and how these will converge to an optimum and complete system 
configuration for the specific aim. The memory needed to run QB on large datasets and 
evaluate the performance of the algorithm must be quantified. (Very large sample 
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datasets to test the memory usage and reproducibility of the results of the QB algorithm 
are being created, as well as to set ranges of parameters for its usage. Parameters 
include the number of bootstrap replications desired (b), the number of variables in the 
multivariate analysis (d), and the size of the dataset used (n). Preliminary data indicate 
that the typical laptop computer can process over one million bootstrap replication 
samples, independent variables, or sample data points when the other two parameters 
are minimized, or over one-thousand bootstrap replications, variables, and data points 
[all maximized at approximately 1000 inputs]). 
 
As the system evolves through the development process, topic experts will be invited to 
later design reviews (especially CDR, TRR, and MRR). System Design Review (SDR) 
acts as a control gate that reviews and approves the top-level system design solution 
and rationale 13 . It is the decision point to proceed with system specification flow down to 
individual physical and process configuration items 13 . System limitations will be refined at 
SDR. 
 
Using the run-time and memory usage data determined in Specific Aim 1, the 
performance capabilities of the algorithm on an NSF supercomputer (XSEDE Comet) will 
be calculated. QB is capable of tackling immensely large datasets, and the computing 
capabilities of the algorithm will be stretched on a massively parallel machine to 
demonstrate proof-of-concept. An SDR report will be added to the Design History file for 
FDA. 
 
A Preliminary Design Review (PDR) will be performed on each configuration item or 
group of configuration items to: (1) Evaluate the progress, technical acceptability, and 
risk resolution, (2) Measure its harmony with performance and engineering specialty 
requirements of the Configuration Item development specification, (3) Evaluate the 
extent of definition and evaluate the technical risk connected with the selected 
methods/processes, and (4) Demonstrate the existence and compatibility of the physical 
and functional interfaces among the configuration item and other items of equipment, 
facilities, computer software, and personnel 13 . Topic experts will also be invited to the 
review. A Blue team and a Red team are used for design and validation, respectively. A 
PDR report will be added to the Design History file for FDA in the annual reporting 
system. 
 
Critical Design Review (CDR) is the last design review conducted before an action is 
taken that is irreversible. (1) CDR is a review to establish that detail design of the 
configuration item under review meets cost, schedule, and performance requirements. 
(2) CDR will establish detail design compatibility among the configuration item and other 
items of equipment, facilities, computer software and personnel. (3) CDR will gauge 
configuration item risk areas (on a technical performance, cost, and schedule basis). 
Topic experts will again be invited to the review. A Blue team and a Red team are used 
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for design and validation, respectively. A CDR report will be added to the Design History 
file for FDA in the annual reporting system. 
 
Deployment Readiness Review (DRR) is held to confirm readiness for deployment. This 
review is conducted to ensure that all deficiencies are corrected before actual use. The 
complete system is challenged every feasible way (conceptually, physically, cyber-, etc.). 
The DRR demands the review and analysis of all subsystem/unit level testing preceding 
the formal acceptance tests. Topic experts will be invited to the review. A Blue team and 
a Red team are used for design and validation, respectively. A DRR report will be added 
to the Design History file for FDA. 
 
The QB algorithm will be translated into Python to make it more accessible to the 
scientific community. Once QB is available in Python it will run on Amazon Web 
Services, Microsoft Azure, and Google Compute Engine as well as the NSF XSEDE 
Comet supercomputer currently being used. The REPLICA algorithm has already been 
translated from Matlab into Python to make it more accessible to the scientific 
community. However, the algorithm on which QB relies has yet to be translated and the 
entirety of the program remains to be validated. 
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CHAPTER 3: ESTABLISHING EDI FOR A CLINICAL TRIAL OF A 
TREATMENT FOR CHIKUNGUNYA 
 
 
Purpose: Establishing the EDI of ellagic acid will assist in the determination of a safe 
starting dose of ellagic acid for clinical trials in BSN476. 
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Establishing EDI for a Clinical Trial of a Treatment for Chikungunya 
Abstract 
 Ellagic acid (EA) is a polyphenolic compound with antiviral activity against chikungunya, 
a rapidly spreading new tropical disease transmitted to humans by mosquitoes and now 
affecting millions worldwide. The most common symptoms of chikungunya virus infection 
are fever and joint pain. Other manifestations of infection can include encephalitis and an 
arthritic joint swelling with pain that may persist for months or years after the initial 
infection. The disease has recently spread to the U.S.A., with locally-transmitted cases 
of chikungunya virus reported in Florida. There is no approved vaccine to prevent or 
medicine to treat chikungunya virus infections. In this study, the Estimated Daily Intake 
(EDI) of EA from the food supply established using the National Health and Nutrition 
Examination Survey (NHANES) is used to set a maximum dose of an EA formulation for 
a high priority clinical trial.  
Keywords: Tropical disease  NHANES  Drug development 
 
1 Introduction 
1.1 Compound 
Ellagic acid (EA) is a polyphenolic compound with health benefits including antioxidant, 
anti-inflammatory, anti-proliferative, athero-protective, anti-hepatotoxic and anti-viral 
properties 1,2 . EA is found in many plant extracts, fruits and nuts, usually in the form of 
hydrolyzable ellagitannins that are complex esters of EA with glucose. Natural sources 
high in ellagitannins include a variety of plant extracts including green tea, nuts such as 
walnuts, pecans and almonds, and fruits, particularly berries, such as blackberries, 
raspberries and strawberries, as well as grapes and pomegranates.  
1.2 Chikungunya 
Chikungunya virus is transmitted to humans by mosquitoes. Typical symptoms of 
chikungunya virus infection are fever and joint pain. Other manifestations may include 
headache, encephalitis, muscle pain, rash, and an arthritis-like joint swelling with pain 
that may persist for months or years after the initial infection. The word ‘chikungunya’ is 
thought to be derived from its description in the Makonde language, meaning “that which 
bends up” the deformed posture of people with the severe joint pain and arthritic 
symptoms associated with this disease 3 . There is no vaccine to prevent or medicine to 
treat chikungunya 
virus infections. 
 
Millions of people worldwide suffer from chikungunya infections. The disease spreads 
quickly once it is established in an area. Outbreaks of chikungunya have occurred in 
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countries in Africa, Asia, Europe, and the Indian and Pacific Oceans. Before 2006, 
chikungunya virus disease was only rarely pinpointed in U.S. travelers. In 2006–2013, 
studies found a mean of 28 people per year in the United States with positive tests for 
recent chikungunya infection. All of these people were travelers visiting or returning to 
the United States from affected areas in Asia, Africa, or the Indian Ocean. 
 
In late 2013, the first local transmission of chikungunya virus in the Americas was 
identified on the island of St. Martin, and since then all of the other Caribbean countries 
and territories. (Local transmission means that mosquitoes in the area have been 
infected with the virus and are spreading it to people.) 
 
Beginning in 2014, chikungunya virus disease cases were reported among U.S. travelers 
returning from affected areas in the Americas and local transmission was identified in 
Florida, Puerto Rico, and the U.S. Virgin Islands. In 2014, there were 11 
locally-transmitted cases of chikungunya virus in the U.S. All were reported in Florida. 
There were 2,781 travel-associated cases reported in the U.S. The first locally acquired 
cases of chikungunya were reported in Florida on July 17, 2014. These cases represent 
the first time that mosquitoes in the continental United States are thought to have spread 
the virus to non-travelers. Unfortunately, this new disease seems certain to spread 
quickly. Data Driven Computational Science (DDCS) offers ways to accelerate drug 
development in response to the spread of this disease. 
 
EA has been shown to be an inhibitor of chikungunya virus replication in high throughput 
screening of small molecules for chikungunya 4 . In screening a natural products library of 
502 compounds from Enzo Life Sciences, EA at 10 μM produced 99.6% inhibition of 
chikungunya in an in vitro assay. 
 
1.3 Metabolism 
Ellagitannins are broken down in the intestine to eventually release EA. The 
bioavailability of ellagitannins and EA have been shown to be low in both humans and in 
animal models, likely because the compounds are hydrophobic and they because are 
metabolized by gut microorganisms 5-8 . The amount of ellagitannins and EA reaching the 
systemic circulation and peripheral tissues after ingestion is small to none 7 . It is 
established that ellagitannins are not absorbed while there is high variability in EA and 
EA metabolites found in human plasma after ingestion of standardized amounts of 
ellagitannins and EA 9-11 . These studies indicate that small amounts of EA are absorbed 
and detectable in plasma with a Cmax of approximately 100 nM (using standardized 
doses) and a Tmax of 1 h 9, 10 . EA is metabolized to glucuronides and methyl-glucuronide 
derivatives in the plasma. The most common metabolite found in urine and plasma is EA 
dimethyl ether glucuronide 12 . 
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It appears that the majority of ingested ellagitannins and EA are metabolized by the gut 
microbiota into a variety of urolithins. Urolithins are dibenzopyran-6-one derivatives that 
are produced from EA through the loss of one of the two lactones present in EA and then 
by successive removal of hydroxyl groups. Urolithin D is produced first, followed 
sequentially by urolithin C, urolithin A, and urolithin B. Urolithins appear in the circulatory 
system almost exclusively as glucuronide, sulfate and methylated forms as a result of 
phase II metabolism after absorption in the colon and passage through the liver 13 . While 
the amount of EA in the circulation is in the nanomolar range, urolithins and their 
glucuronide and sulfate conjugates circulate at concentrations in the range of 0.2–20 
lM 14 . In light of the much larger concentrations of urolithins in the circulation compared to 
EA, it is must be considered that the reported in vivo health effects of ellagitannin and 
EA may be largely due to the gut-produced urolithins. Growing evidence, mostly in vitro, 
supports the idea that urolithins have many of the same effects as EA in vitro. Various 
studies have shown evidence of anti-inflammatory 15-17 , anticarcinogenic 18-21 , 
anti-glycative 22 , possibly antioxidant 6, 23 , and antimicrobial 24  effects of urolithins. 
 
There is variation in how people metabolize EA into the various urolithins 25-27 . This is not 
surprising in light of the known differences between individuals in intestinal microbiotic 
composition. Tomás-Barberán 26  evaluated the urinary urolithin profiles of healthy 
volunteers after consuming walnuts and pomegranate extracts. They found that, 
consistent with previous findings, that urolithin A was the main metabolite produced in 
humans. However, they noted that the subjects could be divided into three groups based 
on their urinary profiles of urolithins. One group excreted only urolithin A metabolites 
while a second group excreted urolithin A and isourolithin A in addition to urolithin B. The 
third group had undetectable levels of urolithins in their urine.  These results suggest that 
people will benefit differently from eating ellagitannin rich foods. 
 
1.4 Use of EDI 
Knowledge of the Estimated Daily Intake (EDI) can permit pharmacokinetic and 
formulation studies to be conducted without prior expensive and time-consuming 
toxicology studies, especially when the molecule is naturally present in the food supply 
(see Figure 16). A subject’s dietary level of the compound would normally vary around 
the EDI. A subject is brought in to the drug evaluation unit, and after the usual ICH E6 
procedures and informed consent, is “washed out” of any of the compound might be 
present from previous food consumption. Typically, washout is accomplished by 
maintaining the subject on a diet containing none of the compound to be investigated 
for a period of five or more half-lives. The subject then receives a dose of the compound 
and blood samples are collected for pharmacokinetic or other analysis. The 
concentration of the dose is calculated to keep the subject’s exposure below the EDI. 
For this reason, it is important to establish the EDI before the clinical trial is designed 
and executed. After sufficient samples have been collected, the subject is released and 
the trial is complete for that subject. The subject then returns to a normal diet and levels 
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increase again to levels similar to those before the study. 
 
 
 
Figure 16:  A Pharmacokinetic Study Can be Conducted Below the EDI of EA  
 
 
2 Assessment of EA Use 
An assessment of the consumption of EA (EA) by the U.S. population resulting from 
the approved uses of EA was conducted. Estimates for the intake of EA were based on 
the approved food uses and maximum use level in conjunction with food consumption 
data included in the National Center for Health Statistics’ (NCHS) 2009–2010, 2011– 
2012, and 2013–2014 National Health and Nutrition Examination Surveys (NHANES) 
[27–29]. Calculations for the mean and 90th percentile intakes were performed for 
representative approved food uses of EA combined. The intakes were reported for these 
seven population groups: 
1. infants, age 0 to 1 year 
2. toddlers, age 1 to 2 years 
3. children, ages 2 to 5 years 
4. children, ages 6 to 12 years 
5. teenagers, ages 13 to 19 years 
6. adults, ages 20 years and up 
7. total population (all age groups combined, excluding ages 0–2 years). 
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3 Food Consumption Survey Data 
3.1 Survey Description 
The most recent National Health and Nutrition Examination Surveys (NHANES) for 
the years 2013–2014 are available for public use. NHANES are conducted as a 
continuous, annual survey, and are released in 2-year cycles. In each cycle, 
approximately 10,000 people across the U.S. complete the health examination 
component of the survey. Any combination of consecutive years of data collection is a 
nationally representative sample of the U.S. population. It is well established that the 
length of a dietary survey affects the estimated consumption of individual users and that 
short-term surveys, such as the typical 1-day dietary survey, overestimate consumption 
over longer time periods 31 . Because two 24-h dietary recalls administered on 2 
non-consecutive days (Day 1 and Day 2) are available from the NHANES 2003–2004 
and 2013–2014 surveys, these data were used to generate estimates for the current 
intake analysis. 
 
The NHANES provide the most appropriate data for evaluating food-use and 
food-consumption patterns in the United States, containing 2 years of data on individuals 
selected via stratified multistage probability sample of civilian 
non-institutionalized population of the U.S. NHANES survey data were collected from 
individuals and households via 24-h dietary recalls administered on 2 non-consecutive 
days (Day 1 and Day 2) throughout all 4 seasons of the year. Day 1 data were collected 
in-person in the Mobile Examination Center (MEC), and Day 2 data were collected by 
telephone in the following 3 to 10 days, on different days of the week, to achieve the 
desired degree of statistical independence. The data were collected by first selecting 
Primary Sampling Units (PSUs), which were counties throughout the U.S. Small 
counties were combined to attain a minimum population size. These PSUs were 
segmented and households were chosen within each segment. One or more participants 
within a household were interviewed. Fifteen PSUs are visited each year. For example, 
in the 2009–2010 NHANES, there were 13,272 persons selected; of these 10,253 were 
considered respondents to the MEC examination and data collection. 9754 of the MEC 
respondents provided complete dietary intakes for Day 1 and of those providing the 
Day 1 data, 8,405 provided complete dietary intakes for Day 2. The release data does 
not necessarily include all the questions asked in a section. Data items may have been 
removed due to confidentiality, quality, or other considerations. For this reason, it is 
possible that a dataset does not completely match all the questions asked in a 
questionnaire section. Each data file has been edited to include only those sample 
persons eligible for that particular section or component, so the numbers vary. 
 
In addition to collecting information on the types and quantities of foods being 
consumed, the NHANES surveys collected socioeconomic, physiological, and 
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demographic information from individual participants in the survey, such as sex, age, 
height and weight, and other variables useful in characterizing consumption. The 
inclusion of this information allows for further assessment of food intake based on 
consumption by specific population groups of interest within the total population. 
 
Sample weights were incorporated with NHANES surveys to compensate for the 
potential under-representation of intakes from specific population groups as a result of 
sample variability due to survey design, differential non-response rates, or other factors, 
such as deficiencies in the sampling frame 29, 30 . 
 
3.2 Methods 
Consumption data from individual dietary records, detailing food items ingested by each 
survey participant, were collated by computer in Matlab and used to generate estimates 
for the intake of EA by the U.S. population. Estimates for the daily intake of EA represent 
projected 2-day averages for each individual from Day 1 and Day 2 of NHANES data; 
these average amounts comprised the distribution from which mean and percentile 
intake estimates were produced. Mean and percentile estimates were generated 
incorporating sample weights in order to provide representative intakes for the entire 
U.S. population. “All-user” intake refers to the estimated intake of EA by those individuals 
consuming food products containing EA. Individuals were considered users if they 
consumed 1 or more food products containing EA on either Day 1 or Day 2 of the survey. 
 
3.3 Food Data 
Food codes representative of each approved use were chosen from the Food and 
Nutrition Database for Dietary Studies (FNDDS) for the corresponding biennial NHANES 
survey. In FNDDS, the primary (usually generic) description of a given food is assigned a 
unique 8-digit food code 29, 30 . 
 
3.4 Food Survey Results 
The estimated “all-user” total intakes of EA from all approved food uses of EA in the U.S. 
by population group is summarized in Figures 17, 18, 19 and 20. 
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 Figure 17: Ellagic Acid Mean EDI  
Children consume more EA on average than adults. Baby foods are often made from 
ingredients high in EA. The blue line shows data from the 2009–2010 NHANES, the 
red line data from the 2011–2012 NHANES, and the green line data from the 
2013–2014 NHANES.  
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 Figure 18: Ellagic Acid 90th %-tile EDI  
Teenagers contribute the highest peak in the 90th percentile consumers of EA. The 
blue line shows data from the 2009–2010 NHANES, the red line data from the 
2011–2012 NHANES, and the green line data from the 2013–2014 NHANES.  
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 Figure 19: Ellagic Acid Mean Weight-Based EDI   When EA exposure is calculated 
on a per kilogram of body weight basis, toddlers aged 1 to 2 years are exposed to the 
most EA on average. The blue line shows data from the 2009–2010 NHANES, the red 
line data from the 2011–2012 NHANES, and the green line data from the 2013–2014 
NHANES.  
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 Figure 20: Ellagic Acid 90th %-tile Weight-Based EDI  
When EA exposure is calculated on a per kilogram of body weight basis for the 90th 
percentile consumers, toddlers aged 1 to 2 years are again exposed to the most EA. 
The blue line shows data from the 2009–2010 NHANES, the red line data from the 
2011–2012 NHANES, and the green line data from the 2013–2014 NHANES.  
 
The estimated “all-user” total intakes of EA from all approved food uses of EA in the U.S. 
by population group are graphed using NHANES data in Figs. 17, 18, 19 and 20 for 
2009–2010, 2011–2012, and 2013–2014. The figures show that over 6 years, the 
consumption of EA has been fairly constant and that children and teenagers are the 
major consumers. 
 
4 Conclusions 
In summary, 28.3% of the total U.S. population of 2+ years was identified as consumers 
of EA from the approved food uses in the 2013–2014 survey. The mean intakes of EA by 
all EA consumers age 2+ (“all-user”) from all approved food uses were estimated to be 
69.58 μg/person/day or 1.05 μg/kg body weight/day. The heavy consumer (90th 
percentile all-user) intakes of EA from all approved food-uses were estimated to be 
258.33 μg/person/day or 3.89 μg/kg body weight/day. The EDI (red line in Figure 16) is 
set at 70 μg/person/day from the 2013-2014 NHANES for consumers ages 2 and up. 
The next experiment will be an actual trial of EA in human subjects at the EDI with a 
dose of 3.89 μg/kg body weight/day (see Figure 16), as determined by this DDCS study. 
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CHAPTER 4: CALCULATING THE ACCEPTABLE DAILY INTAKE OR NOAEL 
WITH QBEST (QNOAEL) 
 
Purpose: The acceptable daily intake (QNOAEL) of ellagic acid is calculated using an 
analysis of animal studies.  This is proof-of-concept that QBEST can be used to 
generate NOAELs and NOELs in a novel fashion. 
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Calculating the Acceptable Daily Intake or NOEL with QBEST (QNOEL) 
  
Introduction: 
Current Best Practice 
Before a novel therapeutic agent can progress from animal studies to first-in-human 
studies, the FDA requires evidence that the investigational new drug will be safe for 
human use.  Determining the No Observed Adverse Effect Limit (NOAEL), or the highest 
dose of a drug that can be administered to an animal without producing any undesirable 
effects, is important in this process because it places an upper bound on the dosage that 
should be administered to a human.  In general, the maximum dose administered to 
humans is limited even further as a precaution in case the drug has unexpectedly 
greater toxicity in humans than in the animal model.  
 
Traditionally, NOAELs have been determined by administering increasingly large doses 
of a drug compound to animal subjects until adverse effects become apparent.  The 
highest dose administered during the course of the study that did not produce any 
adverse effect is designated the NOAEL.  There are problems with this method, namely 
that the NOAEL must be determined to be a dose that was administered in the study, 
and often only 3 or 4 doses, spaced an order of magnitude or more apart, are used 
because of cost. For this reason, the NOAEL determined through traditional means often 
does not capture the true population NOAEL well.  Traditional NOAEL determinations 
can be confounded in other ways, as well, and it is difficult to meta-analyze and pool 
NOAEL studies.  This can lead to NOAEL determinations that are influenced strongly by 
sampling. 
 
The Benchmark Dose Method is another way of estimating toxicity.  The benchmark 
dose is defined as the statistically calculated lower 95 % confidence limit on the dose 
that produces a defined response (called the benchmark response or BMR, usually 5 % 
or 10 %) of an adverse effect compared to background, often defined as 0 % or 5 %. 
The benchmark dose describes a quantity that is in some ways very different from a 
NOAEL; the benchmark dose is an estimate of the quantity of therapeutic agent that will 
cause an adverse reaction, whereas NOAEL indicates the highest dose that is 
completely tolerable.  The benchmark dose (BMD) can be calculated from a series of 
separate studies, unlike to NOAEL.  However, the BMD can be confounded by conflicting 
studies.  In any given population, it is expected that there will be some variation in 
response.  When calculated with conflicting studies shown later in this dissertation, some 
of which found an effect to occur at a given dose while some found no effect at the same 
given dose, the Benchmark Dose Method generates a mean dose-response line through 
studies with opposite conclusions.  Though the Benchmark Dose Method is in many 
 
51
ways superior to the traditional determination of NOAEL, as it is able to meta-analyze 
multiple toxicity studies and can generate a BMD that was not a dose directly 
administered in a study, it is still not an ideal method. 
 
Discriminant Cluster Analysis and QNOAEL 
Discriminant cluster analysis is a method commonly utilized in chemometrics and 
analytical chemistry for determining whether a given sample belongs in the same class 
as a set of training samples.  The QBEST equation is an application of this method to 
estimation of  NOAELs. 
 
At present, the Mahalanobis distance is the more commonly used metric for statistical 
multivariate discriminant cluster analysis.  Though the premise of the Mahalanobis 
equation is basically the same as that of QBEST, the Mahalanobis is limited by a crucial 
requirement: In order to calculate a Mahalanobis distance, the algorithm requires that 
significantly more data points be included in the analysis than variables that describe 
those data points.  In terms of meta-analysis of drug development data, this means that 
in order to use the Mahalanobis equation, one would need to have significantly more 
clinical trials or animal studies than clinical parameters measured in those studies. 
Clinical trials and animal studies are very expensive, and generate vast amounts of data. 
This means that while there may be a dozen or so relevant clinical studies for a given 
drug in the literature (which form rows in a matrix), perhaps upwards of a hundred 
separate measurements will have been collected for each patient (columns in the 
matrix).  Moreover, the change in many biological parameters may be recorded over 
time.  It is mathematically impossible to calculate a Mahalanobis distance using all of the 
parameters of the studies given so very few studies - the number of rows of the matrix 
must exceed the number of columns.  This problem is a result of the matrix inversion / 
factorization method by which Mahalanobis distances are calculated.  
 
QBEST is ideal for these circumstances, and can be applied to generate a QNOAEL 
which is in many ways superior to the traditional NOAEL or BMD.  The method of 
calculation differs from the Mahalanobis equation, and in consequence the number of 
studies can be very low in comparison to the number of variables and the equation still 
maintains mathematical accuracy and precision.  QBEST is able to maximally utilize the 
vast amounts of data generated by clinical studies.  Meta-analyzing with QBEST can 
reduce the need to repeat costly clinical studies, as often occurs with traditional NOAEL 
determination.  Like the Benchmark Dose Method, QBEST is capable of calculating a 
safety limit other than a dose that was administered.  Unlike the Benchmark Dose 
Method, however, QBEST generates a QNOAEL that represents the dose which at a 
given confidence level will produce no effect in the population.  QBEST handles 
conflicting studies in a more intuitively acceptable way than the Benchmark Dose Model, 
which will be seen below.  Unlike the Benchmark Dose Method, the QBEST is a 
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nonparametric statistical test and can be more accurately applied when parametric 
assumptions (such as assumptions of normality) are not met. 
 
Ellagic Acid 
Ellagic acid (EA) is a naturally-occurring polyphenol with strong antiviral, 
anti-inflammatory, and anti-cancer properties.  EA has been shown to significantly 
reduce growth rate and multiplicity of tumors in animals with various cancers.  It also 
affects the clotting of blood and the lipid profile of animals with diabetes or models of 
heart disease.  EA has been reported numerous times to have an attenuating effect on 
physiological changes induced by various chronic disease states.  EA is also the 
principal component of an investigational new drug, BSN476, which will be moved into 
clinical trials as a treatment for Chikungunya. Toxicology tests must be conducted in at 
least one rodent and one nonrodent species prior to human exposure.  (Often rats and 
beagles are used.  Rats are usually the first species, and the rat results help select the 
range of doses for the beagle studies.  The rodent and nonrodent results, in turn, help to 
select the range of doses for first-in-human studies.)   Currently, no NOAEL or NOEL has 
been published in the literature for human consumption of EA, nor has a Generally 
Recognized as Safe (GRAS) memorandum from the US FDA been made publicly 
available.  Tasaki et al estimated the no-observed-effect level (NOEL) to be 3011 mg/kg 
b.w./day for male F344 rats and the NOAEL and NOEL in females were to be 3254 
mg/kg b.w./day and <778 mg/kg b.w./day, respectively 20 .  This determination was made 
on the clinical endpoint of body weight gain suppression 20 .  Tasaki et al. also measured 
alkaline phosphatase activity, but concluded that alterations in this and other enzymatic 
activity were sporadic and not dose-dependent, so did not consider these or blood 
content levels of various ions to be grounds for determining the NOAEL or NOEL 20 . 
Methods: 
Literature Search: 
In order to access a sufficiently large sampling of the literature on ellagic acid, several 
search methods were used.  The results of these searches were documented for 
reproducibility.  A total of 156 published peer-reviewed journal articles were indicated as 
useful by search results.  Only one of the indicated articles could not be obtained, 
namely Yang 2008.  Of the 156 published articles, 82 described animal studies in which 
ellagic acid was administered.  Details of the literature search are as follows. 
 
Literature Search Methodology 
A private corporation provided a small database of studies on ellagic acid, many of which 
were animal studies.  These were all included in the literature review.  Toxnet, University 
of Kentucky Library “InfoKat” database, and  Google Scholar were utilized.  Finally, 
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relevant sources cited by all materials were included. To ensure data integrity, a 
Cochrane protocol was put in place before the selection of studies for review. 
 
Cochrane Protocol: 
In order to maintain research integrity, the following Cochrane Protocol for data selection 
was utilized: 
1. Only animal studies with an n of 6 or greater were considered. 
2. The studies were analyzed for sameness of endpoints.  The most common 
endpoints shared were oxidative damage and inflammatory markers (such as 
levels of interleukins). 
3. All studies falling into these categories of endpoints were compared, and the 
endpoint with the most studies having been conducted using the same 
administrative route in the same animal species for the same time scale (chronic 
or acute administration) was selected. 
4. In the event that there was a tie in the endpoint with the highest number of 
representative studies, priority would have been given first to an endpoint for 
which all studies shared an additional endpoint and then to a numeric response 
variable over a categorical variable. 
5. All studies were validated to have significant difference between the control and 
disease-state control group. 
The study criteria determined by this method were as follows: chronic oral-administration 
studies of ellagic acid performed in rats for a time period of no less than one week that 
reported alkaline phosphatase activity as an endpoint. Eight studies were isolated that 
met these criteria.  [Gumus (2011); Murugan (2009); Panchal (2013); Ahad (2014); Singh 
(2009); Thresiamma (1996); Devipriya (2007); Umesalma (2010)]  Tasaki (2008) was not 
considered.  Distribution of the doses of ellagic acid and the activity of alkaline 
phosphatase are shown in Figure 21.  The level of confidence for this designation was 
p<0.05 for all included studies. 
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 Figure 21: Distribution of Ellagic Acid Doses and the Corresponding Alkaline 
Phosphatase Levels 
 
Converting Enzymatic Activity Units: 
One of the studies indicated by the study criteria, Thresiamma (1996), reported alkaline 
phosphatase activity in terms of Kingston-Armstrong units per 100 mL serum.  The 
activity was converted into international units per liter utilizing conversion data from 
“International Enzyme Units and Isoenzyme Nomenclature”.  The 2-point format of a line 
was used to extrapolate the conversion of KAUs first to Bodansky units, and then to 
international units.  It should be noted that the extrapolated quantity was outside the 
literature range for estimation, which likely contributes to the fact that the alkaline 
phosphatase activity of all groups was reported to be noticeably higher for this study 
than the others. 
 
Application of QBEST to Determine QNOAEL 
First, a bootstrap replication method was applied to the data.  Bootstrapping utilizes 
random sampling of data from the training set of n rows, with replacement from the 
training set, to form a new set of samples of n rows (called a bootstrap sample). 
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Repeated resampling of the training set, forming repeated bootstrap samples, yields the 
bootstrap sample distribution.  The bootstrapping process utilized is multidimensional. 
 
This bootstrapping method is applied because it is nonparametric.  Empirical cumulative 
distribution functions (ECDFs) are functions that approximate the true cumulative 
distribution function of the data.  When the original  observational data are bootstrapped 
nonparametrically using a Monte Carlo approximation to the bootstrap distribution, an 
estimate of the underlying true cumulative distribution function is obtained.  
 
Doses that were determined to have no significant effect on the activity of alkaline 
phosphatase were assigned the label “No Effect Doses”.  Doses that were determined to 
have significant effect on the activity of alkaline phosphatase were assigned the label 
“Effect Doses”.  The ECDF of the “No Effect Doses” dataset was integrated and 
compared with the ECDF of the set of the combined “Effect Doses” and “No Effect 
Doses”, quantile-by-quantile.  The test statistic of this procedure is the correlation 
coefficient between the two ECDFs, based off of the quantile-quantile plot and the 
location and scales of quantiles.  The hypothesis tested is that the two distributions are 
the same - that the correlation between the two ECDFs is close to one - with a 
confidence limit of 98% (the default setting, which can be changed by the user if 
desired).  
 
A simulation run was conducted in which the test set and the training set were moved far 
apart in hyperspace (correlation coefficient <1) and then closer together in hyperspace to 
generate a curve of correlation coefficients at various distances separating the training 
set and test set.  When the simulation finally centered the “Effect Doses” (training) set on 
the “No Effect Doses” (test) set, the correlation coefficient was close to 1 and there was 
no significant difference between the two sets.  The simulation employed a bisecting 
divide and conquer algorithm to move the training set and test set together.  As long as 
the two sets remained statistically different, each successive iteration of the simulation 
run would move the test set one-half the remaining distance toward the training set.  The 
process was repeated until the difference between the sets became statistically 
insignificant, as indicated by a correlation greater than the 98% level between the two 
ECDFs formed by testing the training set against itself.  Stated another way, the 
algorithm progressively translated both sets or clusters of data away from each other 
until it became statistically apparent that the clusters were different.  The 98% 
confidence limits (of the x- and y-axes) on the “Effects” were determined to be the 
QNOAEL for ellagic acid. 
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 Figure 22: Translating Clusters of Data to Attain the 98% Confidence Level of 
Difference 
The above depicts two theoretical clusters of data being translated toward each other 
in a stepwise fashion along both axes until the 98% confidence level of difference 
between the two ECDFs is reached.  
 
 
Results: 
Out of the 82 animal studies reviewed for this experiment, only the following doses were 
reported to have caused harm to the animal rather than attenuation of a symptom or 
imbalance induced by a disease state. 
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 Table 2: Studies Showing Adverse Effects After Administration of Ellagic Acid 
Study Dose Effect 
Damas 1987 “Studies…” 30 mg/kg Intravenous 
Injection 
Swelling of the spleen and 
noticeable histological 
changes in lymph nodes. 
Paivarinta 2006 1,565 mg/kg/day Oral 
Feeding for a Prolonged 
Period 
 
Increases size of 
adenomas in the 
duodenum. 
p=0.029 
Damas 1987 
“Thrombopenic…” 
30 mg/kg Intravenous 
Injection 
Hematological aberrations 
and swelling of the 
lymphatic tissues. 
Hassoun 1997 6 mg/kg/day on days 
10,11,12 of pregnancy and 
3 mg/kg on day 13 
Ellagic acid control 
significantly increased fetal 
death rate despite 
generally protective effects 
against teratogenesis 
when co-administered with 
TCDD 
Bohn 1993 20 microliters in DMSO 
(0.2 microCi and 100 
micrograms) injected into a 
random uterine horn 
Apparent increase in fetal 
mortality, though the 
sample size was only three 
rats. 
 
The most common reported statistically significant effects in the literature were the 
attenuations of various markers of oxidative stress, malignancy, and metabolic 
imbalance.  In all of the eight studies selected, ellagic acid controls showed no significant 
change in alkaline phosphatase activity.  Only in rats with chronic conditions that lowered 
the activity of alkaline phosphatase were significant effects of EA administration 
observed, and levels of alkaline phosphatase were attenuated.  In light of this finding, the 
No Observed Effect Level (QNOEL) of ellagic acid was calculated rather than the 
NOAEL. 
 
The 98% confidence limit on the “Effects Set” was 32.8129 mg/kg/day ellagic acid.  This 
indicates that the QNOEL of ellagic acid is 32.8129 mg/kg/day in rats. 
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Discussion: 
This study demonstrates the feasibility of using the QBEST equation to generate 
QNOAELs and QNOELs from animal studies or clinical trials published in the literature. 
The QBEST equation was utilized to perform discriminant cluster analysis between 
“Effects Doses” and “No Effects Doses” of ellagic acid orally administered to rats. 
“Effect” versus “No Effect” classification was done on the basis of the author’s 
determination that the clinical endpoint was or was not significantly affected with p<0.05. 
The result of this discriminant cluster analysis was a 98% confidence limit QNOEL of 
ellagic acid, or a dose that would cause no observed effects 98% of the time if the same 
studies were to be repeated.  This is the first published study demonstrating the 
feasibility of generating a QNOEL value using the QBEST equation.  It is a novel method 
for estimating the acceptable daily intake (ADI) of a food additive that takes advantage of 
the published literature, reducing the need to perform costly animal studies (or human 
studies where human data is available from the literature). 
 
The QNOEL of ellagic acid was determined to be 32.8129 mg/kg/day in rats on the basis 
of significant increase in alkaline phosphatase activity.  This is generally in keeping with 
the literature in that amelioration of symptoms or attenuation of illness-induced 
symptoms seems generally to be noted at oral doses up to 30 mg/kg. 
 
However, it should be noted that this determination was largely limited by the literature 
available.  Of the studies surveyed, few had overlapping numeric endpoints and as a 
result, only eight studies were eligible for analysis.  A number of doses were repeated in 
those studies, as well, reducing the scope of the analysis further.  Though the QBEST 
Equation is capable of calculating a QNOEL based off of this data, increasing training set 
size has been shown to improve the accuracy of the output.  (See Chapter 5 for the 
effects of training set size on accuracy and precision of QBEST.) 
 
Furthermore, the designation of adverse effect versus effect doses is complicated in the 
case of ellagic acid.  Attenuation of alkaline phosphatase activity which has been 
decreased by an induced illness could arguably be called an effect, but not an adverse 
effect of ellagic acid administration.  Consistently, doses of up to 0.5g/kg are reported to 
have caused attenuation of a symptom when administered to rats with induced chronic 
conditions but no effect on the same endpoint when tested in healthy rats.  In fact, 
Mandal 1990 reported no adverse effects when doses ranging from 0.4 - 8g/kg/day of 
ellagic acid were orally-administered to rats for a period of four weeks.  
 
Paller et al. has administered ellagic acid orally to human cancer patients as a 
component of muscadine grape extract tablets.  At the highest dose permitted by the 
study protocol, 8 tablets/day containing at total of 9.6 mg of ellagic acid per day, patients 
still experienced no adverse effects except for “flatulence, soft stools, and eructation” 
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when the sample size was increased to 14.   Assuming that the average patient in the 
study weighed 62 kg, the highest daily dose of ellagic acid that patients received was 
0.15 mg/kg/day.  This daily dose is approximately 220-fold lower than the calculated 
QNOEL of 32.8129 mg/kg/day in rats. 
 
This discrepancy is important because the literature on ellagic acid strongly suggests a 
dose-dependent attenuation of cancer symptoms, inflammatory responses, and 
inhibition of metastasis and tumor growth.  Largely, though, these effects are not seen 
when less than 30 mg/kg/day is administered orally in rodents.  This is likely due in part 
to EA’s poor solubility in water and relatively poor absorption in its natural state.  
 
The results of the present study suggest that ellagic acid has a wider therapeutic window 
than is currently recognized.  In future human clinical trials, it may be appropriate to 
increase the starting dose of ellagic acid.  Here, the QNOEL of ellagic acid was 
determined to be 32.81 mg/kg/day in rats but current human clinical trials administer a 
maximum daily dose of roughly 0.15 mg/kg/day.  The calculated QNOEL indicates that 
the maximum daily human dose is insufficient to achieve attenuating effects of ellagic 
acid, as measured by alkaline phosphatase activity. 
 
A study of American food consumption data from the NHANES database found that the 
mean estimated intake of ellagic acid from the food supply is 1.05 μg/kg body 
weight/day, while the 90th percentile daily intake is 3.89 μg/kg body weight/day 154 .  The 
90th percentile daily intake of ellagic acid from the food supply is indicative of a “heavy 
user” dose for human administration.  In order to elucidate the NOEL of ellagic acid in 
humans, an administration study should be performed between this value and QNOEL 
determined in rats (with the maximum dose being reduced by a factor of 6.2 155 , as is 
suggested when moving from rat toxicity studies into human studies).  A clarification for 
whether adverse effects are induced by pure ellagic acid at the dose of 0.15 mg/kg/day, 
the ellagic acid dose-equivalent for muscadine grape tablets administered in human 
clinical trials by Paller et al., should be provided by the proposed study and will indicate 
whether ellagic acid alone produces observed effects  
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Appendix: Search Methodology & Cochrane Protocol 
Literature Search Methodology 
Corporate Literature Provision: 
A private corporation provided a small database of studies on ellagic acid, many of which 
were animal studies.  These were all included in the literature review. 
 
Web-Based Search Terms: 
1. “Ellagic Acid” search on Toxnet yielded few relevant results, though all were 
included in the source database. 
2. “Ellagic Acid NOAEL” was searched on the University of Kentucky Library 
“InfoKat” database.  All relevant papers returned in the 69 results were included. 
3. “Ellagic Acid NOEL” returned no relevant results on the first page of UK library 
search, so this search was concluded. 
4. “ellagic acid noael”  Searched on 5/22/2018 returned on Google Scholar 726 
results.  Many are duplicates of papers from Company Files or UK Library 
search.  Relevant non duplicate items in the first 40 results were obtained.  
5. Johanningsmeier 2011 was not included due to the large number of pomegranate 
review papers already included. 
 
 
Sources Cited by Previous Entries: 
Relevant sources cited by the papers found by the above methods (company files, UKY 
search, and Google Scholar search) were determined.  Because the corporate literature 
search provided a fairly comprehensive sampling of papers published up to 2008, 
citations were taken from all papers published in 2008 or later. 
1. In reviewing previously obtained sources, some citations stood out in the bodies 
of the text as being particularly relevant.  If a source was noted in the body of text 
as being a human or animal study involving ellagic acid, the cited source was 
generally obtained immediately. 
2. The titles of all sources in the citation sections were reviewed.  Any titles 
including the words “ellagic acid” were obtained, unless the study titles directly 
indicated that the source was an  in vitro study or cell assay.  Studies whose titles 
indicated that they covered only the administration of pomegranate products or 
plant extracts were also omitted.  Articles of questionable relevance were 
reviewed briefly before being included in the in-depth literature review. 
3. Resources were not duplicated if they were already included. 
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4. Sources were not taken from Faria 2011 because a copy was not obtained before 
the citation search.  No sources were used from this article as it could not be 
gotten in full and there are more recent pomegranate review articles, the sources 
of which were reviewed.  
5. The search for cited sources was begun with the most recent references.  
6. A very few papers used citation methods that omit the title of the cited article. 
The text was searched for instances of relevant citations, and then relevance was 
validated by obtaining the journal article. 
 
Cochrane Protocol: 
In order to maintain research integrity, the following Cochrane Protocol for data selection 
was utilized: 
6. Only animal studies were considered with an n of 6 or greater. 
7. The studies were analyzed for sameness of endpoints.  The most common 
endpoints shared were oxidative damage and inflammatory markers (such as 
levels of interleukins). 
8. All studies falling into these categories of endpoints were compared, and the 
endpoint with the most studies having been conducted using the same 
administrative route in the same animal species for the same time scale (chronic 
or acute administration) was selected. 
9. In the event that there was a tie in the endpoint with the highest number of 
representative studies, priority would have been given first to an endpoint for 
which all studies shared an additional endpoint and then to a numeric response 
variable over a categorical variable. 
10. All studies were validated to have significant difference between the control and 
disease-state control group. 
The study criteria determined by this method were as follows: chronic oral-administration 
studies of ellagic acid performed in rats for a time period of no less than one week that 
reported alkaline phosphatase activity as an endpoint. 
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CHAPTER 5: VALIDATING THE ACCURACY OF QBEST ON SYNTHETIC 
DATA: ROUND THE COMPASS ROSE 
 
Purpose: This chapter evaluates the accuracy of the QBEST algorithm on synthetic data 
and evaluates what factors most affect the accuracy of the algorithm. 
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 Validating the Accuracy of QBEST on Synthetic Data: Round the Compass 
Rose 
 
Introduction:  
QBEST is a discriminant cluster analysis method that can be used to identify whether a 
new point ought to be classified as a member of one or another multivariate data 
clusters 4 .  It is an improvement over the Mahalanobis equation, which has been 
described as “a rubber ruler”.  Specifically, the Mahalanobis equation calculates the 
number of standard deviation units of a point from the center of a cluster of normally 
distributed data points along a given axis, or off that axis.  QBEST, on the other hand, is 
a “rubber ruler with a nail in the center”, meaning that it calculates the standard deviation 
of a point from a cluster of data points along a given vector, extending from the center of 
the cluster towards the test point.  This strength allows the QBEST to be applied to 
multivariate clusters of data that are irregular in shape (e.g., not normally distributed) 
with greater accuracy than the Mahalanobis. 
 
QBEST has already been applied to real-world problems of sample differentiation. 
QBEST has been applied to the problem of differentiating clusters of data from infrared 
(IR) spectroscopy of medicine capsule samples 1, 5 .  QBEST was demonstrated to be able 
to identify capsules contaminated with metals or cyanide 5 .  In another experiment 
utilizing QBEST, pure Anacin capsules were distinguished from capsules contaminated 
with common industrial contaminants, such as aluminum powder and dust 6 .  It has also 
been used to differentiate between benzoic acid and false samples via IR analysis 7 . 
 
The algorithm’s accuracy and performance when handling spherically distributed  N (0,1) 
data has been evaluated  3,4 , but  an evaluation of the algorithm’s accuracy and bias when 
handling elliptically distributed  N (0,1) data has never been calculated.  The purposes of 
this experiment were (1) to validate QBEST’s accurate handling of elliptical data; (2) to 
evaluate what factors most influence the accuracy of the algorithm; (3) to determine the 
maximum accuracy with which the average laptop computer could calculate BEST 
distances for elliptical data.  To this end, synthetic data clusters’ known statistical 
parameters were compared to the theoretical QBEST distance calculated by the 
algorithm.  A standard ellipse served as the basis of this model.  Future research should 
evaluate QBEST’s treatment of skewed clusters. 
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Materials: 
System Specifications: 
As reported by Matlab’s “memory” command, the laptop used for the memory usage test 
had the following capabilities: 
  
Maximum possible array: 5089 MB (5.337e+009 bytes) * 
Memory available for all arrays: 5089 MB (5.337e+009 bytes) * 
Memory used by MATLAB: 624 MB (6.545e+008 bytes) 
Physical Memory (RAM): 7366 MB (7.724e+009 bytes) 
 
 
All memory data was generated on a laptop PC with 7366 MB of RAM.  The operating 
system used was Windows 10.  
 
Other data were generated on a Lenovo 3437CTO X-64 based laptop PC with an IntelⓇ 
Core™ i7-3520M CPU at 2.90 GHz, 2901 MHz, with 2 cores and 4 logical processors. 
The operating system used was Windows 7 Professional, Version 6.1.701 Service Pack 
1 Build 7601. 
 
Matlab R2017a was used for all calculations. 
Methods: 
Standard Circular Data: 
In order to validate the program for the standard data generation, first a circular cluster of 
data were generated in Matlab.  Utilizing the mvnrnd() function, data with a known 
standard deviation of 1 along both the x and y axes, centered on the point (0,0) were 
generated.  Figure 23 is an example of a cluster of data thus generated.  The mean, or 
center point, of the cluster is shown as a red point and the theoretical first standard 
deviation is shown as a red circle with radius=1.  The second standard deviation is 
shown in blue.  In this example,  45/100 fall within the red circle. 43/100 points fall 
between the red and blue circles or on the blue circle. 12/100 points fall further from 
center than the second standard deviation. Theoretically, for normally distributed data, 
68% of the points should fall within one standard deviation of the mean, and 95% within 
two standard deviations, leaving less than 2% of data outside the blue circle.  It is known 
that random number generators do not perfectly generate data fitting the input 
parameters, but an approximation is required for this research.  Furthermore, it is likely 
that the command in question merely considers the standard deviation along the x axis 
when generating the x coordinates and the standard deviation along the y-axis when 
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generating the y-coordinates; that is to say that Matlab does not use a target covariance 
matrix when generating points using mvrnd(). 
 
Figure 23: Standard Circle  
A standard circular cluster of data with center (0,0) and standard deviation of 1 in all 
directions.  The first standard deviation distance is shown in red and the second 
standard deviation distance in blue. 
Standard Elliptical Data: 
Then, using the mvnrnd() function, data were generated with a known standard deviation 
of 1 along the y axis and 2 along the x axis.  Figure 32 is an example of 100 data points 
generated in this fashion with center shown in red and the standard ellipse with principal 
axis length equal to 2 and minor axis length equal to 1 shown in red.  The eight compass 
points utilized in the experiment are shown in red. 
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 Figure 24: Stylized 
Standard Ellipse 
A stylized standard ellipse 
with major principal axis 
points shown in black, minor 
principal axis points in blue, 
and diagonal points in pink. 
 
 
 
Figure 25: Standard Ellipse with Compass Points 
 An example of the elliptical cluster of data generated in this experiment with mu = 
(0,0) and sigma=(2,1).  Compass points on the standard ellipse shown in red.  The red 
line indicates 1 standard deviation distance from center. 
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The eight compass points shown are as follows, and comprise the farthest points along 
the major and minor axes as well as the points located at a 45-degree angle from the x 
and y axes: 
 
Table 3: The Eight Compass Points of the Standard Ellipse 
Principal Axis Points Non-Principal Axis Points 45 Degree Diagonal Points 
( -2,0) (0,1) (-2/(sqrt(5))),(2/(sqrt(5))) 
( 2,0) ( 0,-1) (-2/(sqrt(5))),(-2/(sqrt(5))) 
  (2/(sqrt(5))),(-2/(sqrt(5))) 
  (2/(sqrt(5))),(2/(sqrt(5))) 
 
Increasing Dimensions: 
The same process was used to increase the dimensionality of the circular and elliptical 
clusters.  For increased dimensions in the data, the center remained the same but was 
assigned additional zero-coordinates.  For example, the three-dimensional center would 
be (0,0,0).  A standard deviation of 1 was assigned to the mvrnd() cluster in all 
directions. 
 
Nested Iterative Loops 
The program Round_The_Compass_Rose_increasing_training_set.m was used to 
evaluate the algorithm’s handling of the data as each variable increased.  This program, 
available at our lab website (link) utilizes a series of nested iterative loops.  
 
The outermost loop changes the fraction of data points used in the generation of the 
hypercylinder, “radfrac”.  A minimum, step, and maximum value are set for radfrac. 
 
The second nested iterative loop increases the number of datapoints in the training set 
(denoted by the variable “u”) by increasing the number of points generated by the 
mvrnd() function.  Note that the actual number of training points generated is equivalent 
to 50*u.  The line of code relevant to this command is: 
TNSPEC=mvnrnd(mu,sigma,50*u); 
 
The third nested iterative loop increases the dimensions or number of wavelengths of the 
data points (denoted by the variable “v”).  “v” is indicative of the number of dimensions of 
the data points above two.  That is, when v=0, the data is generated in a 2-D ellipse. 
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When v=1, the data is three-dimensional; when v=2, the data is four-dimensional; etc. 
Dimension is increased in the training set by centering the mvrnd() cluster on 
(0,0,........0), with the appropriate number of zeroes being added to the coordinate for the 
number of dimensions - that center point being assigned to the variable “mu”.  Then, 
“sigma” is addended such that the standard deviation of the mvrnd() cluster is (2,1, 
1…...1), with ones being appended such that the number of dimensions is increased to 
the proper value.  In this loop, as well, the compass points are defined and addended 
with zeroes to make them the proper dimensions.  The compass points are defined: 
 compass_points=[0,1;(-2/(sqrt(5))),(2/(sqrt(5))); -2,0;(-2/(sqrt(5))),(-2/(sqrt(5)));  
    0,-1;(2/(sqrt(5))),(-2/(sqrt(5))); 2,0; (2/(sqrt(5))),(2/(sqrt(5)))]; 
 
Compass points of increased dimensions would have all further dimensions equal to 
zero. (0,1, 0,0…...0), for example. 
 
Furthermore, this loop defines the expected standard deviation from center of each 
compass point: 
expected_standard_deviation = [1;1.2649;2;1.2649;1;1.2649;2;1.2649]; 
 
The fourth nested iterative loop defines “newspec”, the test spectrum, as being 
equivalent to one of the eight compass points.  This loop tests each compass point using 
the method of the fifth iterative loop.  It also creates storage for the solutions generated 
in the fifth iterative loop.  The fifth iterative loop is run a total of six times, with different 
bootstrap replicates being generated, and the average and standard deviation of the 
outputs is calculated and stored. 
 
The fifth iterative loop increases the number of bootstrap replicates generated. 
Bootstrap replicates are equivalent to 50* “z”.  This loop actually calls the qb.m program. 
The code for this loop is: 
for i=1:z 
  
     B=50*i; 
     sds = nan; bias = nan; sdskew = nan; 
        try 
     [BTRAIN,CNTER]=replica(TNSPEC,B); 
     [sds,sdskew,qrr] = qb(TNSPEC,BTRAIN,newspec,CNTER,radfrac,sensitiv); 
     bias=sds-expected_standard_deviation(j); 
            catch ME 
        end 
         SDS_matrix((i),:)=[compass_points(j,:),B,sds,bias,sdskew]; 
    end 
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The program used for multivariate polynomial regression of the final results was 
https://www.mathworks.com/matlabcentral/fileexchange/34918-multivariate-polynomial-r
egression . 
Memory Usage Tests: 
In order to determine the maximum parameter size for each required input of the 
algorithm, the input values of each variable training set size, number of bootstrap 
replications,  and dimension were increased until the program ran for a continuous 20 
minutes without completing.  (This was determined to be indicative that the program 
would not complete its run, even given more than an hour.)  Then, variables were 
increased together.  For these tests, the same input was used for both or all variables 
being tested.  All variables were increased until the run time exceeded 20 minutes, the 
program raised a memory error and terminated, or the cpu time of the last run 
approached 200 seconds (as this was also indicative of an imminent crash). 
Results: 
Memory Usage: 
The following chart shows the maximum input sizes attained for each variable alone or in 
concert with another variable.  The amount of data that a personal laptop computer can 
analyze far exceeds what is possible using the Mahalanobis equation.  A personal laptop 
computer can run up to 6 million bootstrap replications with a small dataset,  or can 
handle 1 million dimensional data, or 5 million training points provided that the other 
parameters are small with a run time of less than 20 minutes.  This far exceeds the 
needs of most research scientists. 
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Table 4: Memory Usage of QBEST 
Bootstrap Dimension TNSPEC 
Memory Used 
by Matlab (MB) 
Clock Time of 
Second 
Operation (s) 
6*10^6 2 100 
Not  
Determined 
Not 
Determined 
100 10^6 150 
Not  
Determined 
Not 
Determined 
100 2 5*10^6 
Not  
Determined 
Not 
Determined 
10^4 2 10^4 490 11.803887 
100 10^4 10^4 1257 839.131357 
10^4 10^4 100 1225 194.179892 
10^3 10^3 10^3 464 42.909076 
3*10^6 2 2*10^2 500 87.75957 
3*10^6 30 100 1182 66.53017 
100 5*10^5 1.5*10^2 1422 268.2744 
150 5*10^5 150 1608 405.3309 
5*10^3 350 5*10^3 473 198.7201 
10^4 200 10^4 476 489.2994 
125 10^4 10^4 1257 1359.073 
150 5*10^3 5*10^3 685 155.3649 
10^4 10^4 150 1257 387.0736 
5*10^3 5*10^3 200 668 105.0412 
100 50 2.5*10^6 1466 1073.131 
10^2 2 2.5*10^6 579 56.26981 
Relative Error or Bias 
The algorithm’s absolute error was calculated to be equal to one minus the average sds 
output of qb.m, over a course of six runs.  Tested at each compass point, the theoretical 
true number of standard deviations of distance that each test point has from center is 
one.  SDs represents the number of standard deviations of distance calculated by the 
algorithm.  Thus, the absolute error of the answer is one minus the average value of sds. 
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Effect of Radfrac & Bootstrap Replication on Average Relative Error: 
Relative error remains constant regardless of the the number of bootstrap replications 
performed or the fraction of points used in generating the hypercylinder (when 
considering elliptical data that has no concavities).  As shown in Figure 26, the average 
percent error remains relatively unchanged as bootstrap replicates increase (across the 
x-axes of each graph) or as radfrac increases (increased from top figure to bottom 
figure). 
 
Figure 26: Average Percent Error As Bootstrap Replications and Radfrac 
Increase 
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Figure 26 Continued 
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Figure 26 Continued 
 
 
Effect of Training Spectrum Size and Dimension on Relative Error:  
Neither training spectrum size nor dimension are significant predictors of relative error. 
Increasing the size of the training spectrum appears to decrease the percent error 
slightly, though it is difficult to say how much of this decrease is due to the inborn error of 
the training spectrum generation by the mvrnd() command and how much of the 
decrease is due to increased competency when the algorithm bootstrap replicates from a 
larger training set of data.  Increasing the number of dimensions of the datapoints in 
question while holding other factors constant appears to slightly increase absolute error. 
These effects are largely negligible, though.  This data is shown in Figure 27. 
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Figure 27:  Effect of Training Spectrum Size and Dimension on Relative Error 
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Figure 27 Continued 
 
 
 
 
 
Effect of Compass Point on Relative Error: 
Compass point is not a significant predictor of relative error.  However, like compass 
points tend to cluster together in terms of relative error due to eccentricities in the 
training set.  The training set largely determines the relative error of each compass point. 
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Figure 28: Average Relative Error As Bootstrap Replicates Increase by Compass 
Point 
Non-principal axis points are marked in red, principal axis points in black, and diagonal 
points in blue. 
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Relative Standard Deviation: 
The algorithm’s relative standard deviation (RSD) was calculated by dividing the 
standard deviation of the six runs by the average distances in SDs of the six runs. 
Relative standard deviation is decreased by increasing the number of bootstrap 
replications run on the data.  Increasing the size of the training spectrum or increasing 
the number of dimensions of the data appears to have no significant effect on the 
relative standard deviation of the output of the algorithm.  This indicates that the 
algorithm handles with equivalent precision increasingly multivariate datasets, as well as 
datasets for which more or less training points were input.  The effect of  radfrac, or 
fraction of points used to generate the hypercylinder on relative standard deviation is low 
in proportion to the effect of bootstrap replication for data that is elliptical, or lacking in 
concavities. Non-linear functions, such as those seen in acoustic data, can create data 
clusters with concavities (e.g., clusters that appear shaped like the letter “c”).  In these 
instances, the influence of radfrac should theoretically be quite great.   Further research 
should be done on data clusters including concavities to determine the nature of this 
effect. 
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 Figure 29:  Relative Standard Deviation as Bootstrap Replicates and Radfrac Increase 
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Figure 29 Continued 
* 
Reseeded with rng(2)
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RSD is Dependent on Training Set 
The relative standard deviation of QBEST’s output is most significantly affected by the 
training set chosen.  In Figure 30, below, three different elliptical clusters of data have 
been randomly generated using the same parameters.  The RSD vs. bootstrap replicate 
graphs below them are three graphs generated from the same training spectrum, but 
bootstrap replicated with a different random number generator seed.  Graphs generated 
from the same training spectrum are nearly identical to one another, but significant 
variation exists between graphs generated from a different training spectrum. 
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 Figure 30: Relative Standard Deviation as Bootstrap Replicates Increase: Effect 
of Training Sample and Random Bootstrap Replicates 
Training Set 1 Training Set 2 Training Set 3 
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Number of Training Points Does Not Significantly Affect RSD 
Figure 31 below shows elliptical clusters with the same parameters but different numbers 
of generated points.  RSD calculations were run in triplicate for each training spectrum 
using a different random number generator seed for the bootstrapping process. 
Changing the training set size does not appear to significantly affect relative standard 
deviation and is not a significant predictor of RSD.  Increasing the number of bootstrap 
replicates even marginally drastically reduces the RSD.  Bootstrap replicate number is a 
far more important factor in the RSD than number of training points. 
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 Figure 31: Relative Standard Deviation as Bootstrap Replicates Increase: Effect 
of Training Set Size and Random Bootstrap Replicates 
rng(1) rng(1) rng(1) 
 
rng(10) rng(10) rng(10) 
rng(20) rng(20) rng(20) 
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Relative Standard Deviation as TNSPEC and Dimension Increase: 
 
RSD is not significantly affected by the training spectrum size or dimension increase. 
Neither of these are significant predictors of RSD. 
 
Figure 32: Relative Standard Deviation as Training Set Size and Dimension 
Increase 
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Figure 32 Continued 
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Mahalanobis Comparison 
 
 
Figure 33: Standard Circle Used for Mahalanobis vs. BEST Comparison 3  
When the number of samples greatly exceeds the number of dimensions (independent 
variables), the BEST and the Mahalanobis metrics produce similar answers. 
Theoretically, the on-axis points (1,3, and 5) should be 1 SD from the center while the 
off-axis points (2,4, and 6) should be 1.414 SD away.  
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Figure 34: Comparison of Mahalanobis and BEST to Actual Distance when 
Dimension is Low and Number of Samples is High 
With only 2 dimensions (independent variables) and 100 samples from a synthetic 
N(0,1) distribution, the accuracy of the BEST metric is about the same as the 
Mahalanobis metric.  The error in the red and green lines comes from the 100 
randomly selected samples poorly representing the N(0,1) distribution.  The variation 
from run to run largely results from differences in the training set. 
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Figure 35: Accuracy and Precision of the BEST and Mahalanobis Metrics Using 
an N(0,1) Synthetic Data Set 
In this experiment, the number of samples (rows) always exceeded the number of 
dimensions (columns) by 2.  The Mahalanobis metric can be very wrong. 
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Figure 36: Run Time of Mahalanobis and QBEST as Dimension Increases 
The running time of the BEST calculation is n2 faster than the Mahalanobis even 
without parallelization. 
 
Discussion: 
Equal Precision for Small and Large Datasets 
Relative error is slightly decreased when the number of training points input are 
increased, but precision as measured by the relative standard deviation of the output is 
unaffected.  This indicates that QBEST is capable of calculating multivariate standard 
deviation units with predictable error for both small and large datasets.  QBEST is ideal 
for extrapolation from small datasets, as it is able to process these with nearly the same 
precision as large datasets. 
 
Influence of Bootstrap Replication 
For elliptical data, bias remains constant regardless of the the number of bootstrap 
replications, but  relative standard deviation of the algorithm’s output is decreased by 
increasing the number of bootstrap replications run on the data.  This indicates that the 
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number of bootstrap replications does not significantly affect the accuracy of the 
algorithm’s measurements, but by increasing the number of bootstrap replications, the 
user can ensure greater precision and a more consistent output from run to run.  
Influence of Dimension 
For data with very large numbers of dimensions, it is important that the training set size 
be increased to offset increasing bias. 
Influence of Radfrac 
For this elliptically-distributed data that has no concavities, bias remains constant 
regardless of the fraction of points used in generating the hypercylinder.  The effect of 
radfrac, or fraction of points used to generate the hypercylinder on relative standard 
deviation is low, as is to be expected with symmetrically-dispersed data.  In other words, 
it is safe to use a radfrac of 1.0, all of the data points in the cluster, for elliptical data.  
Relative Error 
Bias remains constant regardless of the the number of bootstrap replications performed 
or the fraction of points used in generating the hypercylinder (when considering elliptical 
data that has no concavities).  
 
Increasing the size of the training spectrum appears to decrease the bias slightly, though 
it is difficult to say how much of this decrease is due to the inborn error of the training 
spectrum generation by the mvrnd() command and how much of the decrease is due to 
increased competency when the algorithm bootstrap replicates from a larger training set 
of data.  Increasing the number of dimensions of the datapoints in question while holding 
other factors constant appears to slightly increase bias. 
Relative Standard Deviation (RSD)  
The algorithm’s precision was calculated by dividing the standard deviation of the six 
runs by the average sds of the six runs.  Relative standard deviation is decreased by 
increasing the number of bootstrap replications run on the data.  Increasing the size of 
the training spectrum or increasing the number of dimensions of the data appears to 
have no significant effect on the relative standard deviation of the output of the algorithm. 
This indicates that the algorithm handles with equivalent precision increasingly 
multivariate datasets, as well as datasets for which more or less training points were 
input.  
 
The effect of  radfrac, or fraction of points used to generate the hypercylinder on relative 
standard deviation is low in proportion to the effect of bootstrap replication for data that is 
elliptical, or lacking in concavities. Non-linear functions, such as those seen in acoustic 
data, can create data clusters with concavities (clusters that appear shaped like the letter 
“c”).  In these instances, the influence of radfrac should theoretically be quite great. 
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Further research should be done on data clusters including concavities to determine the 
nature of this effect. 
 
Influence of Training Spectrum 
The most important factor that influences relative standard deviation of the QBEST 
output is the quality of the training set.  The particular points chosen for the training set 
can cause a great deal of variability in the relative standard deviation of the output.  This 
is to be expected, because good results require good data input.  
 
  
 
92
CONCLUSION 
Summary of Chapters 
Chapter 1 
Summary: Chapter 1 introduced the QBEST method and compared it in general to the 
Mahalanobis method. 
 
QBEST is a statistical algorithm for discriminant cluster analysis, and is the basis for 
qb.m, a program written in Matlab (and currently being translated into Python 2.7) for 
testing whether a test sample varies from a training set, library of spectra, or other 
multivariate data.  A bootstrap replication method is used to generate a hypercluster 
from training spectra samples and the QB program calculates the probability that the test 
sample is the same as the training samples by measuring the distance of the test sample 
from the center of the hypercluster in multidimensional skew-adjusted nonparametric 
standard deviations.  The method allows for differential directional weight of different 
variables.  
Chapter 2 
Summary: Chapter 2 outlined the method of research for the following chapters and 
discussed the application of quantile bootstrap (QB) methods to the problem of 
estimating the No Observed Adverse Effect Level (NOAEL) of a New Molecular Entity 
(NME) to anticipate a safe starting dose for beginning clinical trials. An estimate of the 
NOAEL from the extended QB method (called the QNOAEL) can be calculated using 
multiple disparate studies in the literature and/or from laboratory experiments.  The 
QNOAEL of ellagic acid was calculated using this method in Chapter 4, and is the ADI 
(Acceptable Daily Intake).  
 
Significance: The QNOAEL is similar in some ways to the Benchmark Dose (BMD) and 
is superior to the BMD in others. The Benchmark Dose method is currently widely used 
in toxicological research. Results are used in a meta-analysis simulation based on 
nonparametric cluster analysis methods to calculate confidence levels on the difference 
between the Effect and the No Effect studies. The QNOAEL simulation generates an 
intuitive curve that is comparable to the dose-response curve. The QNOAEL of ellagic 
acid (EA) was calculated in Chapter 4 for clinical trials of its use as a component 
therapeutic agent (in BSN476) for treating Chikungunya infections. This is the first 
application of QB to the problem of NOAEL estimation for a drug.  
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Chapter 3 
Summary: Chapter 3 describes the determination of the Estimated Daily Intake (EDI) of 
ellagic acid.  The purpose of this paper was to determine how much ellagic acid is 
consumed daily by the average American to serve as a baseline safe dose for human 
clinical trials.  The United States Food and Drug Administration (FDA) describes food 
stuffs as “Generally Recognized as Safe” (GRAS) at some level (the ADI or less).   For 
example, many GRAS products are classified as dietary supplements, which require less 
testing than drugs.  Products that are GRAS typically do not require the manufacturers to 
repeatedly conduct the same battery of toxicity testing and clinical trials that drugs need 
to have to be be FDA-approved. 
 
Ellagic acid is a major component of BSN476.  It is also a naturally-occurring polyphenol 
found in fruits and nuts.  In this paper, the mean EDI of ellagic acid was determined to be 
69.58 micrograms/person/day or 1.05 micrograms/kg body weight/day.  The 90th 
percentile EDI was determined to be 258.33 μg/person/day or 3.89 μg/kg body 
weight/day, far less than the ADI and QNOAEL.  This provides support for starting any 
human clinical trial of BSN476 at a daily dose containing a comparable amount of ellagic 
acid to the 95th percentile of ellagic acid consumption.  Ellagic acid is safe in the food 
supply at a dose of 3.89 micrograms/kg body weight/day, so as long as there are no 
interactions between other components of the drug, there should be no concerns of 
toxicity to humans.  Having demonstrated the expected daily intake of ellagic acid, there 
is little reason for any initial toxicity tests of ellagic acid before studies proceed to clinical 
trials. 
 
Significance: The 90th percentile daily intake of a chemical occurring naturally in the 
food supply should be indicative of a safe dose for PK/PD.  This number provides 
evidence for the level of a compound as Generally Recognized as Safe and represents 
an upper threshold for the starting dose in human clinical trials.  This data analysis 
indicated that the 90th percentile expected daily intake of ellagic acid is 3.89 
micrograms/kg body weight/day.  Future PK human trials therefore should be started at a 
dose equal to or less than 3.89 micrograms/kg body weight/day. 
Chapter 4 
Summary: In Chapter 4, the acceptable daily intake has been extrapolated from animals 
studies treated with the QBEST to yield a QNOAEL of 32.8 mg/kg body weight/day.  The 
ADI reinforces the assertion that conducting a PK trial below the EDI should be a safe 
approach to formulation development.  Chapter 3 demonstrated that ellagic acid is a safe 
component of the food supply up to a dose of 3.89 μg/kg body weight/day (which was 
determined as a safe dose because it is the 90th percentile daily intake of ellagic acid 
from the food supply).  In this chapter, the acceptable daily intake of ellagic acid was 
calculated to be 32.8129 mg/kg/day.   Human clinical studies should be started at a 
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value below the 90th percentile estimated daily intake, well below the QNOAEL.  Taken 
together, these two chapters form the basis for an exploratory IND filing at the FDA to 
expedite formulation testing for human clinical trials. 
 
Significance: More than simply providing this specific opportunity to expedite the testing 
of BSN476 and to avoid early costly toxicity testing of a formulation, this chapter is 
important because it specifically provides proof of concept that QBEST and discriminant 
cluster analysis can be applied to obtain QNOAELs.  QBEST is superior to the current 
standard practice of safety data analysis.  It allows for the meta-analysis of data that has 
already been generated by numerous small studies, increasing the statistical power of 
small studies by bootstrap replication from numerous small studies.  The QBEST method 
of generating QNOAELs clearly solves numerous scientific issues encountered when 
calculating a traditional NOAEL.  QBEST can be used to determine with statistical 
confidence limits the highest dose of a drug that will cause no adverse effect; traditional 
NOAELs are determined by simply increasing an administered dose by arbitrary 
increments until an adverse effect is noted.  Whatever highest dose was administered 
that is less than the lowest adverse effect dose is considered to be the NOAEL. 
NOAELs can never be determined to be anything other than an exact dose which was 
administered, so the NOAEL determination is imprecise.  Furthermore, it is difficult to 
meta-analyze NOAELs, so to increase the precision of a NOAEL test, a completely new 
test would be required. 
 
The current alternate method to safety determination is the Benchmark Dose Method 
(BMD).  The BMD is determined by administering increasing doses of a pharmaceutical 
until a specific physiological response is elicited.  The benchmark dose is considered to 
be the dose at which it is likely that a given response will occur.  The BMD can be used 
to meta-analyze multiple studies, but can generate confusing and non-intuitive response 
curve when there are conflicting results of studies.  QBEST solves this problem by 
generating a single QNOAEL from an array of studies in a simulation.   Finally, 
QNOAELs remove the subject bias from study weighting that accompanies any 
meta-analysis.  The bootstrapping algorithm causes there to be no need to subjectively 
assign weights to studies. QBEST naturally causes the typical studies to outweigh the 
outlier studies through a simple rule of probability. 
 
Chapter 5 
Summary: Chapter 5 covered the Round-the-Compass Rose experiment which validates 
that the QBEST is capable of handling non-spherical distributions of data, like that used 
in the ADI calculation, accurately and reproducibly.  It also proves the concept that this 
algorithm can be used for very large datasets even on a personal laptop computer, 
unlike the Mahalanobis distance.  
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The purpose of this experiment was to explore sources of bias in the output of the QB 
program.  To that end, synthetic data with known parameters were generated and the 
output number of distances in standard deviation units calculated by the QB program 
was analyzed for consistency and accuracy.  Furthermore, symmetrical elliptical clusters 
of data were analyzed in order to determine whether compass location around the 
cluster significantly affected consistency or accuracy of the algorithm’s output. 
 
It was determined that the most significant factor that affects the algorithm’s accuracy is 
the training spectrum used, which makes intuitive sense.  Accurate results require good 
input data.  The training set must accurately reflect the population that it seeks to 
represent.  Average bias is largely unaffected by the number of bootstrap replicates 
used.  Percent error is largely unaffected by the training set size.  QBEST is capable of 
calculating with accuracy even when input parameters are at the extremes.  Relative 
standard deviation of the algorithm’s outputs is reduced when the number of bootstrap 
replicates is increased. 
 
Significance:  The specific aim of Chapter 5 is to evaluate the accuracy and precision of 
the QB Simulation.  The differential directional weight is a key attribute of the QB 
program, as the direction of skew of a sample from the training sample may shed light on 
the nature of an impurity.  This concept can be illustrated by the following: in an elliptical 
cluster of training points, there is a "long axis" - that is, an axis in which greater deviation 
can be expected from the mean, as well as a "short axis" along which training points are 
tightly clustered and little variation is expected of a pure sample in keeping with the 
training samples.  The QB program is able to analyze points along any axis of any 
n-dimensional cluster of training points and determine whether significant skew exists 
along any of those axes. Before this work, only data clusters having an equivalent 
standard deviation along all vectors - that is, circular, spherical, or similar n-dimensional 
data clusters -  had been analyzed.  This work was the first to analyze the performance 
of QBEST when faced with clusters having non-equal standard deviations along two 
axes.  The differential handling of data on the left versus right-hand side of the center of 
the cluster is the most important improvement of QBEST over the Mahalanobis equation; 
this experiment paves the way for future experiments exploring data that are 
asymmetrically distributed on either side of the center (unlike the ellipses used in this 
experiment). 
 
Future Applications: 
QBEST represents a significant improvement over the Mahalanobis equation for the 
nonparametric analysis of multivariate data.  The most notable improvements are (1) that 
QBEST calculates standard deviation units separately for points to one side or the other 
of center (asymmetrical determination of standard deviation units); (2) QBEST is 
mathematically capable of determining with accuracy the QBEST distance even when 
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the number of observations are fewer than the number of dimensions or variables of the 
data; and (3) QBEST requires d 2  less computing power than the Mahalanobis equation. 
These improvements are functionally important, respectively, because: 
 
1) Calculating the symmetrical Mahalanobis distance introduces inaccuracy when 
the cluster being evaluated is asymmetrically distributed.  The Mahalanobis 
equation is insufficient for evaluating data that are not symmetrically distributed 
along any given line.  Real-world data does not tend to be symmetrically 
distributed.  Furthermore, the tailing observed in data clusters can show 
important information about a dataset.  It is inappropriate to ignore the distribution 
of points differently along the “left and right hand” vectors from the center of the 
data distribution to a given test point. 
2) It is mathematically impossible to utilize the Mahalanobis equation to determine a 
Mahalanobis distance when the number of datapoints or observations are far less 
than the number of dimensions or variables measured describing the data.  The 
Mahalanobis equation relies on matrix factorization that cannot be performed in 
this instance.  This means that the Mahalanobis equation cannot be utilized to 
evaluate, for example, all of the data gathered by a handful of clinical trials with 
one hundred endpoints each; the infrared spectra of a hundred duplicate 
chemical samples taken at ten-thousand wavelengths; or the massive amounts of 
data processed by an artificial intelligence program that it uses to make 
decisions.  When the number of variables is close to the number of observations, 
but still exceeds the number of observations, QBEST is often more accurate. As 
the number of observations approaches the number of variables, the 
Mahalanobis distance becomes increasingly inaccurate.The QBEST Equation is 
capable of solving these mathematical problems and as yet unimagined others 
as our world rapidly becomes dependent on larger and more complicated 
massive data sets.  In this way, QBEST is the statistical equation of the future. 
3) Even if the number of observations required by the Mahalanobis equation is met, 
the number of dimensions of data that can be analyzed in a reasonable amount 
of time is severely limited.  The Mahalanobis equation is an order of d 3  algorithm, 
which means that for every d dimensions increased in the data, the computer will 
need d 3  more computing power to solve for the Mahalanobis distance.  In 
comparison, QBEST is an order of d algorithm.  Computing power equates to run 
time for a given processor.  Simply stated, a QBEST distance that could be run in 
an afternoon on a typical personal computer would have to be run on a 
supercomputer to be solved with the Mahalanobis equation in the same amount 
of time.  In Chapter 5, it was determined that a typical laptop personal computer 
can calculate the QBEST distance for data with 6*10 6  dimensions in 
approximately twenty minutes or less.  It is difficult to imagine any current 
pharmaceutical application which would require 6*10 6  dimensions of data, but 
this is an emerging problem in the physical and computer sciences.  However, as 
medical monitoring becomes more advanced, an increasing amount of data will 
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be generated and stored, particularly in the case of biological parameters which 
are continuously monitored.  The analysis of increasingly massively multivariate 
data is a serious emerging problem in statistics.  QBEST provides the best 
solution to this problem at present. 
 
Applications in Pharmaceutical Science: 
As pharmaceutical science and computer science progress, Big Data continue to get 
bigger.  Unfortunately, computing power is not improving as quickly as the capability to 
generate information, leaving scientists and businessmen alike with an information 
surplus.  Before QBEST, there was not an algorithm capable of discriminant cluster 
analysis on massively multivariate data that could be run on a personal computer.  In 
practical terms, QBEST can process with accuracy a handful of instances of 
million-dimensional data.  This capability will allow scientists at startup research 
companies and university researchers, including students, to perform the kind of 
calculations that traditionally required the use of a supercomputer. 
 
At present, most pharmaceutical data are generally not considered to fall under the 
umbrella of Big Data, or databases consisting of hundreds of thousands of datapoints 
with thousands of variables, but the trend of technology in medicine is moving toward Big 
Data.  Currently, insurance databases and hospital databases do fall into the category of 
big data.  Pharmaceutical companies, health care providers, and public policy makers 
draw on these massive databases to make generalizations about populations and enact 
policy changes.  The push towards personalized medicine will also require the analysis 
of big data problems increasingly in the future.  
Big Data in Health Insurance 
Major insurance providers now complement their own massive databases by purchasing 
additional databases from commercial vendors.  This strategy is necessary to be 
competitive in the modern market 2 .  The decisions that insurers make regarding care has 
a tremendous impact on the treatment chosen for a given patient, particularly as the 
industry pushes wellness incentives as a cost-saving measure. 
 
Humana’s proprietary algorithm, the Anvita Engine™, analyzes basic wellness 
measurements, such as weight, heart rate, BMI, etc. measured over time and makes 
predictions about possible chronic conditions that the patient could develop, based on 
patterns of disease progression noted in a training sample of patients 5,6 .  The algorithm 
then places flags in the patient’s online medical file that appear to any physician who 
bills the insurance 5,6 .  These flags suggest that the doctor perform various routine tests 
or recommend preventative medicine for the patient.  If performed, the treating physician 
is paid a fee by the insurer 5,6 .  This is only one of the first generation of algorithms storing 
and comparing massively multivariate patient data to make treatment decisions for a 
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patient.  These databases grow larger and more sophisticated each year.  As the scope 
of data analysis increases, it is necessary to have statistical algorithms capable of 
keeping pace while making accurate decisions for patient care. 
 
On the surface, algorithms such as Humana’s Anvita Engine appear to work using only 
information recorded by a patient’s doctor.  In reality, major insurers pool information 
from all of their patients for training sets, and actually purchase databases of outside 
information from commercial vendors and compile this information when making 
predictions for a given patient.  Some examples of the types of databases bought by 
major insurers are as follows:  
● Store loyalty card information - Major grocery store chains maintain records of 
grocery purchases.  Healthy and unhealthy foods, cigarettes, alcohol, pregnancy 
tests, prophylactics, prescriptions, over-the-counter medicines, and pharmacy 
purchases made at grocery store chains using the store loyalty or discount card 
are stored in the corporate database.  Grocery store chains such as Kroger, 
Safeway and Target use this information when sending out personalized coupons 
and deals.  There is a great deal of money to be made in predicting certain 
medical conditions, and then in marketing to that prediction.  Target has openly 
admitted to predicting which of its customers are pregnant as early as possible so 
that it can mail coupons for large-ticket baby necessities, such as cribs, before 
the shopper has the opportunity to purchase those items from a competitor 4 .  In 
fact, Target’s loyalty card algorithm is so accurate that it has been documented to 
have predicted a woman’s pregnancy before her family was made aware of it 4 .  A 
Target spokesperson has confirmed that Target’s shopper algorithm can predict 
not only pregnancy, but also the trimester of a customer’s pregnancy with 
accuracy from a single shopping visit 4 .  Pregnancy is not the only condition that a 
store chain has the impetus to monitor; consider that major retailers of exercise 
equipment, orthotics, and prescription medications also collect shopper data. 
● Social Media - Some insurance companies are purchasing databases from social 
media sites such as Facebook. One Facebook algorithm keeps track of a user’s 
mood based off of whether his posts seem to be positive or negative 7,8,9 .  In a 
recent scandal, Facebook was accused of performing unethical research on 
unwilling subjects by altering the number of positive or negative posts a user saw 
on his news feed and then monitoring the user’s mood over time 7,8,9 .  Social 
media posts have the potential to provide incredible insight into the risk of 
insuring a potential policyholder, as they include information about the person’s 
habits, including drinking, tobacco use, recreational drug use, mental health, 
sexual activity and orientation, current health conditions, and all of the 
aforementioned information as it relates to the user’s relatives.  Harnessing 
Facebook’s mood algorithm could prove extremely valuable in the treatment of 
depression, suicidal tendencies, and other mental disorders.  
● Phone Applications or “Apps” - Numerous applications exist for smartphone 
users wishing to monitor their personal health.  Some are free, while others are 
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paid services that collect and analyze daily health information.  Various insurers 
have contracts with various app makers to receive databases of these user 
reports 2 . 
● Commercial Fitness Devices - According to a recent report, John Hancock has a 
standing contract with Vitality that integrates wellness initiatives into its life 
insurance policies 2 .  Policyholders can earn discounts on their life insurance 
policies if they register internet-connected commercial wellness devices, such as 
FitBits 2 .  In this way, John Hancock is using big data analysis when analyzing 
basic vital signs of policy holders and comparing them to standards of healthy 
and at-risk patients 2 . 
● Workplace Wellness Programs - Workplace wellness programs are 
company-instituted programs that encourage employees to increase their 
fitness 1 .  These programs are largely unregulated with very lax privacy laws, as 
they are not subject to HIPAA or to the provisions of Obamacare that prevent 
premium discrimination on the basis of pre-existing conditions 1 .  Increasingly, 
workplace wellness program data are being used to increase the costs of 
company insurance by up to 30% for overweight or otherwise unhealthy 
non-tobacco using employees 1 .  Associations such as the American Diabetes 
Association warn that under the guise of giving monetary incentive for healthy 
employees, employers are legally penalizing people with chronic conditions such 
as diabetes by increasing the cost of their health insurance, leading to decreased 
access to medical care for people with chronic and pre-chronic conditions 1 .  
 
Algorithms owned by data-mining companies piece together and re-identify consumer 
information, attempting to pair consumers to their respective identities as insurance 
customers.  This is an easy task in the case of store loyalty cards, social media 
accounts, and personal health devices, since these things are tied to consumer names, 
addresses, and/or phone numbers.  However, for those databases of truly de-identified 
data, there are algorithms capable of re-identifying particular consumers.  In this way, the 
insurance company stores a comprehensive database of not only strict health 
information, but also related dietary health, wellness, and behavioral risk information for 
each of its customers.  There is a large push in the industry now to develop newer and 
more powerful methods of analyzing and using this data to increase profits, either by 
adjusting policy payments for at-risk policy holders, or by implementing wellness 
programs that include preventative medicine and health screenings.  Additionally, 
de-identified but localized data can shed light on the health of particular populations, 
such as the alcohol consumption across a particular zip code, or the purchases of 
populations of various racial compositions. 
 
 
 
100
Big Data in Personalized Medicine 
Personalized medicine, the process of tailoring treatment to the individual patient on the 
basis of metrics relating to that patient, is also an emerging necessity in the industry. 
Some pharmaceutical devices have already begun to move toward the storing of 
continuous health data for patients; this is most clearly seen in the blood glucose 
monitoring systems and paired insulin pumps that have been developed for Type I 
diabetics. Recall from Chapter 1 that any variable with continuous monitoring can be 
represented as a multivariate data point with coordinates at each time point (or 
wavelength in the case of spectral data).  As more health endpoint monitors become 
continuous (such as heart rate monitors, blood content monitors, physical exercise 
monitors, and neurological activity monitors), more data will be generated for each 
individual patient, which can be utilized in care decisions.  Even now, Fitbits™ and smart 
devices continuously monitor basic vital signs.  Most of these devices have their own 
apps that can be synced with physician’s offices, but there is a large push to make a 
universal record keeping system that can store the information generated by all of these 
devices and make comparisons across the patient population. 
 
This massive amount of information is useless, however, unless baselines are 
established for a particular patient and deviations from that baseline are monitored. 
QBEST answers the important question: Does the current state differ significantly from 
the baseline training set of data?  QBEST allows a chunk of daily data - either in blood 
glucose patterns or general vital signs - to serve as a training set, while the present 
measurements could be used as a test set.  QBEST would then detect whether there 
was a significant difference between the spectra of patient’s current status and the blood 
glucose spectra corresponding to the last finger stick.  It could also compare a 
significantly different result with training sets of known glucose levels or disease states 
and suggest what problem was developing in the patient. 
 
Big Data in Safety Analysis 
Finally, QBEST has the potential to revolutionize analysis of toxicology data.  Risk is an 
important factor in the regulation of pharmaceuticals.  Initially, determinations of risk vs. 
benefit form the basis of FDA decisions regarding the approval and marketing of a new 
pharmaceutical, including its on-label usage, dose, and black box warnings. 
Post-marketing, risk plays strongly into civil suits when an injury has occurred, allegedly 
caused by a pharmaceutical agent. QBEST offers a method for the statistical 
determination of risk.  As demonstrated in Chapter 4, QBEST can be used to determine 
a 98% confidence limit QNOEL of a drug, or a dose that would cause no observed 
effects 98% of the time if the same studies were to be repeated.  Pre-marketing, QBEST 
can be used to inform executive decisions regarding the safety of a pharmaceutical and, 
as demonstrated in this work, can help to clarify the therapeutic window. 
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Post-marketing, QBEST can assist in retrospective analysis of what was known about 
the safety of a pharmaceutical agent at the time it was administered (a key component of 
pharmaceutical and other toxic exposure lawsuits) by simply performing an analysis with 
all data published at the time of the incident. 
Applications in Computer Science and Robotics 
Future applications of the QBEST will likely involve Artificial Intelligence and adaptive 
resonance.  When does a neural net need to be re-trained?  QBEST could provide an 
answer.  With the QBEST, it is now possible to solve mathematical problems not even 
dreamed of before.  QBEST’s efficient computation makes it an ideal algorithm that can 
compute six million bootstrap replications, find significant differences in data with one 
million dimensions, or process 5 million training data points on a cheap laptop computer. 
This convenient method of quickly analyzing health data will become integral in 
personalized medicine. 
 
Weaknesses of QBEST and Further Work that Must Be Done 
Though QBEST represents a significant improvement over the Mahalanobis equation 
and fulfills a similar purpose, there are still some datasets which would be handled very 
ineffectively by QBEST.  Nonlinear data sets present potential problems.  Take for 
example the figure below:  
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Figure 37: An Example of a Poor Dataset for Application of QBEST  
The above data cluster has an obvious concavity.  The red star marks the center of the 
cluster as calculated by QBEST and the green point is a theoretical test point.  Note 
that if a QBEST “rubber ruler with a nail in the center” were drawn from the center to 
the green test point, no other points would fall along the ruler unless the width of the 
ruler (radfrac) was very great. 
 
In the above example, QBEST would generate a poor QBEST distance between the 
calculated center and the green test point.  There is not a linear relationship between the 
x axis and the y axis.  Use of QBEST is not advisable when the test point falls on the 
other side of a concavity from center in the data.  It is also not advisable to use QBEST 
when an obvious visual pattern in the data would indicate that there are zones where 
points should not ever fall in space (for example, if data were following a sine curve, 
there would be obvious concavities in the data following a clear visual pattern).  These 
types of nonlinear patterns are difficult for the algorithm to handle because QBEST 
assumes that the center of the data cluster actually falls within the data cluster.  Before 
using QBEST, the analyst should graph the data and visually inspect the clusters.  As 
with any statistical analysis method, the analyst should plot all combinations of variables 
against one another and determine that nothing contraindicates use of the QBEST 
method. 
 
It has been suggested by a colleague that QBEST could be improved upon by defining 
the center of the data cluster differently 10 .  Rather than finding the average coordinate 
value on each axis and defining that point as the center (as was done in the example 
above), it is possible to define coordinate space as the area inside of a multidimensional 
figure 10 .  Then, the calculated center of the data would be forced to fall within the defined 
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coordinate space 10 .  In this way, the center of the data could never be calculated to fall 
within a concavity of the figure 10 .  This method is in keeping with the Principal Curve 
Method, which calculates a center curve through a gray zone and measures points back 
orthogonally 3 .  A similar definition of coordinate space could be used in the QBEST 
distance calculation.  QBEST is not currently written to do this, but could be.  However, it 
would probably be better to use a central curve (or a 1-D manifold) as in Hastie et al 3 . 
See Figure 38, below. 
 
 
Figure 38: An Example of Coordinate Space Redefined for Purposes of 
Calculating the Center of a Data Cluster  
 
It should be noted, however, that QBEST can in fact be used to calculate a QBEST 
distance in the given example (Figure 37).  The test spectrum is defined as the point 
(2,1).  The QBEST distance is 2.2976 standard deviation units, with 2.8302 standard 
deviation units of skew. 
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APPENDICES: 
 
Appendix A: Equations 
The Mahalanobis equation: 
The Mahalanobis distance of an observation from a set of  
 
observations with mean  
 
 
and covariance matrix S is defined as: 
 
 
 
Equation Source:  
R. De Maesschalck, D. Jouan-Rimbaud, D.L. Massart. “The Mahalanobis distance.” 
Chemometrics and Intelligent Laboratory Systems. Volume 50, Issue 1, 
2000, Pages 1-18. ISSN 0169-7439. <https://doi.org/10.1016/S0169-7439(99)00047-7> 
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Appendix B: Computer Programs 
QBEST Algorithm: 
REPLICA 
function [BTRAIN,CNTER]=replica(TNSPEC,B) 
% TNSPEC=training spectra, B=number of replicates desired. 
% REPLICA outputs BTRAIN replicates, and the center of the replicates in CNTER 
% "Copyright 2003 Robert A. Lodder & Bin Dai" 
[N,D]=size(TNSPEC); 
BTRAIN=zeros(B,D); 
CNTER=zeros(D,1); 
BSAMP=zeros(N,D); 
PICKS=rand(B*N,1); 
index=find(PICKS==1); 
PICKS(index)=0.9999; 
PICKS=reshape(PICKS,B,N); 
PICKS=fix(N*PICKS+1); 
for I=1:B 
BSAMP=TNSPEC(PICKS(I,:),:); 
BTRAIN(I,:)=sum(BSAMP)/N; 
end 
BTRAIN; 
CNTER=sum(BTRAIN)/B; 
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SOB 
function [ECDF,TCDF,R]=SOB(BTRAIN,CTN,NTN,TESTSPEC) 
% This routine takes 2 spectral groups (with = numbers of samples) 
% and calculates an ECDF and TCDF for QQ plotting. The routine 
% also returns a correlation coefficient between the 2 CDFs. 
% Training replicates and center must be provided, along with 
% test spectra. BNUM = the number of replicates used. 
% Note: you may have to set EPSILON(1e-200) or greater to prevent 
% underflow errors in high dimensional hyperspaces 
% Copyright 2003 Dr. Robert.A.Lodder & Bin Dai 
[NTEST,C]=size(TESTSPEC); 
[BTEST,CTEST]=replica(TESTSPEC,NTN); 
[M,C]=size(BTRAIN); 
p=0.1; 
CTNN=repmat(CTN,M,1); 
ST=(sum(((BTRAIN-CTNN).^C)')).^(1/C); 
CTNN=repmat(CTN,NTN,1); 
SX=(sum(((BTEST-CTNN).^C)')).^(1/C);  
M=2*M; 
TRIM=fix((M*p)+1):fix(M-(M*p)); 
ECDF=[ST,SX]; 
TCDF=[ST,ST]; 
ECDF=sort(ECDF); 
TCDF=sort(TCDF); 
ECDF=ECDF(TRIM); 
TCDF=TCDF(TRIM); 
R=corrcoef(TCDF,ECDF) 
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Estimated Daily Intake Programs: 
EDI 
 
function [zarray] = EDI(serving_sizes,dose,age,day1,day2,mass) 
%% This function solves for Expected Daily Intakes (EDIs) using the NHANES and 
FNDDS databases. 
% This program requires that the “NHANES basic startup workspace.mat” workspace be 
present. 
% The programs searchnzero, searchfoods.m, and searchsizes.m must all be in 
% the working directory path. 
% serving sizes = in rows to target_codes, 1st col.=food codes, 2nd 
%                 col. = serving sizes in g 
% dose is a scalar variable specified by the client 
% age, day1, day2, and mass are all in the “NHANES basic startup workspace.mat” 
workspace 
% zarray returns the mean mass of all ages just to put something into the output variable 
and avoid an error 
% 
% Start with all patient sequence numbers in age groups 
% Time to make food code tables for each group 
% 
% loop through Day1 and check each row to see if the SEQN in the first column is in the 
set of SEQN for each age group 
% if so, leave the row as is. if not, then replace the row with all zeros and eliminate the 
zeros later 
% get all foods consumed by each age group 
target_codes = serving_sizes(:,1); % target_codes is a vector food codes of length = 
number of rows in serving_sizes 
% find the infant groups 
ind_age0_1 = find((age(:,2)>0)&(age(:,2)<13)) ; 
age0_1=age(ind_age0_1,1); 
disp('Number of infants aged 0-1') 
size(ind_age0_1) 
ind_age1_2 = find((age(:,2)>14)&(age(:,2)<24)); 
age1_2=age(ind_age1_2,1); 
disp('Number of toddlers aged 1-2') 
size(ind_age1_2) 
ind_age2_5 = find((age(:,2)>23)&(age(:,2)<61)); % create indexes for age groups, ages 
are given in months, not years 
age2_5=age(ind_age2_5,1);  
disp('Number of subjects aged 2-5') 
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size(age2_5) 
ind_age6_12 = find((age(:,2)>62)&(age(:,2)<145)); 
age6_12=age(ind_age6_12,1); 
disp('Number of subjects aged 6-12') 
size(age6_12) 
ind_age13_19 = find((age(:,2)>146)&(age(:,2)<229)); 
age13_19=age(ind_age13_19,1); 
disp('Number of subjects aged 13-19') 
size(age13_19) 
ind_age20_up = find((age(:,2)>229)); 
age20_up=age(ind_age20_up,1); 
disp('Number of subjects aged 20 and up') 
size(ind_age20_up) 
% find all ages > 2 years 
ind_age2up = find((age(:,2)>23)&(age(:,2)<2000)); 
age2up=age(ind_age2up,1); 
disp('Total number of subjects aged 2 and up') 
size(ind_age2up) 
% Day 1, delete entries not in specified age group 
day1_age0_1 = searchnzero(age0_1,day1); 
day1_age1_2 = searchnzero(age1_2,day1); 
day1_age2_5 = searchnzero(age2_5,day1); 
day1_age6_12 = searchnzero(age6_12,day1); 
day1_age13_19 = searchnzero(age13_19,day1); 
day1_age20_up = searchnzero(age20_up,day1); 
day1_age2up = searchnzero(age2up,day1); 
% Day 2 
day2_age0_1 = searchnzero(age0_1,day2); 
day2_age1_2 = searchnzero(age1_2,day2); 
day2_age2_5 = searchnzero(age2_5,day2); 
day2_age6_12 = searchnzero(age6_12,day2); 
day2_age13_19 = searchnzero(age13_19,day2); 
day2_age20_up = searchnzero(age20_up,day2); 
day2_age2up = searchnzero(age2up,day2); 
% throw away all food codes for each age's dietary data that are not in the targeted food 
code list 
% 
day1_fc_age0_1 = searchfoods(day1_age0_1,target_codes); 
day1_fc_age1_2 = searchfoods(day1_age1_2,target_codes); 
day1_fc_age2_5 = searchfoods(day1_age2_5,target_codes); 
day1_fc_age6_12 = searchfoods(day1_age6_12,target_codes); 
day1_fc_age13_19 = searchfoods(day1_age13_19,target_codes); 
day1_fc_age20_up = searchfoods(day1_age20_up,target_codes); 
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day1_fc_age2up = searchfoods(day1_age2up,target_codes); 
% 
day2_fc_age0_1 = searchfoods(day2_age0_1,target_codes); 
day2_fc_age1_2 = searchfoods(day2_age1_2,target_codes); 
day2_fc_age2_5 = searchfoods(day2_age2_5,target_codes); 
day2_fc_age6_12 = searchfoods(day2_age6_12,target_codes); 
day2_fc_age13_19 = searchfoods(day2_age13_19,target_codes); 
day2_fc_age20_up = searchfoods(day2_age20_up,target_codes); 
day2_fc_age2up = searchfoods(day2_age2up,target_codes); 
% 
disp('Number of subjects eating target food on Day 1 aged 0-1') 
size(day1_fc_age0_1) 
disp('Number of subjects eating target food on Day 1 aged 1-2') 
size(day1_fc_age1_2) 
disp('Number of subjects eating target food on Day 1 aged 2-5') 
size(day1_fc_age2_5) 
disp('Number of subjects eating target food on Day 1 aged 6-12') 
size(day1_fc_age6_12) 
disp('Number of subjects eating target food on Day 1 aged 13-19') 
size(day1_fc_age13_19) 
disp('Number of subjects eating target food on Day 1 aged 20 and up') 
size(day1_fc_age20_up) 
disp('Number of subjects eating target food on Day 1 aged 2 and up') 
size(day1_fc_age2up) 
% 
disp('Number of subjects eating target food on Day 2 aged 0-1') 
size(day2_fc_age0_1) 
disp('Number of subjects eating target food on Day 2 aged 1-2') 
size(day2_fc_age1_2) 
disp('Number of subjects eating target food on Day 2 aged 2-5') 
size(day2_fc_age2_5) 
disp('Number of subjects eating target food on Day 2 aged 6-12') 
size(day2_fc_age6_12) 
disp('Number of subjects eating target food on Day 2 aged 13-19') 
size(day2_fc_age13_19) 
disp('Number of subjects eating target food on Day 2 aged 20 and up') 
size(day2_fc_age20_up) 
disp('Number of subjects eating target food on Day 2 aged 2 and up') 
size(day2_fc_age2up) 
% scale food consumption of each food in grams to number of servings 
% now do Day 1 
serv_day1_age0_1 = searchsizes(day1_fc_age0_1,serving_sizes); 
serv_day1_age1_2 = searchsizes(day1_fc_age1_2,serving_sizes); 
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serv_day1_age2_5 = searchsizes(day1_fc_age2_5,serving_sizes); 
serv_day1_age6_12 = searchsizes(day1_fc_age6_12,serving_sizes); 
serv_day1_age13_19 = searchsizes(day1_fc_age13_19,serving_sizes); 
serv_day1_age20_up = searchsizes(day1_fc_age20_up,serving_sizes); 
serv_day1_age2up = searchsizes(day1_fc_age2up,serving_sizes); 
% now do Day 2 
serv_day2_age0_1 = searchsizes(day2_fc_age0_1,serving_sizes); 
serv_day2_age1_2 = searchsizes(day2_fc_age1_2,serving_sizes); 
serv_day2_age2_5 = searchsizes(day2_fc_age2_5,serving_sizes); 
serv_day2_age6_12 = searchsizes(day2_fc_age6_12,serving_sizes); 
serv_day2_age13_19 = searchsizes(day2_fc_age13_19,serving_sizes); 
serv_day2_age20_up = searchsizes(day2_fc_age20_up,serving_sizes); 
serv_day2_age2up = searchsizes(day2_fc_age2up,serving_sizes); 
% now calculate mean Expected Daily Intakes (EDIs) using the mass of additive that the 
client wants to add to each food. 
% Day 1 
disp('Mean Expected Daily Intakes (EDIs)') 
mean0_1day1 = mean(serv_day1_age0_1(:,4))*dose; % mg EDI 
mean1_2day1 = mean(serv_day1_age1_2(:,4))*dose; % mg EDI 
mean2_5day1 = mean(serv_day1_age2_5(:,4))*dose; % mg EDI 
mean6_12day1 = mean(serv_day1_age6_12(:,4))*dose; % mg EDI 
mean13_19day1 = mean(serv_day1_age13_19(:,4))*dose; % mg EDI 
mean20_upday1 = mean(serv_day1_age20_up(:,4))*dose; % mg EDI 
mean2upday1 = mean(serv_day1_age2up(:,4))*dose; % mg EDI 
% now do day 2 
mean0_1day2 = mean(serv_day2_age0_1(:,4))*dose; % mg EDI 
mean1_2day2 = mean(serv_day2_age1_2(:,4))*dose; % mg EDI 
mean2_5day2 = mean(serv_day2_age2_5(:,4))*dose; % mg EDI 
mean6_12day2 = mean(serv_day2_age6_12(:,4))*dose; % mg EDI 
mean13_19day2 = mean(serv_day2_age13_19(:,4))*dose; % mg EDI 
mean20_upday2 = mean(serv_day2_age20_up(:,4))*dose; % mg EDI 
mean2upday2 = mean(serv_day2_age2up(:,4))*dose; % mg EDI 
% to make histograms of exposure data here, add a breakpoint and use 
% hist().  For example, copy and paste 
% bins=round(sqrt(size(serv_day2_age2up(:,4)))) 
% bins=bins(1) 
% hist(serv_day2_age2up(:,4),bins) 
% 
% average day 1 and day 2 
disp('Mean EDI ages 0 to 1') 
medi0_1=(mean0_1day1+mean0_1day2)/2 
disp('Mean EDI ages 1-2') 
medi1_2=(mean1_2day1+mean1_2day2)/2 
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disp('Mean EDI ages 2-5') 
medi2_5=(mean2_5day1+mean2_5day2)/2  
disp('Mean EDI ages 6-12') 
medi6_12=(mean6_12day1+mean6_12day2)/2 
disp('Mean EDI ages 13-19') 
medi13_19=(mean13_19day1+mean13_19day2)/2 
disp('Mean EDI ages 20 and up') 
medi20up=(mean20_upday1+mean20_upday2)/2 
disp('Mean EDI ages 2 and up') 
medi2up=(mean2upday1+mean2upday2)/2 
% for 90th percentile calculation of Day 1, produces sorted doses in each age group 
sort_day1_age0_1 = sort(serv_day1_age0_1(:,4))*dose;  
sort_day1_age1_2 = sort(serv_day1_age1_2(:,4))*dose;  
sort_day1_age2_5 = sort(serv_day1_age2_5(:,4))*dose;  
sort_day1_age6_12 = sort(serv_day1_age6_12(:,4))*dose; 
sort_day1_age13_19 = sort(serv_day1_age13_19(:,4))*dose; 
sort_day1_age20_up = sort(serv_day1_age20_up(:,4))*dose; 
sort_day1_age2up = sort(serv_day1_age2up(:,4))*dose;  
% 
sort_day1_age0_1_d1 = sort_day1_age0_1(round(.9*size(sort_day1_age0_1))); 
sort_day1_age1_2_d1 = sort_day1_age1_2(round(.9*size(sort_day1_age1_2))); 
sort_day1_age2_5_d1 = sort_day1_age2_5(round(.9*size(sort_day1_age2_5))); % 90th 
percentile 
sort_day1_age6_12_d1 = sort_day1_age6_12(round(.9*size(sort_day1_age6_12))); 
sort_day1_age13_19_d1 = sort_day1_age13_19(round(.9*size(sort_day1_age13_19))); 
sort_day1_age20_up_d1 = sort_day1_age20_up(round(.9*size(sort_day1_age20_up))); 
sort_day1_age2up_d1 = sort_day1_age2up(round(.9*size(sort_day1_age2up))); 
% 
% Day 2 for 90th percentile calculation, produces sorted doses in each age group 
sort_day2_age0_1 = sort(serv_day2_age0_1(:,4))*dose;  
sort_day2_age1_2 = sort(serv_day2_age1_2(:,4))*dose; 
sort_day2_age2_5 = sort(serv_day2_age2_5(:,4))*dose; 
sort_day2_age6_12 = sort(serv_day2_age6_12(:,4))*dose; 
sort_day2_age13_19 = sort(serv_day2_age13_19(:,4))*dose; 
sort_day2_age20_up = sort(serv_day2_age20_up(:,4))*dose;  
sort_day2_age2up = sort(serv_day2_age2up(:,4))*dose;  
% 
sort_day2_age0_1_d2 = sort_day2_age0_1(round(.9*size(sort_day2_age0_1))); 
sort_day2_age1_2_d2 = sort_day2_age1_2(round(.9*size(sort_day2_age1_2))); 
sort_day2_age2_5_d2 = sort_day2_age2_5(round(.9*size(sort_day2_age2_5))); % 90th 
percentile 
sort_day2_age6_12_d2 = sort_day2_age6_12(round(.9*size(sort_day2_age6_12))); 
sort_day2_age13_19_d2 = sort_day2_age13_19(round(.9*size(sort_day2_age13_19))); 
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sort_day2_age20_up_d2 = sort_day2_age20_up(round(.9*size(sort_day2_age20_up))); 
sort_day2_age2up_d2 = sort_day2_age2up(round(.9*size(sort_day2_age2up))); 
% 
% calculate means of day 1 and day 2 90th percentiles 
disp('Mean 90th percentiles') 
M90_age0_1 = (sort_day1_age0_1_d1 + sort_day2_age0_1_d2)/2 
M90_age1_2 = (sort_day1_age1_2_d1 + sort_day2_age1_2_d2)/2 
M90_age2_5 = (sort_day1_age2_5_d1 + sort_day2_age2_5_d2)/2 
M90_age6_12 = (sort_day1_age6_12_d1 +  sort_day2_age6_12_d2)/2 
M90_age13_19 = (sort_day1_age13_19_d1 + sort_day2_age13_19_d2)/2 
M90_age20_up = (sort_day1_age20_up_d1 + sort_day2_age20_up_d2)/2 
M90_age2up = (sort_day1_age2up_d1 + sort_day2_age2up_d2)/2 
% now do body mass calculations 
% find masses of each age group 
mass0_1 = searchnzero(age0_1,mass); 
mass1_2 = searchnzero(age1_2,mass); 
mass2_5 = searchnzero(age2_5,mass); 
mass6_12 = searchnzero(age6_12,mass); 
mass13_19 = searchnzero(age13_19,mass); 
mass20_up = searchnzero(age20_up,mass); 
mass2up = searchnzero(age2up,mass); 
% calculate the mean masses of each age group 
disp('Mean mass of each age group') 
age_group_masses = 
[mean(mass0_1(:,2)),mean(mass1_2(:,2)),mean(mass2_5(:,2)),mean(mass6_12(:,2)),m
ean(mass13_19(:,2)),mean(mass20_up(:,2)),mean(mass2up(:,2))] 
allmass_ages=[mean(mass0_1(:,2));mean(mass1_2(:,2));mass2_5(:,2);mass6_12(:,2);m
ass13_19(:,2);mass20_up(:,2);mean(mass2up(:,2))]; 
disp('Total number of subjects in all mass/age groups') 
size(allmass_ages) 
disp('Mean weight of all mass/age groups') 
mean(allmass_ages) 
disp('Percent Users') 
disp('age 0-1') 
(size(day1_fc_age0_1)/size(ind_age0_1))*100 
disp('age 1-2') 
(size(day1_fc_age1_2)/size(ind_age1_2))*100 
disp('age 2-5') 
(size(day1_fc_age2_5)/size(ind_age2_5))*100 
disp('age 6-12') 
(size(day1_fc_age6_12)/size(ind_age6_12))*100 
disp('age 13-19') 
(size(day1_fc_age13_19)/size(ind_age13_19))*100 
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disp('age 20+') 
(size(day1_fc_age20_up)/size(ind_age20_up))*100 
disp('age 2+') 
(size(day1_fc_age2up)/size(ind_age2up))*100 
% now adjust the mean EDI and 90th %-tile for weight 
disp('Weight-based Mean EDIs') 
disp('age 0-1') 
medi0_1/mean(mass0_1(:,2)) 
disp('age 1-2') 
medi1_2/mean(mass1_2(:,2)) 
disp('age 2-5') 
medi2_5/mean(mass2_5(:,2)) 
disp('age 6-12') 
medi6_12/mean(mass6_12(:,2)) 
disp('age 13-19') 
medi13_19/mean(mass13_19(:,2)) 
disp('age 20+') 
medi20up/mean(mass20_up(:,2)) 
disp('age 2+') 
medi2up/mean(mass2up(:,2)) 
% 
disp('Weight-based 90th Percentile EDIs') 
disp('age 0-1') 
M90_age0_1/mean(mass0_1(:,2)) 
disp('age 1-2') 
M90_age1_2/mean(mass1_2(:,2)) 
disp('age 2-5') 
M90_age2_5/mean(mass2_5(:,2)) 
disp('age 6-12') 
M90_age6_12/mean(mass6_12(:,2)) 
disp('age 13-19') 
M90_age13_19/mean(mass13_19(:,2)) 
disp('age 20+') 
M90_age20_up/mean(mass20_up(:,2)) 
disp('age 2+') 
M90_age2up/mean(mass2up(:,2)) 
% At this point it would be good to print out the food codes and serving 
% sizes used to produce these data.  Also the dose of proposed additive. 
disp('Dose of Proposed Additive') 
dose 
disp('Food Codes and Serving Sizes Used to Produce These Data') 
serving_sizes 
zarray = mean(allmass_ages);     % just to put something into the output variable and 
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avoid an error 
end  
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searchfoodcodes 
 
function [foodnums,longfooddesc] = searchfoodcodes(targ_codes) 
% This function takes a 1-D list food codes (targ_codes) targeted for an EDI  
% calculation in NHANES and zeros out rows (foods) in the food code list 
% (food codes.xls, must be in path) that are not in the targeted food code list 
[num,txt,raw] = xlsread('food codes.xls');   % read in food codes 
                % column 1=numbers, 2=TEXT CAPS, 3=long text 
c=size(num);                 % setting counter maximum 
c=c(1);                      % first number is loop size needed 
zarray = txt(:,3);           % fill output array with long food descriptors 
for i=1:c                    % loop over all food codes 
    if any(num(i,1) == targ_codes);  % compare subject SEQNs to target codes 
        a=1;                 % if match, do nothing, leave line there 
    else 
        zarray(i,1) = cellstr('X0');     % else zero it 
    end 
end 
unkeep=find(strcmp(zarray(:,1),'X0'));   % delete these foods in the food code list 
tu=transpose(unkeep);                    % vectors must be the same type, row vector 
k=zeros(1,c);                            % create indices for set of all food codes 
k=k+(1:c);                               % indices are now a row vector 
keep=setdiff(k,tu);     % keep the set of foods we are not deleting 
zarray = zarray(keep,:);       % by deleting lines with x zeros 
longfooddesc = zarray;         % return the long food descriptors 
foodnums = num(keep);          % return the corresponding food codes  
 
116
searchfoods 
function zarray = searchfoods(age_diet,targ_codes) 
% This function takes the food groups (targ_codes) targeted for an EDI  
% calculation in NHANES and zeros out rows (foods) in a dietary age group 
% (age_diet) that are not in the targeted food code list 
zarray = age_diet;       % initialize output array 
c=size(age_diet(:,2));   % setting counter maximum 
c=c(1);                      % first number is loop size needed 
for i=1:c 
    if any(age_diet(i,2) == targ_codes);  % compare subject SEQNs 
        a=1;                 % do nothing 
    else 
        zarray(i,:) = 0; 
    end 
end 
keep=find(zarray(:,2) ~= 0);   % keep foods in the food code list 
zarray = zarray(keep,:);  
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searchnzero 
function zarray = searchnzero(age_group,dietary_data) 
% This function takes the SEQN numbers for an age group for an EDI  
% calculation in NHANES and zeros out rows not in that age group 
zarray = dietary_data;       % initialize output array 
c=size(dietary_data(:,1));   % setting counter maximum 
c=c(1);                      % first number is loop size needed 
for i=1:c 
    if any(dietary_data(i,1) == age_group);  % compare subject SEQNs 
        a=1;                 % do nothing 
    else 
        zarray(i,:) = 0; 
    end 
end 
keep=find(zarray(:,1) ~= 0); 
zarray = zarray(keep,:);  
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searchsizes 
function zarray = searchsizes(age_diet_fc,serving_sizes) 
% This function takes the food groups (targ_codes) targeted for an EDI  
% calculation in NHANES and zeros out rows (foods) in a dietary age group 
% (age_diet) that are not in the targeted food code list 
zarray = age_diet_fc;        % initialize output array 
c=size(age_diet_fc(:,2));    % setting counter maximum 
c=c(1);                      % first number is loop size needed 
for i=1:c 
    if any(age_diet_fc(i,2) == serving_sizes(:,1));  % compare subject SEQNs 
         [l,loc_fc]=ismember(age_diet_fc(i,2),serving_sizes(:,1));  % find serving size 
         zarray(i,4)=zarray(i,3)/serving_sizes(loc_fc,2);  % scale g to servings 
    end 
end  
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ADI Programs: 
 
Generate_ADI_translation_figure 
%This program generates two  
 %elliptical clusters of data for demonstrating translation of clusters 
 %for ellagic acid ADI paper 
    mu=[0,0]; 
    sigma=[2,1]; 
    SavedTNSPEC=mvnrnd(mu,sigma,25); 
 
figure 
scatter(SavedTNSPEC(:,1),SavedTNSPEC(:,2)) 
hold on 
 mu=[3,3]; 
    sigma=[2,1]; 
    SavedTNSPEC=mvnrnd(mu,sigma,25); 
scatter(SavedTNSPEC(:,1),SavedTNSPEC(:,2)) 
 
%Graph Center 
scatter(0,0,50,'b','filled') 
 
%Graph Center 
scatter(3,3,50,'r','filled') 
 
legend('No Effects Set','Effects Set',... 
    'No Effects Set Center','Effects Set Center') 
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International Units from King-Bodansky Units 
%Conversion of King Armstrong Units into International Units 
%This program uses the math laid out by  
%“International Enzyme Units and Isoenzyme Nomenclature.”  
%Journal of Clinical Pathology 16.4 (1963): 391–393. Print. 
%and the two-point definition of a line to predict the equivalent value of  
%International Units of enzyme activity from King-Armstrong Units. 
 
%This program requires the input of an integer KingArmstrong. 
 
%The text defines that the commonly accepted range of normal values of 
%3 to 13 K.A. units/100 ml. corresponds to about 20 to 90 
%micromoles/min./litre. 
%The equation of the line that runs through those points is y=7x-1 
 
micromoles_per_min_per_liter=7*(KingArmstrong)-1; 
 
%Bodansky Unit is defined by text as 0.535 micromol/min 
Bodansky_Units=micromoles_per_min_per_liter/0.535; 
 
 
%The text defines that the commonly accepted range of normal values of 
%1 to 5 Bodansky units/100 ml. blood plasma corresponds to  
%about 5.4 to 27 micromoles/min./litre. 
%The equation of the line that runs through those points is y=5.4x 
International_Units=5.4*(Bodansky_Units) 
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Round the Compass Rose Experiment Programs: 
Round the Compass Rose (Simplified) 
 %Round the Compass Rose 
  
   %Description:  
 %This program tests increasing bootstrap replicates increasing, number of  
 %dimensions (wavelengths), increasing size of training set, and  
 %differential proportion of points chosen to be inside of the  
 %hypercyllinder (radfrac).  Radfrac is tested with a given minimum 
 %radfrac, a step value, and a maximum value. 
%Tests the performance of replica.m and qb.m on elliptical clusters of 
%data. 
 
%Parameters: 
%z: maximum number of bootstrap replicates desired/50. 
%dimension: the maximum number of dimensions (variables) wished to be 
%           tested 
%Max_training: the maximum training set size desired/50, represented by "u" 
%Radfrac_min: the minimum radfrac wished to be tested.  Radfrac_min must be 
%             <=1. 
%Radfrac_step: the step wished for testing radfrac 
%Radfac_max: the maximum radfrac wished to be tested. Radfrac_max must be 
%            <=1. 
%Radfrac_min = 1, Radfrac_step=0 is an invalid input. 
  
 
 
%CODE BEGINS HERE 
%Start by initializing the random number generator. 
rng('default'); 
rng(1); 
 
 
sensitiv=0; 
  
 
%Initialize the iteration counter for radfrac loops.  Since radfrac is a 
%non-integer value that can vary, it can't be used as an index for a cell 
%array.  Thus, radfrac_iteration_count is used for the index instead. 
 
radfrac_iteration_count=0; 
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for radfrac= Radfrac_min : Radfrac_step : Radfrac_max  
    %a123=1; %This line only exists for the purpose of utilizing 
    %breakpoints. 
    if Radfrac_min==1 
        disp('Radfrac_min must not be 1.') 
        break %Should resolve Radfrac_min!=1 problem and just 
        %exit the loop. 
    elseif Radfrac_step==0 
            disp('Radfrac_step must not be 0') 
            break 
    elseif Radfrac_min==Radfrac_max 
            disp('Radfrac_min may not equal Radfrac_max.') 
            break 
    else radfrac_iteration_count=radfrac_iteration_count+1; 
    end 
  
    for u=1:Max_training 
  
%Begin for-loop.  This will allow for the increase of dimensions from 1 
%to dimensions with a step of one.  Further uses of i are to concatenate 
%columns of zeroes and ensure the correct number of coordinates for mu (0  
%in all dimensions)and sigma (1 in all dimensions other than one). 
 
        for v=0:dimension; %%this was originally from v=1:dimension so that the cell  
            %indices could be x(v), but it has been modified to 
            %x(v+1)this has been modified from v=0:dimension so that the cell indices work 
  
  
        %Generate an ellipse 
        mu=[0,0]; 
        mu = [mu zeros(size(mu,1),(v))]; 
        sigma=[2,1]; 
        sigma=[sigma ones(size(sigma,1),(v))]; 
    TNSPEC=mvnrnd(mu,sigma,50*u);compass_points=[0,1;(-2/(sqrt(5))),(2/(sqrt(5))); 
-2,0;(-2/(sqrt(5))),(-2/(sqrt(5)));  
    0,-1;(2/(sqrt(5))),(-2/(sqrt(5))); 2,0; (2/(sqrt(5))),(2/(sqrt(5)))]; 
 
        %Add a column of zeros to compass_points indicating coordinate in  
        %each of the the new dimensions 
        compass_points=[compass_points zeros(size(compass_points,1),(v))]; 
 
        %Define expected standard deviations.  CHANGE THIS LINE IF POINTS 
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        % CHANGE. 
        expected_standard_deviation = [1;1.2649;2;1.2649;1;1.2649;2;1.2649]; 
 
        %Test point at each point of the compass rose 
 
        for j=1:8 
            newspec = [compass_points(j,:)]; 
            %This is the innermost iterative loop of the program. 
  
            %Initialize storage matrices of sds and sdsskew 
            %(6+v) syntax increases the size of SDS_matrix to fit the  
            %coordinate points of each dimension 
            SDS_matrix=zeros(z,(6+(v))); 
            SDS_matrix_2=zeros(z,(6+v)); 
            SDS_matrix_3=zeros(z,(6+v)); 
            SDS_matrix_4=zeros(z,(6+v)); 
            SDS_matrix_5=zeros(z,(6+v)); 
            SDS_matrix_6=zeros(z,(6+v)); 
  
  
%How number of bootstrap replicates affects SDS and SDS Skew at those 
%points on the compass rose 
%SDS_matrix contains [compass_points(j,:),B,sds,bias,sdskew] in that order 
    for i=1:z 
  
     B=50*i; 
     sds = nan; bias = nan; sdskew = nan; 
        try 
     [BTRAIN,CNTER]=replica(TNSPEC,B); 
     [sds,sdskew,qrr] = qb(TNSPEC,BTRAIN,newspec,CNTER,radfrac,sensitiv); 
     bias=sds-expected_standard_deviation(j); 
            catch ME 
        end 
         SDS_matrix((i),:)=[compass_points(j,:),B,sds,bias,sdskew]; 
    end 
  
  
    %Repeat the process to generate SDS_matrix_2 
     for i=1:z 
          B=50*i; 
     sds = nan; bias = nan; sdskew = nan; 
        try 
         [BTRAIN,CNTER]=replica(TNSPEC,B); 
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     [sds,sdskew,qrr] = qb(TNSPEC,BTRAIN,newspec,CNTER,radfrac,sensitiv); 
     bias=sds-expected_standard_deviation(j); 
        catch ME 
  
        end 
       SDS_matrix_2((i),:)=[compass_points(j,:),B,sds,bias,sdskew]; 
     end 
  
     %Repeat the process to generate SDS_matrix_3 
     for i=1:z 
          B=50*i; 
     sds = nan; bias = nan; sdskew = nan; 
        try 
         [BTRAIN,CNTER]=replica(TNSPEC,B); 
     [sds,sdskew,qrr] = qb(TNSPEC,BTRAIN,newspec,CNTER,radfrac,sensitiv); 
     bias=sds-expected_standard_deviation(j); 
        catch ME 
        end 
         SDS_matrix_3((i),:)=[compass_points(j,:),B,sds,bias,sdskew]; 
     end 
  
     %Repeat the process to generate SDS_matrix_4 
    for i=1:z 
         B=50*i; 
     sds = nan; bias = nan; sdskew = nan; 
        try 
         [BTRAIN,CNTER]=replica(TNSPEC,B); 
     [sds,sdskew,qrr] = qb(TNSPEC,BTRAIN,newspec,CNTER,radfrac,sensitiv); 
     bias=sds-expected_standard_deviation(j); 
        catch ME 
        end 
         SDS_matrix_4((i),:)=[compass_points(j,:),B,sds,bias,sdskew]; 
    end 
  
    %Repeat the process to generate SDS_matrix_5 
    for i=1:z 
         B=50*i; 
     sds = nan; bias = nan; sdskew = nan; 
        try 
          [BTRAIN,CNTER]=replica(TNSPEC,B); 
     [sds,sdskew,qrr] = qb(TNSPEC,BTRAIN,newspec,CNTER,radfrac,sensitiv); 
     bias=sds-expected_standard_deviation(j); 
        catch ME 
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        end 
     SDS_matrix_5((i),:)=[compass_points(j,:),B,sds,bias,sdskew]; 
  
    end 
  
    %Repeat the process to generate SDS_matrix_6 
    for i=1:z 
         B=50*i; 
     sds = nan; bias = nan; sdskew = nan; 
        try 
         [BTRAIN,CNTER]=replica(TNSPEC,B); 
     [sds,sdskew,qrr] = qb(TNSPEC,BTRAIN,newspec,CNTER,radfrac,sensitiv); 
     bias=sds-expected_standard_deviation(j); 
        catch ME 
        end 
        SDS_matrix_6((i),:)=[compass_points(j,:),B,sds,bias,sdskew]; 
    end 
  
%***All storage has to happen here*** 
%This is the innermost iterative loop of the program. 
 
 
%Generate a matrix of the average of the 6 runs. 
%AVERAGE contains[compass_points(j,:),B,sds,bias,sdskew] in that order 
%Note that AVERAGE increases in size as dimension increases.  
%When dimension increases by one, one additional column is inserted in 
%the three position.  This can be expressed by the following:  
 
    %sdskew is located in a column position equal to 6+v, or in 
    %AVERAGE(:,6+v) 
    %bias is located in (:,5+v) 
    %sds is located in (:,4+v) 
    %B is located in (:,3+v,) 
    %compass points are located in(:,1:v+2) 
AVERAGE=zeros(size(SDS_matrix)); 
AVERAGE=((SDS_matrix + SDS_matrix_2 + SDS_matrix_3 +SDS_matrix_4 + 
SDS_matrix_5 + SDS_matrix_6))/6; 
 
%Populate SDS_X_STDEV with the SD values of each run 
%sds is located in (:,4:v) 
SDS_1_STDEV=zeros(z,1); 
SDS_1_STDEV(:,1)=SDS_matrix(:,(4+v)); 
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SDS_2_STDEV=zeros(z,1); 
SDS_2_STDEV(:,1)=SDS_matrix_2(:,(4+v)); 
 
SDS_3_STDEV=zeros(z,1); 
SDS_3_STDEV(:,1)=SDS_matrix_3(:,(4+v)); 
 
SDS_4_STDEV=zeros(z,1); 
SDS_4_STDEV(:,1)=SDS_matrix_4(:,(4+v)); 
 
SDS_5_STDEV=zeros(z,1); 
SDS_5_STDEV(:,1)=SDS_matrix_5(:,(4+v)); 
 
SDS_6_STDEV=zeros(z,1); 
SDS_6_STDEV(:,1)=SDS_matrix_6(:,(4+v)); 
 
%Populate SDS_X_STDEV_calc with SDS_X_STDEV - average for STDEV 
SDS_1_STDEV_calc=zeros(z,1); 
SDS_1_STDEV_calc(:,1)=((SDS_1_STDEV(:,1)-AVERAGE(:,(4+v))).^2); 
 
SDS_2_STDEV_calc=zeros(z,1); 
SDS_2_STDEV_calc(:,1)=((SDS_2_STDEV(:,1)-AVERAGE(:,(4+v))).^2); 
 
SDS_3_STDEV_calc=zeros(z,1); 
SDS_3_STDEV_calc(:,1)=((SDS_3_STDEV(:,1)-AVERAGE(:,(4+v))).^2); 
 
SDS_4_STDEV_calc=zeros(z,1); 
SDS_4_STDEV_calc(:,1)=((SDS_4_STDEV(:,1)-AVERAGE(:,(4+v))).^2); 
 
SDS_5_STDEV_calc=zeros(z,1); 
SDS_5_STDEV_calc(:,1)=((SDS_5_STDEV(:,1)-AVERAGE(:,(4+v))).^2); 
 
SDS_6_STDEV_calc=zeros(z,1); 
SDS_6_STDEV_calc(:,1)=((SDS_6_STDEV(:,1)-AVERAGE(:,(4+v))).^2); 
 
% Sum the above and calculate STANDARD_DEVIATION= 
FINAL_STDEV=zeros(z,1); 
FINAL_STDEV=(((SDS_1_STDEV_calc + SDS_2_STDEV_calc + SDS_3_STDEV_calc 
+ SDS_4_STDEV_calc + SDS_5_STDEV_calc + SDS_6_STDEV_calc)/6).^.5); 
 
 
 
%Store bias vs. B for each of the eight points of the ellipse,each TNSPEC, 
%and each Radfrac 
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    %bias is located in AVERAGE(:,5+v) 
    %B is located in AVERAGE(:,3+v,) 
Bias_plot=zeros(z,7); 
Bias_plot(:,1)=AVERAGE(:,(3+v)); 
Bias_plot(:,2)=AVERAGE(:,(5+v)); 
Bias_plot(:,3)=(v+2); 
Bias_plot(:,4)=AVERAGE(:,1); 
Bias_plot(:,5)=AVERAGE(:,2); 
Bias_plot(:,6)=radfrac; 
Bias_plot(:,7)=u*50; 
%"NumVL{v+1}=Bias_plot" so that I v=0:dimension can be used at the  
%beginning of the v loop 
NumVL{radfrac_iteration_count,u,(v+1),j}=Bias_plot; 
%Indexing is {radfrac number, training, dimension - 1, compass point 
%number} 
 
%B is located in Bias_plot(:,1) 
%bias is located in Bias_plot(:,2) 
%dimension is located in Bias_plot(:,3) 
%First 2 coordinates of compass point located in Bias_plot(:,4) and (:,5) 
%radfrac located in Bias_plot(:,6) 
%Training set size located in Bias_plot(:,7) 
 
 
%Store Relative Standard Deviation (average standard deviation/ 
%average) 
%RSD holds [compass point coordinate, compass point coordinate,B,RSD of 
%returned standard deviation, total number of dimensions (v+2), radfrac,  
%Training Set Size] 
RSD=zeros(z,7); 
RSD(:,1)=AVERAGE(:,1); 
RSD(:,2)=AVERAGE(:,2); 
RSD(:,3)=AVERAGE(:,(v+3)); 
RSD(:,4)=(FINAL_STDEV(:,1)./AVERAGE(:,(v+4))); 
RSD(:,5)=(v+2); 
RSD(:,6)=radfrac; 
RSD(:,7)=u*50; 
 
%Hold all RSD plots for all runs 
%Indexing is {Radfrac Iteration Count (must 
%separately count Radfrac value),Training Set Size,dimension,Compass Point,} 
RSD_NumVL{radfrac_iteration_count,u,(v+1),j}=RSD; 
 
 
128
 
 
end 
end 
end 
end 
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Regression Codes 
RSD_Regression_2 
 
%Regresses RSD as function of Bootstrapping Only 
%Requires workspace variables NumVL and RSD_NumVL, Max_training,  
 
%Indexing in NumVL Cell Matrix is as Follows: 
%Indexing is {Radfrac Iteration Count (must separately count... 
%Radfrac value),Training Set Size,dimension,Compass Point,} 
%RSD_NumVL{radfrac_iteration_count,u,(v+1),j}=RSD; 
 
%Within matrix: 
%Store Relative Standard Deviation (average standard deviation/ 
%average) 
%RSD holds [1.compass point coordinate, 2.compass point coordinate,... 
%3.B, 4.RSD of returned standard deviation, ... 
%5.total number of dimensions (v+2), 6.radfrac,  
%7.Training Set Size] 
 
%Make sure these exist. 
NumVL; 
RSD_NumVL; 
 
out=[cat(1,RSD_NumVL{:})]; 
x=size(out); 
w=x(:,1); 
y=zeros(x(:,1),1); 
 
%Designate compass points - work in progress 
newmatrix=[out,y]; 
 
%nonprincipal axis points 
    npa=newmatrix(:,1)==0; 
  
%principal axis points 
    pa=newmatrix(:,1)==2; 
    opa=newmatrix(:,1)==-2; 
  
 %since diagonals have a calculation that determines the value 
 %it is hard to tell how many digits of precision  
 %therefore, diagonals are not equal to 0, 2, or -2. 
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    %First find indices ~=0 
    dp=newmatrix(:,1)~=0; 
    dp2=newmatrix(dp,:); 
    %Now find indices in the ~=0 subset also ~= 2 
    fdp=dp2(:,1)~=2; 
    dp3=dp2(fdp,:); 
    %Last, find indices in that subset also ~= to -2 
    ffdp=dp3(:,1)~=-2; 
  
    nonprincipalaxis=[newmatrix(npa,:)]; 
    principalaxis=[newmatrix(pa,:);newmatrix(opa,:)]; 
    diagonalpoints=[dp3(ffdp,:)]; 
  
    for i=1:3 
        %try to regress output for each degree. 
        degree=i 
  
  
        %Regress Non-Principal 
        disp('Non-Principal Axis Regression') 
        npa_output=[nonprincipalaxis(:,4)]; 
        npa_input=[nonprincipalaxis(:,3)]; 
        %,nonprincipalaxis(:,5),... 
           % nonprincipalaxis(:,6),nonprincipalaxis(:,7)]; 
        reg = MultiPolyRegress(npa_input,npa_output,degree) 
 
 
        %Regress Principal 
        disp('Principal Axis Regression') 
        pa_output=[principalaxis(:,4)]; 
        pa_input=[principalaxis(:,3)]; 
        %,principalaxis(:,5),... 
           % principalaxis(:,6),principalaxis(:,7)]; 
        reg = MultiPolyRegress(pa_input,pa_output,degree) 
 
 
        %Regress Diagonal 
        disp('Diagonal Regression') 
        d_output=[diagonalpoints(:,4)]; 
        d_input=[diagonalpoints(:,3)]; 
        %,diagonalpoints(:,5),... 
         %   diagonalpoints(:,6),diagonalpoints(:,7)]; 
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        reg = MultiPolyRegress(d_input,d_output,degree) 
    end 
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 Plotting Codes: 
RTCR_Defined_TNSPEC_Size 
 
%Generate and save a training spectrum of a given size, then run and  
%increase with different numbers of bootstrap 
%replicates to determine whether TNSPEC is the cause of erractic RSD in 
%samples 
 
%TNSPEC was saved as SavedTNSPEC 
%U HAS CHANGED.  CHANGE INDEXING IN PLOT CODE 
%RNG is now 20 
 
  
%Parameters: 
%z: maximum number of bootstrap replicates desired/50. 
%dimension: the maximum number of dimensions (variables) wished to be 
%           tested 
%Max_training: the maximum training set size desired/50, represented by "u" 
%Radfrac_min: the minimum radfrac wished to be tested.  Radfrac_min must be 
%             <=1. 
%Radfrac_step: the step wished for testing radfrac 
%Radfac_max: the maximum radfrac wished to be tested. Radfrac_max must be 
%            <=1. 
%Radfrac_min = 1, Radfrac_step=0 is an invalid input. 
  
 
 
%CODE BEGINS HERE 
%Start by initializing the random number generator. 
rng('default'); 
rng(20); 
 
 
sensitiv=0; 
  
 
%Initialize the iteration counter for radfrac loops.  Since radfrac is a 
%non-integer value that can vary, it can't be used as an index for a cell 
%array.  Thus, radfrac_iteration_count is used for the index instead. 
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radfrac_iteration_count=4; 
radfrac=0.8; 
u=200; 
z=10; 
 
%Begin for-loop.  This will allow for the increase of dimensions from 1 
%to dimensions with a step of one.  Further uses of i are to concatenate 
%columns of zeroes and ensure the correct number of coordinates for mu (0  
%in all dimensions)and sigma (1 in all dimensions other than one). 
 
        v=0;  
  
        %Generate an ellipse 
        mu=[0,0]; 
        mu = [mu zeros(size(mu,1),(v))]; 
        sigma=[2,1]; 
        sigma=[sigma ones(size(sigma,1),(v))]; 
        TNSPEC=mvnrnd(mu,sigma,50*u); 
        SavedTNSPEC=TNSPEC 
%Compass Points & Expected Standard Deviation 
 
    compass_points=[0,1;(-2/(sqrt(5))),(2/(sqrt(5))); -2,0;(-2/(sqrt(5))),(-2/(sqrt(5)));... 
         0,-1;(2/(sqrt(5))),(-2/(sqrt(5))); 2,0; (2/(sqrt(5))),(2/(sqrt(5)))]; 
 
      expected_standard_deviation=[1;1.2649;2;1.2649;1;1.2649;2;1.2649]; 
        %Test point at each point of the compass rose 
 
        for j=1:8 
            newspec = [compass_points(j,:)]; 
            %This is the innermost iterative loop of the program. 
  
            %Initialize storage matrices of sds and sdsskew 
            %(6+v) syntax increases the size of SDS_matrix to fit the  
            %coordinate points of each dimension 
            SDS_matrix=zeros(z,(6+(v))); 
            SDS_matrix_2=zeros(z,(6+v)); 
            SDS_matrix_3=zeros(z,(6+v)); 
            SDS_matrix_4=zeros(z,(6+v)); 
            SDS_matrix_5=zeros(z,(6+v)); 
            SDS_matrix_6=zeros(z,(6+v)); 
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%How number of bootstrap replicates affects SDS and SDS Skew at those 
%points on the compass rose 
%SDS_matrix contains [compass_points(j,:),B,sds,bias,sdskew] in that order 
    for i=1:z 
  
     B=50*i; 
     sds = nan; bias = nan; sdskew = nan; 
        try 
     [BTRAIN,CNTER]=replica(TNSPEC,B); 
     [sds,sdskew,qrr] = qb(TNSPEC,BTRAIN,newspec,CNTER,radfrac,sensitiv); 
     bias=sds-expected_standard_deviation(j); 
            catch ME 
        end 
         SDS_matrix((i),:)=[compass_points(j,:),B,sds,bias,sdskew]; 
    end 
  
  
    %Repeat the process to generate SDS_matrix_2 
     for i=1:z 
          B=50*i; 
     sds = nan; bias = nan; sdskew = nan; 
        try 
         [BTRAIN,CNTER]=replica(TNSPEC,B); 
     [sds,sdskew,qrr] = qb(TNSPEC,BTRAIN,newspec,CNTER,radfrac,sensitiv); 
     bias=sds-expected_standard_deviation(j); 
        catch ME 
  
        end 
       SDS_matrix_2((i),:)=[compass_points(j,:),B,sds,bias,sdskew]; 
     end 
  
     %Repeat the process to generate SDS_matrix_3 
     for i=1:z 
          B=50*i; 
     sds = nan; bias = nan; sdskew = nan; 
        try 
         [BTRAIN,CNTER]=replica(TNSPEC,B); 
     [sds,sdskew,qrr] = qb(TNSPEC,BTRAIN,newspec,CNTER,radfrac,sensitiv); 
     bias=sds-expected_standard_deviation(j); 
        catch ME 
        end 
         SDS_matrix_3((i),:)=[compass_points(j,:),B,sds,bias,sdskew]; 
     end 
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     %Repeat the process to generate SDS_matrix_4 
    for i=1:z 
         B=50*i; 
     sds = nan; bias = nan; sdskew = nan; 
        try 
         [BTRAIN,CNTER]=replica(TNSPEC,B); 
     [sds,sdskew,qrr] = qb(TNSPEC,BTRAIN,newspec,CNTER,radfrac,sensitiv); 
     bias=sds-expected_standard_deviation(j); 
        catch ME 
        end 
         SDS_matrix_4((i),:)=[compass_points(j,:),B,sds,bias,sdskew]; 
    end 
  
    %Repeat the process to generate SDS_matrix_5 
    for i=1:z 
         B=50*i; 
     sds = nan; bias = nan; sdskew = nan; 
        try 
          [BTRAIN,CNTER]=replica(TNSPEC,B); 
     [sds,sdskew,qrr] = qb(TNSPEC,BTRAIN,newspec,CNTER,radfrac,sensitiv); 
     bias=sds-expected_standard_deviation(j); 
        catch ME 
        end 
     SDS_matrix_5((i),:)=[compass_points(j,:),B,sds,bias,sdskew]; 
  
    end 
  
    %Repeat the process to generate SDS_matrix_6 
    for i=1:z 
         B=50*i; 
     sds = nan; bias = nan; sdskew = nan; 
        try 
         [BTRAIN,CNTER]=replica(TNSPEC,B); 
     [sds,sdskew,qrr] = qb(TNSPEC,BTRAIN,newspec,CNTER,radfrac,sensitiv); 
     bias=sds-expected_standard_deviation(j); 
        catch ME 
        end 
        SDS_matrix_6((i),:)=[compass_points(j,:),B,sds,bias,sdskew]; 
    end 
  
%***All storage has to happen here*** 
%This is the innermost iterative loop of the program. 
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%Generate a matrix of the average of the 6 runs. 
%AVERAGE contains[compass_points(j,:),B,sds,bias,sdskew] in that order 
%Note that AVERAGE increases in size as dimension increases.  
%When dimension increases by one, one additional column is inserted in 
%the three position.  This can be expressed by the following:  
 
    %sdskew is located in a column position equal to 6+v, or in 
    %AVERAGE(:,6+v) 
    %bias is located in (:,5+v) 
    %sds is located in (:,4+v) 
    %B is located in (:,3+v,) 
    %compass points are located in(:,1:v+2) 
AVERAGE=zeros(size(SDS_matrix)); 
AVERAGE=((SDS_matrix + SDS_matrix_2 + SDS_matrix_3 +SDS_matrix_4 + 
SDS_matrix_5 + SDS_matrix_6))/6; 
 
%Populate SDS_X_STDEV with the SD values of each run 
%sds is located in (:,4:v) 
SDS_1_STDEV=zeros(z,1); 
SDS_1_STDEV(:,1)=SDS_matrix(:,(4+v)); 
 
SDS_2_STDEV=zeros(z,1); 
SDS_2_STDEV(:,1)=SDS_matrix_2(:,(4+v)); 
 
SDS_3_STDEV=zeros(z,1); 
SDS_3_STDEV(:,1)=SDS_matrix_3(:,(4+v)); 
 
SDS_4_STDEV=zeros(z,1); 
SDS_4_STDEV(:,1)=SDS_matrix_4(:,(4+v)); 
 
SDS_5_STDEV=zeros(z,1); 
SDS_5_STDEV(:,1)=SDS_matrix_5(:,(4+v)); 
 
SDS_6_STDEV=zeros(z,1); 
SDS_6_STDEV(:,1)=SDS_matrix_6(:,(4+v)); 
 
%Populate SDS_X_STDEV_calc with SDS_X_STDEV - average for STDEV 
SDS_1_STDEV_calc=zeros(z,1); 
SDS_1_STDEV_calc(:,1)=((SDS_1_STDEV(:,1)-AVERAGE(:,(4+v))).^2); 
 
SDS_2_STDEV_calc=zeros(z,1); 
 
137
SDS_2_STDEV_calc(:,1)=((SDS_2_STDEV(:,1)-AVERAGE(:,(4+v))).^2); 
 
SDS_3_STDEV_calc=zeros(z,1); 
SDS_3_STDEV_calc(:,1)=((SDS_3_STDEV(:,1)-AVERAGE(:,(4+v))).^2); 
 
SDS_4_STDEV_calc=zeros(z,1); 
SDS_4_STDEV_calc(:,1)=((SDS_4_STDEV(:,1)-AVERAGE(:,(4+v))).^2); 
 
SDS_5_STDEV_calc=zeros(z,1); 
SDS_5_STDEV_calc(:,1)=((SDS_5_STDEV(:,1)-AVERAGE(:,(4+v))).^2); 
 
SDS_6_STDEV_calc=zeros(z,1); 
SDS_6_STDEV_calc(:,1)=((SDS_6_STDEV(:,1)-AVERAGE(:,(4+v))).^2); 
 
% Sum the above and calculate STANDARD_DEVIATION= 
FINAL_STDEV=zeros(z,1); 
FINAL_STDEV=(((SDS_1_STDEV_calc + SDS_2_STDEV_calc + SDS_3_STDEV_calc 
+ SDS_4_STDEV_calc + SDS_5_STDEV_calc + SDS_6_STDEV_calc)/6).^.5); 
 
 
 
%Store bias vs. B for each of the eight points of the ellipse,each TNSPEC, 
%and each Radfrac 
    %bias is located in AVERAGE(:,5+v) 
    %B is located in AVERAGE(:,3+v,) 
Bias_plot=zeros(z,7); 
Bias_plot(:,1)=AVERAGE(:,(3+v)); 
Bias_plot(:,2)=AVERAGE(:,(5+v)); 
Bias_plot(:,3)=(v+2); 
Bias_plot(:,4)=AVERAGE(:,1); 
Bias_plot(:,5)=AVERAGE(:,2); 
Bias_plot(:,6)=radfrac; 
Bias_plot(:,7)=u; 
%"NumVL{v+1}=Bias_plot" so that I v=0:dimension can be used at the  
%beginning of the v loop 
NumVL{radfrac_iteration_count,u,(v+1),j}=Bias_plot; 
%Indexing is {radfrac number, training, dimension - 1, compass point 
%number} 
 
%B is located in Bias_plot(:,1) 
%bias is located in Bias_plot(:,2) 
%dimension is located in Bias_plot(:,3) 
%First 2 coordinates of compass point located in Bias_plot(:,4) and (:,5) 
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%radfrac located in Bias_plot(:,6) 
%Training set size located in Bias_plot(:,7) 
 
 
%Store Relative Standard Deviation (average standard deviation/ 
%average) 
%RSD holds [compass point coordinate, compass point coordinate,B,RSD of 
%returned standard deviation, total number of dimensions (v+2), radfrac,  
%Training Set Size] 
RSD=zeros(z,7); 
RSD(:,1)=AVERAGE(:,1); 
RSD(:,2)=AVERAGE(:,2); 
RSD(:,3)=AVERAGE(:,(v+3)); 
RSD(:,4)=(FINAL_STDEV(:,1)./AVERAGE(:,(v+4))); 
RSD(:,5)=(v+2); 
RSD(:,6)=radfrac; 
RSD(:,7)=u; 
 
%Hold all RSD plots for all runs 
%Indexing is {Radfrac Iteration Count (must 
%separately count Radfrac value),Training Set Size,dimension,Compass Point,} 
RSD_NumVL{radfrac_iteration_count,u,(v+1),j}=RSD; 
end 
 
 
 
 
%Plot Code 
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Plotting Relative Standard Deviation 
 
%Plotting Relative Standard Deviation 
%as Bootstrapping and Radfrac Increase 
 
%This code plots bootstrapping vs. RSD as radfrac increases 
%for run_TNSPEC code ONLY 
 
%Changes: u has changed in the run_TNPSEC code from what it 
%has in Round_the_Compass_Rose_simplified.m 
 
%Indexing in NumVL Cell Matrix is as Follows: 
%Indexing is {Radfrac Iteration Count (must separately count... 
%Radfrac value),Training Set Size,dimension,Compass Point,} 
%RSD_NumVL{radfrac_iteration_count,u,(v+1),j}=RSD; 
 
%Within matrix: 
%Store Relative Standard Deviation (average standard deviation/ 
%average) 
%RSD holds [1.compass point coordinate, 2.compass point coordinate,... 
%3.B, 4.RSD of returned standard deviation, ... 
%5.total number of dimensions (v+2), 6.radfrac,  
%7.Training Set Size] 
 
 
 
    figure('Name','4,1,1 npa') 
    r4_t50_d2_c01=[RSD_NumVL{4,200,1,1}] 
    plot (r4_t50_d2_c01(:,3),r4_t50_d2_c01(:,4)); 
    hold on 
    r4_t50_d2_cneg01=[RSD_NumVL{4,200,1,5}]; 
    plot (r4_t50_d2_cneg01(:,3),r4_t50_d2_cneg01(:,4)); 
    title({'Relative Standard Deviation as Bootstrap Replicates Increase';... 
        'Radfrac=0.8 Dimension=2 TNSPEC=50'}) 
    xlabel('Bootstrap Replications') 
    ylabel('Relative Standard Deviation') 
    legend('CP=(0,1)','CP=(0,-1)') 
    hold off 
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Run TNSPEC Version 2 
%Re-run premade Training spectrum with different numbers of bootstrap 
%replicates to determine whether TNSPEC is the cause of erractic RSD in 
%samples 
 
%TNSPEC was saved as  
%U HAS CHANGED.  CHANGE INDEXING IN PLOT CODE 
 
  
%Parameters: 
%z: maximum number of bootstrap replicates desired/50. 
%dimension: the maximum number of dimensions (variables) wished to be 
%           tested 
%Max_training: the maximum training set size desired/50, represented by "u" 
%Radfrac_min: the minimum radfrac wished to be tested.  Radfrac_min must be 
%             <=1. 
%Radfrac_step: the step wished for testing radfrac 
%Radfac_max: the maximum radfrac wished to be tested. Radfrac_max must be 
%            <=1. 
%Radfrac_min = 1, Radfrac_step=0 is an invalid input. 
  
 
 
%CODE BEGINS HERE 
%Start by initializing the random number generator. 
%Input this first: 
%rng('default'); 
%rng(10); 
 
 
sensitiv=0; 
  
 
%Initialize the iteration counter for radfrac loops.  Since radfrac is a 
%non-integer value that can vary, it can't be used as an index for a cell 
%array.  Thus, radfrac_iteration_count is used for the index instead. 
 
radfrac_iteration_count=4; 
radfrac=0.8; 
[u,other]=size(SavedTNSPEC); 
z=10; 
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%Begin for-loop.  This will allow for the increase of dimensions from 1 
%to dimensions with a step of one.  Further uses of i are to concatenate 
%columns of zeroes and ensure the correct number of coordinates for mu (0  
%in all dimensions)and sigma (1 in all dimensions other than one). 
 
        v=0;  
  
        %Generate an ellipse 
        mu=[0,0]; 
        mu = [mu zeros(size(mu,1),(v))]; 
        sigma=[2,1]; 
        sigma=[sigma ones(size(sigma,1),(v))]; 
    TNSPEC=SavedTNSPEC 
%Compass Points & Expected Standard Deviation 
 
    compass_points=[0,1;(-2/(sqrt(5))),(2/(sqrt(5))); -2,0;(-2/(sqrt(5))),(-2/(sqrt(5)));... 
         0,-1;(2/(sqrt(5))),(-2/(sqrt(5))); 2,0; (2/(sqrt(5))),(2/(sqrt(5)))]; 
 
      expected_standard_deviation=[1;1.2649;2;1.2649;1;1.2649;2;1.2649]; 
        %Test point at each point of the compass rose 
 
        for j=1:8 
            newspec = [compass_points(j,:)]; 
            %This is the innermost iterative loop of the program. 
  
            %Initialize storage matrices of sds and sdsskew 
            %(6+v) syntax increases the size of SDS_matrix to fit the  
            %coordinate points of each dimension 
            SDS_matrix=zeros(z,(6+(v))); 
            SDS_matrix_2=zeros(z,(6+v)); 
            SDS_matrix_3=zeros(z,(6+v)); 
            SDS_matrix_4=zeros(z,(6+v)); 
            SDS_matrix_5=zeros(z,(6+v)); 
            SDS_matrix_6=zeros(z,(6+v)); 
  
  
%How number of bootstrap replicates affects SDS and SDS Skew at those 
%points on the compass rose 
%SDS_matrix contains [compass_points(j,:),B,sds,bias,sdskew] in that order 
    for i=1:z 
  
     B=50*i; 
     sds = nan; bias = nan; sdskew = nan; 
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        try 
     [BTRAIN,CNTER]=replica(TNSPEC,B); 
     [sds,sdskew,qrr] = qb(TNSPEC,BTRAIN,newspec,CNTER,radfrac,sensitiv); 
     bias=sds-expected_standard_deviation(j); 
            catch ME 
        end 
         SDS_matrix((i),:)=[compass_points(j,:),B,sds,bias,sdskew]; 
    end 
  
  
    %Repeat the process to generate SDS_matrix_2 
     for i=1:z 
          B=50*i; 
     sds = nan; bias = nan; sdskew = nan; 
        try 
         [BTRAIN,CNTER]=replica(TNSPEC,B); 
     [sds,sdskew,qrr] = qb(TNSPEC,BTRAIN,newspec,CNTER,radfrac,sensitiv); 
     bias=sds-expected_standard_deviation(j); 
        catch ME 
  
        end 
       SDS_matrix_2((i),:)=[compass_points(j,:),B,sds,bias,sdskew]; 
     end 
  
     %Repeat the process to generate SDS_matrix_3 
     for i=1:z 
          B=50*i; 
     sds = nan; bias = nan; sdskew = nan; 
        try 
         [BTRAIN,CNTER]=replica(TNSPEC,B); 
     [sds,sdskew,qrr] = qb(TNSPEC,BTRAIN,newspec,CNTER,radfrac,sensitiv); 
     bias=sds-expected_standard_deviation(j); 
        catch ME 
        end 
         SDS_matrix_3((i),:)=[compass_points(j,:),B,sds,bias,sdskew]; 
     end 
  
     %Repeat the process to generate SDS_matrix_4 
    for i=1:z 
         B=50*i; 
     sds = nan; bias = nan; sdskew = nan; 
        try 
         [BTRAIN,CNTER]=replica(TNSPEC,B); 
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     [sds,sdskew,qrr] = qb(TNSPEC,BTRAIN,newspec,CNTER,radfrac,sensitiv); 
     bias=sds-expected_standard_deviation(j); 
        catch ME 
        end 
         SDS_matrix_4((i),:)=[compass_points(j,:),B,sds,bias,sdskew]; 
    end 
  
    %Repeat the process to generate SDS_matrix_5 
    for i=1:z 
         B=50*i; 
     sds = nan; bias = nan; sdskew = nan; 
        try 
          [BTRAIN,CNTER]=replica(TNSPEC,B); 
     [sds,sdskew,qrr] = qb(TNSPEC,BTRAIN,newspec,CNTER,radfrac,sensitiv); 
     bias=sds-expected_standard_deviation(j); 
        catch ME 
        end 
     SDS_matrix_5((i),:)=[compass_points(j,:),B,sds,bias,sdskew]; 
  
    end 
  
    %Repeat the process to generate SDS_matrix_6 
    for i=1:z 
         B=50*i; 
     sds = nan; bias = nan; sdskew = nan; 
        try 
         [BTRAIN,CNTER]=replica(TNSPEC,B); 
     [sds,sdskew,qrr] = qb(TNSPEC,BTRAIN,newspec,CNTER,radfrac,sensitiv); 
     bias=sds-expected_standard_deviation(j); 
        catch ME 
        end 
        SDS_matrix_6((i),:)=[compass_points(j,:),B,sds,bias,sdskew]; 
    end 
  
%***All storage has to happen here*** 
%This is the innermost iterative loop of the program. 
 
 
%Generate a matrix of the average of the 6 runs. 
%AVERAGE contains[compass_points(j,:),B,sds,bias,sdskew] in that order 
%Note that AVERAGE increases in size as dimension increases.  
%When dimension increases by one, one additional column is inserted in 
%the three position.  This can be expressed by the following:  
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    %sdskew is located in a column position equal to 6+v, or in 
    %AVERAGE(:,6+v) 
    %bias is located in (:,5+v) 
    %sds is located in (:,4+v) 
    %B is located in (:,3+v,) 
    %compass points are located in(:,1:v+2) 
AVERAGE=zeros(size(SDS_matrix)); 
AVERAGE=((SDS_matrix + SDS_matrix_2 + SDS_matrix_3 +SDS_matrix_4 + 
SDS_matrix_5 + SDS_matrix_6))/6; 
 
%Populate SDS_X_STDEV with the SD values of each run 
%sds is located in (:,4:v) 
SDS_1_STDEV=zeros(z,1); 
SDS_1_STDEV(:,1)=SDS_matrix(:,(4+v)); 
 
SDS_2_STDEV=zeros(z,1); 
SDS_2_STDEV(:,1)=SDS_matrix_2(:,(4+v)); 
 
SDS_3_STDEV=zeros(z,1); 
SDS_3_STDEV(:,1)=SDS_matrix_3(:,(4+v)); 
 
SDS_4_STDEV=zeros(z,1); 
SDS_4_STDEV(:,1)=SDS_matrix_4(:,(4+v)); 
 
SDS_5_STDEV=zeros(z,1); 
SDS_5_STDEV(:,1)=SDS_matrix_5(:,(4+v)); 
 
SDS_6_STDEV=zeros(z,1); 
SDS_6_STDEV(:,1)=SDS_matrix_6(:,(4+v)); 
 
%Populate SDS_X_STDEV_calc with SDS_X_STDEV - average for STDEV 
SDS_1_STDEV_calc=zeros(z,1); 
SDS_1_STDEV_calc(:,1)=((SDS_1_STDEV(:,1)-AVERAGE(:,(4+v))).^2); 
 
SDS_2_STDEV_calc=zeros(z,1); 
SDS_2_STDEV_calc(:,1)=((SDS_2_STDEV(:,1)-AVERAGE(:,(4+v))).^2); 
 
SDS_3_STDEV_calc=zeros(z,1); 
SDS_3_STDEV_calc(:,1)=((SDS_3_STDEV(:,1)-AVERAGE(:,(4+v))).^2); 
 
SDS_4_STDEV_calc=zeros(z,1); 
SDS_4_STDEV_calc(:,1)=((SDS_4_STDEV(:,1)-AVERAGE(:,(4+v))).^2); 
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SDS_5_STDEV_calc=zeros(z,1); 
SDS_5_STDEV_calc(:,1)=((SDS_5_STDEV(:,1)-AVERAGE(:,(4+v))).^2); 
 
SDS_6_STDEV_calc=zeros(z,1); 
SDS_6_STDEV_calc(:,1)=((SDS_6_STDEV(:,1)-AVERAGE(:,(4+v))).^2); 
 
% Sum the above and calculate STANDARD_DEVIATION= 
FINAL_STDEV=zeros(z,1); 
FINAL_STDEV=(((SDS_1_STDEV_calc + SDS_2_STDEV_calc + SDS_3_STDEV_calc 
+ SDS_4_STDEV_calc + SDS_5_STDEV_calc + SDS_6_STDEV_calc)/6).^.5); 
 
 
 
%Store bias vs. B for each of the eight points of the ellipse,each TNSPEC, 
%and each Radfrac 
    %bias is located in AVERAGE(:,5+v) 
    %B is located in AVERAGE(:,3+v,) 
Bias_plot=zeros(z,7); 
Bias_plot(:,1)=AVERAGE(:,(3+v)); 
Bias_plot(:,2)=AVERAGE(:,(5+v)); 
Bias_plot(:,3)=(v+2); 
Bias_plot(:,4)=AVERAGE(:,1); 
Bias_plot(:,5)=AVERAGE(:,2); 
Bias_plot(:,6)=radfrac; 
Bias_plot(:,7)=u; 
%"NumVL{v+1}=Bias_plot" so that I v=0:dimension can be used at the  
%beginning of the v loop 
NumVL{radfrac_iteration_count,u,(v+1),j}=Bias_plot; 
%Indexing is {radfrac number, training, dimension - 1, compass point 
%number} 
 
%B is located in Bias_plot(:,1) 
%bias is located in Bias_plot(:,2) 
%dimension is located in Bias_plot(:,3) 
%First 2 coordinates of compass point located in Bias_plot(:,4) and (:,5) 
%radfrac located in Bias_plot(:,6) 
%Training set size located in Bias_plot(:,7) 
 
 
%Store Relative Standard Deviation (average standard deviation/ 
%average) 
%RSD holds [compass point coordinate, compass point coordinate,B,RSD of 
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%returned standard deviation, total number of dimensions (v+2), radfrac,  
%Training Set Size] 
RSD=zeros(z,7); 
RSD(:,1)=AVERAGE(:,1); 
RSD(:,2)=AVERAGE(:,2); 
RSD(:,3)=AVERAGE(:,(v+3)); 
RSD(:,4)=(FINAL_STDEV(:,1)./AVERAGE(:,(v+4))); 
RSD(:,5)=(v+2); 
RSD(:,6)=radfrac; 
RSD(:,7)=u; 
 
%Hold all RSD plots for all runs 
%Indexing is {Radfrac Iteration Count (must 
%separately count Radfrac value),Training Set Size,dimension,Compass Point,} 
RSD_NumVL{radfrac_iteration_count,u,(v+1),j}=RSD; 
end 
 
 
 
 
%Plot Code  
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Plotting_Code_Increase_Radfrac_Bootstrap 
%This code plots bootstrapping vs. bias as radfrac increases 
 
%Indexing in NumVL Cell Matrix is as Follows: 
%{radfrac number, training, dimension - 1, compass point 
%number} 
 
%Within matrix: 
%B is located in Bias_plot(:,1) 
%bias is located in Bias_plot(:,2) 
%dimension is located in Bias_plot(:,3) 
%First 2 coordinates of compass point located in Bias_plot(:,4) and (:,5) 
%radfrac located in Bias_plot(:,6) 
%Training set size located in Bias_plot(:,7) 
 
%Set Axis Limits for All Graphs: 
graphlimits=[50,500,-40,40]; 
 
figure('Name','1,1,1 npa') 
r1_t50_d2_c01=[NumVL{1,1,1,1}] 
%x 100 to make a percent error 
r1_t50_d2_c01per=[r1_t50_d2_c01(:,:).*100] 
%x is out of original plot, y out of x 100 
plot (r1_t50_d2_c01(:,1),r1_t50_d2_c01per(:,2)); 
hold on 
r1_t50_d2_cneg01=[NumVL{1,1,1,5}] 
%x 100 to make a percent error 
r1_t50_d2_cneg01per=[r1_t50_d2_cneg01(:,:).*100] 
%x is out of original plot, y out of x 100 
plot (r1_t50_d2_cneg01(:,1),r1_t50_d2_cneg01per(:,2)); 
title({'Average Percent Error as Bootstrap Replicates Increase';'Radfrac=0.5 
Dimension=2 TNSPEC=50'}) 
xlabel('Bootstrap Replications') 
ylabel('Percent Error') 
legend('CP=(0,1)','CP=(0,-1)') 
axis(graphlimits) 
hold off 
 
 
 
    figure('Name','2,1,1 npa') 
    r2_t50_d2_c01=[NumVL{2,1,1,1}]; 
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    %x 100 to make a percent error 
    r2_t50_d2_c01per=[r2_t50_d2_c01(:,:).*100] 
    %x is out of original plot, y out of x 100 
    plot (r2_t50_d2_c01(:,1),r2_t50_d2_c01per(:,2)); 
       hold on 
    r2_t50_d2_cneg01=[NumVL{2,1,1,5}]; 
    %x 100 to make a percent error 
    r2_t50_d2_cneg01per=[r2_t50_d2_cneg01(:,:).*100] 
    %x is out of original plot, y out of x 100 
    plot (r2_t50_d2_cneg01(:,1),r2_t50_d2_cneg01per(:,2)); 
    title({'Average Percent Error as Bootstrap Replicates Increase';'Radfrac=0.6 
Dimension=2 TNSPEC=50'}) 
    xlabel('Bootstrap Replications') 
    ylabel('Percent Error') 
    legend('CP=(0,1)','CP=(0,-1)') 
    axis(graphlimits) 
    hold off 
 
figure('Name','3,1,1 npa') 
r3_t50_d2_c01=[NumVL{3,1,1,1}] 
%x 100 to make a percent error 
r3_t50_d2_c01per=[r3_t50_d2_c01(:,:).*100] 
%x is out of original plot, y out of x 100 
plot (r3_t50_d2_c01(:,1),r3_t50_d2_c01per(:,2)); 
 
hold on 
r3_t50_d2_cneg01=[NumVL{3,1,1,5}]; 
%x 100 to make a percent error 
r3_t50_d2_cneg01per=[r3_t50_d2_cneg01(:,:).*100]; 
%x is out of original plot, y out of x 100 
plot (r3_t50_d2_cneg01(:,1),r3_t50_d2_cneg01per(:,2)); 
title({'Average Percent Error as Bootstrap Replicates Increase';'Radfrac=0.7 
Dimension=2 TNSPEC=50'}) 
xlabel('Bootstrap Replications') 
ylabel('Percent Error') 
legend('CP=(0,1)','CP=(0,-1)') 
axis(graphlimits) 
hold off 
 
    figure('Name','4,1,1 npa') 
    r4_t50_d2_c01=[NumVL{4,1,1,1}] 
    %x 100 to make a percent error 
    r4_t50_d2_c01per=[r4_t50_d2_c01(:,:).*100] 
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    %x is out of original plot, y out of x 100 
    plot (r4_t50_d2_c01(:,1),r4_t50_d2_c01per(:,2)); 
    hold on 
    r4_t50_d2_cneg01=[NumVL{4,1,1,5}]; 
    %x 100 to make a percent error 
    r4_t50_d2_cneg01per=[r4_t50_d2_cneg01(:,:).*100] 
    %x is out of original plot, y out of x 100 
    plot (r4_t50_d2_cneg01(:,1),r4_t50_d2_cneg01per(:,2)); 
    title({'Average Percent Error as Bootstrap Replicates Increase';... 
        'Radfrac=0.8 Dimension=2 TNSPEC=50'}) 
    xlabel('Bootstrap Replications') 
    ylabel('Percent Error') 
    legend('CP=(0,1)','CP=(0,-1)') 
    axis(graphlimits) 
    hold off 
  
figure('Name','5,1,1 npa') 
r5_t50_d2_c01=[NumVL{5,1,1,1}] 
%x 100 to make a percent error 
r5_t50_d2_c01per=[r5_t50_d2_c01(:,:).*100] 
%x is out of original plot, y out of x 100 
plot (r5_t50_d2_c01(:,1),r5_t50_d2_c01per(:,2)); 
hold on 
r5_t50_d2_cneg01=[NumVL{5,1,1,5}] 
%x 100 to make a percent error 
r5_t50_d2_cneg01per=[r5_t50_d2_cneg01(:,:).*100]; 
%x is out of original plot, y out of x 100 
plot (r5_t50_d2_cneg01(:,1),r5_t50_d2_cneg01per(:,2)); 
title({'Average Percent Error as Bootstrap Replicates Increase';... 
'Radfrac=0.9 Dimension=2 TNSPEC=50'}) 
xlabel('Bootstrap Replications') 
ylabel('Percent Error') 
legend('CP=(0,1)','CP=(0,-1)') 
axis(graphlimits) 
hold off 
 
%Generate Last Figure 
    figure('Name','6,1,1 npa') 
    r6_t50_d2_c01=[NumVL{6,1,1,1}] 
     %Out of matrix variables to assign, so is being multiplied 
    %x 100 to make a percent error 
    %x 100 to make a percent error 
    r6_t50_d2_c01per=[r6_t50_d2_c01(:,:).*100] 
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    %x is out of original plot, y out of x 100 
    plot (r6_t50_d2_c01(:,1),r6_t50_d2_c01per(:,2)) 
    hold on 
    r6_t50_d2_cneg01=[NumVL{6,1,1,5}]; 
    %x 100 to make a percent error 
    r6_t50_d2_cneg01per=[r6_t50_d2_cneg01(:,:).*100]; 
    %x is out of original plot, y out of x 100 
    plot(r6_t50_d2_cneg01(:,1),r6_t50_d2_cneg01per(:,2)) 
    title({'Average Percent Error as Bootstrap Replicates Increase';... 
        'Radfrac=1.0 Dimension=2 TNSPEC=50'}) 
    xlabel('Bootstrap Replications') 
    ylabel('Percent Error') 
    legend('CP=(0,1)','CP=(0,-1)') 
    axis(graphlimits) 
    hold off  
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Plotting_Code_Increase_TNSPEC_Dimension 
%This code plots tnspec vs. bias as dimension increases 
 
 
%Indexing in NumVL Cell Matrix is as Follows: 
%{radfrac number, training, dimension - 1, compass point 
%number} 
 
%Within matrix: 
%B is located in Bias_plot(:,1) 
%bias is located in Bias_plot(:,2) 
%dimension is located in Bias_plot(:,3) 
%First 2 coordinates of compass point located in Bias_plot(:,4) and (:,5) 
%radfrac located in Bias_plot(:,6) 
%Training set size located in Bias_plot(:,7) 
 
%Get all for (0,1) Compass Points 
r1_t50_d2_c01=[NumVL{1,1,1,1}]; 
r1_t100_d2_c01=[NumVL{1,2,1,1}]; 
r1_t150_d2_c01=[NumVL{1,3,1,1}]; 
r1_t200_d2_c01=[NumVL{1,4,1,1}]; 
r1_t250_d2_c01=[NumVL{1,5,1,1}]; 
r1_t300_d2_c01=[NumVL{1,6,1,1}]; 
r1_t350_d2_c01=[NumVL{1,7,1,1}]; 
r1_t400_d2_c01=[NumVL{1,8,1,1}]; 
r1_t450_d2_c01=[NumVL{1,9,1,1}]; 
r1_t500_d2_c01=[NumVL{1,10,1,1}]; 
 
Increasing_TNSPEC=[r1_t50_d2_c01(10,:);r1_t100_d2_c01(10,:);... 
    r1_t150_d2_c01(10,:);r1_t200_d2_c01(10,:);r1_t250_d2_c01(10,:);... 
    r1_t300_d2_c01(10,:);r1_t350_d2_c01(10,:);r1_t400_d2_c01(10,:);... 
    r1_t450_d2_c01(10,:);r1_t500_d2_c01(10,:)] 
 
%Get all (0,-1) Compass Points 
r1_t50_d2_cneg01=[NumVL{1,1,1,5}]; 
r1_t100_d2_cneg01=[NumVL{1,2,1,5}]; 
r1_t150_d2_cneg01=[NumVL{1,3,1,5}]; 
r1_t200_d2_cneg01=[NumVL{1,4,1,5}]; 
r1_t250_d2_cneg01=[NumVL{1,5,1,5}]; 
r1_t300_d2_cneg01=[NumVL{1,6,1,5}]; 
r1_t350_d2_cneg01=[NumVL{1,7,1,5}]; 
r1_t400_d2_cneg01=[NumVL{1,8,1,5}]; 
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r1_t450_d2_cneg01=[NumVL{1,9,1,5}]; 
r1_t500_d2_cneg01=[NumVL{1,10,1,5}]; 
 
Increasing_TNSPEC_neg=[r1_t50_d2_cneg01(10,:);r1_t100_d2_cneg01(10,:);... 
    r1_t150_d2_cneg01(10,:);r1_t200_d2_cneg01(10,:);r1_t250_d2_cneg01(10,:);... 
    r1_t300_d2_cneg01(10,:);r1_t350_d2_cneg01(10,:);r1_t400_d2_cneg01(10,:);... 
    r1_t450_d2_cneg01(10,:);r1_t500_d2_cneg01(10,:)] 
 
figure('Name','1,1,1 npa') 
plot (Increasing_TNSPEC(:,7),(Increasing_TNSPEC(:,2).*100)); 
%gives relative error b/c true value is 1.  Answer/1*100% = relative error 
 
hold on 
plot (Increasing_TNSPEC_neg(:,7),(Increasing_TNSPEC_neg(:,2).*100)); 
title({'Average Percent Error as Training Set Size Increases';'Dimension=2 Radfrac=0.5 
Bootstrap Replicates=500'}) 
xlabel('Training Set Size') 
ylabel('Percent Error') 
legend('CP=(0,1)','CP=(0,-1)') 
hold off 
 
 
    %Make second graph for dimension=3 
 
    r1_t50_d3_c01=[NumVL{1,1,2,1}] 
    r1_t100_d3_c01=[NumVL{1,2,2,1}] 
    r1_t150_d3_c01=[NumVL{1,3,2,1}]; 
    r1_t200_d3_c01=[NumVL{1,4,2,1}]; 
    r1_t250_d3_c01=[NumVL{1,5,2,1}]; 
    r1_t300_d3_c01=[NumVL{1,6,2,1}]; 
    r1_t350_d3_c01=[NumVL{1,7,2,1}]; 
    r1_t400_d3_c01=[NumVL{1,8,2,1}]; 
    r1_t450_d3_c01=[NumVL{1,9,2,1}]; 
    r1_t500_d3_c01=[NumVL{1,10,2,1}]; 
 
    Increasing_TNSPEC2=[r1_t50_d3_c01(10,:);r1_t100_d3_c01(10,:);... 
        r1_t150_d3_c01(10,:);r1_t200_d3_c01(10,:);r1_t250_d3_c01(10,:);... 
        r1_t300_d3_c01(10,:);r1_t350_d3_c01(10,:);r1_t400_d3_c01(10,:);... 
        r1_t450_d3_c01(10,:);r1_t500_d3_c01(10,:)] 
  
    r1_t50_d3_cneg01=[NumVL{1,1,2,5}] 
    r1_t100_d3_cneg01=[NumVL{1,2,2,5}] 
    r1_t150_d3_cneg01=[NumVL{1,3,2,5}]; 
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    r1_t200_d3_cneg01=[NumVL{1,4,2,5}]; 
    r1_t250_d3_cneg01=[NumVL{1,5,2,5}]; 
    r1_t300_d3_cneg01=[NumVL{1,6,2,5}]; 
    r1_t350_d3_cneg01=[NumVL{1,7,2,5}]; 
    r1_t400_d3_cneg01=[NumVL{1,8,2,5}]; 
    r1_t450_d3_cneg01=[NumVL{1,9,2,5}]; 
    r1_t500_d3_cneg01=[NumVL{1,10,2,5}]; 
 
    Increasing_TNSPEC2neg=[r1_t50_d3_cneg01(10,:);r1_t100_d3_cneg01(10,:);... 
        r1_t150_d3_cneg01(10,:);r1_t200_d3_cneg01(10,:);r1_t250_d3_cneg01(10,:);... 
        r1_t300_d3_cneg01(10,:);r1_t350_d3_cneg01(10,:);r1_t400_d3_cneg01(10,:);... 
        r1_t450_d3_cneg01(10,:);r1_t500_d3_cneg01(10,:)] 
 
    figure('Name','1,1,2 npa') 
    plot (Increasing_TNSPEC2(:,7),(Increasing_TNSPEC2(:,2).*100)); 
    hold on 
   plot (Increasing_TNSPEC2neg(:,7),(Increasing_TNSPEC2neg(:,2).*100)); 
    title({'Average Percent Error as Training Set Size Increases';... 
        'Dimension=3 Radfrac=0.5 Bootstrap Replicates=500'}) 
    xlabel('Training Set Size') 
    ylabel('Percent Error') 
    legend('CP=(0,1)','CP=(0,-1)') 
    hold off 
  
  
    %Make a third graph for 4 dimensions 
r1_t50_d4_c01=[NumVL{1,1,3,1}]; 
r1_t100_d4_c01=[NumVL{1,2,3,1}]; 
r1_t150_d4_c01=[NumVL{1,3,3,1}]; 
r1_t200_d4_c01=[NumVL{1,4,3,1}]; 
r1_t250_d4_c01=[NumVL{1,5,3,1}]; 
r1_t300_d4_c01=[NumVL{1,6,3,1}]; 
r1_t350_d4_c01=[NumVL{1,7,3,1}]; 
r1_t400_d4_c01=[NumVL{1,8,3,1}]; 
r1_t450_d4_c01=[NumVL{1,9,3,1}]; 
r1_t500_d4_c01=[NumVL{1,10,3,1}]; 
 
Increasing_TNSPEC3=[r1_t50_d4_c01(10,:);r1_t100_d4_c01(10,:);... 
    r1_t150_d4_c01(10,:);r1_t200_d4_c01(10,:);r1_t250_d4_c01(10,:);... 
    r1_t300_d4_c01(10,:);r1_t350_d4_c01(10,:);r1_t400_d4_c01(10,:);... 
    r1_t450_d4_c01(10,:);r1_t500_d4_c01(10,:)] 
 
r1_t50_d4_cneg01=[NumVL{1,1,3,5}]; 
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r1_t100_d4_cneg01=[NumVL{1,2,3,5}]; 
r1_t150_d4_cneg01=[NumVL{1,3,3,5}]; 
r1_t200_d4_cneg01=[NumVL{1,4,3,5}]; 
r1_t250_d4_cneg01=[NumVL{1,5,3,5}]; 
r1_t300_d4_cneg01=[NumVL{1,6,3,5}]; 
r1_t350_d4_cneg01=[NumVL{1,7,3,5}]; 
r1_t400_d4_cneg01=[NumVL{1,8,3,5}]; 
r1_t450_d4_cneg01=[NumVL{1,9,3,5}]; 
r1_t500_d4_cneg01=[NumVL{1,10,3,5}]; 
 
Increasing_TNSPEC3neg=[r1_t50_d4_cneg01(10,:);r1_t100_d4_cneg01(10,:);... 
    r1_t150_d4_cneg01(10,:);r1_t200_d4_cneg01(10,:);r1_t250_d4_cneg01(10,:);... 
    r1_t300_d4_cneg01(10,:);r1_t350_d4_cneg01(10,:);r1_t400_d4_cneg01(10,:);... 
    r1_t450_d4_cneg01(10,:);r1_t500_d4_cneg01(10,:)] 
 
figure('Name','1,1,3 npa') 
plot (Increasing_TNSPEC3neg(:,7),(Increasing_TNSPEC3(:,2).*100)); 
hold on 
plot (Increasing_TNSPEC_neg(:,7),(Increasing_TNSPEC_neg(:,2).*100)); 
title({'Average Percent Error as Training Set Size Increases';... 
    'Dimension=4 Radfrac=0.5 Bootstrap Replicates=500'}) 
xlabel('Training Set Size') 
ylabel('Percent Error') 
legend('CP=(0,1)','CP=(0,-1)') 
hold off 
 
 
%Make a graph for 11 dimensions 
r1_t50_d11_c01=[NumVL{1,1,10,1}]; 
r1_t100_d11_c01=[NumVL{1,2,10,1}]; 
r1_t150_d11_c01=[NumVL{1,3,10,1}]; 
r1_t200_d11_c01=[NumVL{1,4,10,1}]; 
r1_t250_d11_c01=[NumVL{1,5,10,1}]; 
r1_t300_d11_c01=[NumVL{1,6,10,1}]; 
r1_t350_d11_c01=[NumVL{1,7,10,1}]; 
r1_t400_d11_c01=[NumVL{1,8,10,1}]; 
r1_t450_d11_c01=[NumVL{1,9,10,1}]; 
r1_t500_d11_c01=[NumVL{1,10,10,1}]; 
 
Increasing_TNSPEC11=[r1_t50_d11_c01(10,:);r1_t100_d11_c01(10,:);... 
    r1_t150_d11_c01(10,:);r1_t200_d11_c01(10,:);r1_t250_d11_c01(10,:);... 
    r1_t300_d11_c01(10,:);r1_t350_d11_c01(10,:);r1_t400_d11_c01(10,:);... 
    r1_t450_d11_c01(10,:);r1_t500_d11_c01(10,:)] 
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r1_t50_d11_cneg01=[NumVL{1,1,10,5}]; 
r1_t100_d11_cneg01=[NumVL{1,2,10,5}]; 
r1_t150_d11_cneg01=[NumVL{1,3,10,5}]; 
r1_t200_d11_cneg01=[NumVL{1,4,10,5}]; 
r1_t250_d11_cneg01=[NumVL{1,5,10,5}]; 
r1_t300_d11_cneg01=[NumVL{1,6,10,5}]; 
r1_t350_d11_cneg01=[NumVL{1,7,10,5}]; 
r1_t400_d11_cneg01=[NumVL{1,8,10,5}]; 
r1_t450_d11_cneg01=[NumVL{1,9,10,5}]; 
r1_t500_d11_cneg01=[NumVL{1,10,10,5}]; 
 
Increasing_TNSPEC11neg=[r1_t50_d11_cneg01(10,:);r1_t100_d11_cneg01(10,:);... 
    r1_t150_d11_cneg01(10,:);r1_t200_d11_cneg01(10,:);r1_t250_d11_cneg01(10,:);... 
    r1_t300_d11_cneg01(10,:);r1_t350_d11_cneg01(10,:);r1_t400_d11_cneg01(10,:);... 
    r1_t450_d11_cneg01(10,:);r1_t500_d11_cneg01(10,:)] 
 
figure('Name','1,1,10 npa') 
plot (Increasing_TNSPEC11(:,7),(Increasing_TNSPEC11(:,2).*100)); 
hold on 
plot (Increasing_TNSPEC11neg(:,7),(Increasing_TNSPEC11neg(:,2).*100)); 
title({'Average Percent Error as Training Set Size Increases';'Dimension=11 Radfrac=0.5 
Bootstrap Replicates=500'}) 
xlabel('Training Set Size') 
ylabel('Percent Error') 
legend('CP=(0,1)','CP=(0,-1)') 
hold off  
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Plotting_Code_Increase_Radfrac_Bootstrap 
%This code plots bootstrapping vs. bias as radfrac increases 
%Indexing in NumVL Cell Matrix is as Follows: 
%{radfrac number, training, dimension - 1, compass point 
%number} 
%Within matrix: 
%B is located in Bias_plot(:,1) 
%bias is located in Bias_plot(:,2) 
%dimension is located in Bias_plot(:,3) 
%First 2 coordinates of compass point located in Bias_plot(:,4) and (:,5) 
%radfrac located in Bias_plot(:,6) 
%Training set size located in Bias_plot(:,7) 
%Set Axis Limits for All Graphs: 
graphlimits=[50,500,-40,40]; 
figure('Name','1,1,1 npa') 
r1_t50_d2_c01=[NumVL{1,1,1,1}] 
%x 100 to make a percent error 
r1_t50_d2_c01per=[r1_t50_d2_c01(:,:).*100] 
%x is out of original plot, y out of x 100 
plot (r1_t50_d2_c01(:,1),r1_t50_d2_c01per(:,2)); 
hold on 
r1_t50_d2_cneg01=[NumVL{1,1,1,5}] 
%x 100 to make a percent error 
r1_t50_d2_cneg01per=[r1_t50_d2_cneg01(:,:).*100] 
%x is out of original plot, y out of x 100 
plot (r1_t50_d2_cneg01(:,1),r1_t50_d2_cneg01per(:,2)); 
title({'Average Percent Error as Bootstrap Replicates Increase';'Radfrac=0.5 
Dimension=2 TNSPEC=50'}) 
xlabel('Bootstrap Replications') 
ylabel('Percent Error') 
legend('CP=(0,1)','CP=(0,-1)') 
axis(graphlimits) 
hold off 
    figure('Name','2,1,1 npa') 
    r2_t50_d2_c01=[NumVL{2,1,1,1}]; 
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    %x 100 to make a percent error 
    r2_t50_d2_c01per=[r2_t50_d2_c01(:,:).*100] 
    %x is out of original plot, y out of x 100 
    plot (r2_t50_d2_c01(:,1),r2_t50_d2_c01per(:,2)); 
       hold on 
    r2_t50_d2_cneg01=[NumVL{2,1,1,5}]; 
    %x 100 to make a percent error 
    r2_t50_d2_cneg01per=[r2_t50_d2_cneg01(:,:).*100] 
    %x is out of original plot, y out of x 100 
    plot (r2_t50_d2_cneg01(:,1),r2_t50_d2_cneg01per(:,2)); 
    title({'Average Percent Error as Bootstrap Replicates Increase';'Radfrac=0.6 
Dimension=2 TNSPEC=50'}) 
    xlabel('Bootstrap Replications') 
    ylabel('Percent Error') 
    legend('CP=(0,1)','CP=(0,-1)') 
    axis(graphlimits) 
    hold off 
 
figure('Name','3,1,1 npa') 
r3_t50_d2_c01=[NumVL{3,1,1,1}] 
%x 100 to make a percent error 
r3_t50_d2_c01per=[r3_t50_d2_c01(:,:).*100] 
%x is out of original plot, y out of x 100 
plot (r3_t50_d2_c01(:,1),r3_t50_d2_c01per(:,2)); 
 
hold on 
r3_t50_d2_cneg01=[NumVL{3,1,1,5}]; 
%x 100 to make a percent error 
r3_t50_d2_cneg01per=[r3_t50_d2_cneg01(:,:).*100]; 
%x is out of original plot, y out of x 100 
plot (r3_t50_d2_cneg01(:,1),r3_t50_d2_cneg01per(:,2)); 
title({'Average Percent Error as Bootstrap Replicates Increase';'Radfrac=0.7 
Dimension=2 TNSPEC=50'}) 
xlabel('Bootstrap Replications') 
ylabel('Percent Error') 
legend('CP=(0,1)','CP=(0,-1)') 
axis(graphlimits) 
hold off 
 
    figure('Name','4,1,1 npa') 
    r4_t50_d2_c01=[NumVL{4,1,1,1}] 
    %x 100 to make a percent error 
    r4_t50_d2_c01per=[r4_t50_d2_c01(:,:).*100] 
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    %x is out of original plot, y out of x 100 
    plot (r4_t50_d2_c01(:,1),r4_t50_d2_c01per(:,2)); 
    hold on 
    r4_t50_d2_cneg01=[NumVL{4,1,1,5}]; 
    %x 100 to make a percent error 
    r4_t50_d2_cneg01per=[r4_t50_d2_cneg01(:,:).*100] 
    %x is out of original plot, y out of x 100 
    plot (r4_t50_d2_cneg01(:,1),r4_t50_d2_cneg01per(:,2)); 
    title({'Average Percent Error as Bootstrap Replicates Increase';... 
        'Radfrac=0.8 Dimension=2 TNSPEC=50'}) 
    xlabel('Bootstrap Replications') 
    ylabel('Percent Error') 
    legend('CP=(0,1)','CP=(0,-1)') 
    axis(graphlimits) 
    hold off 
  
figure('Name','5,1,1 npa') 
r5_t50_d2_c01=[NumVL{5,1,1,1}] 
%x 100 to make a percent error 
r5_t50_d2_c01per=[r5_t50_d2_c01(:,:).*100] 
%x is out of original plot, y out of x 100 
plot (r5_t50_d2_c01(:,1),r5_t50_d2_c01per(:,2)); 
hold on 
r5_t50_d2_cneg01=[NumVL{5,1,1,5}] 
%x 100 to make a percent error 
r5_t50_d2_cneg01per=[r5_t50_d2_cneg01(:,:).*100]; 
%x is out of original plot, y out of x 100 
plot (r5_t50_d2_cneg01(:,1),r5_t50_d2_cneg01per(:,2)); 
title({'Average Percent Error as Bootstrap Replicates Increase';... 
'Radfrac=0.9 Dimension=2 TNSPEC=50'}) 
xlabel('Bootstrap Replications') 
ylabel('Percent Error') 
legend('CP=(0,1)','CP=(0,-1)') 
axis(graphlimits) 
hold off 
 
%Generate Last Figure 
    figure('Name','6,1,1 npa') 
    r6_t50_d2_c01=[NumVL{6,1,1,1}] 
     %Out of matrix variables to assign, so is being multiplied 
    %x 100 to make a percent error 
    %x 100 to make a percent error 
    r6_t50_d2_c01per=[r6_t50_d2_c01(:,:).*100] 
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    %x is out of original plot, y out of x 100 
    plot (r6_t50_d2_c01(:,1),r6_t50_d2_c01per(:,2)) 
    hold on 
    r6_t50_d2_cneg01=[NumVL{6,1,1,5}]; 
    %x 100 to make a percent error 
    r6_t50_d2_cneg01per=[r6_t50_d2_cneg01(:,:).*100]; 
    %x is out of original plot, y out of x 100 
    plot(r6_t50_d2_cneg01(:,1),r6_t50_d2_cneg01per(:,2)) 
    title({'Average Percent Error as Bootstrap Replicates Increase';... 
        'Radfrac=1.0 Dimension=2 TNSPEC=50'}) 
    xlabel('Bootstrap Replications') 
    ylabel('Percent Error') 
    legend('CP=(0,1)','CP=(0,-1)') 
    axis(graphlimits) 
    hold off  
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Plotting_Code_Increase_Bootstrap_Radfrac 
%This code plots bootstrapping vs. bias as radfrac increases 
%Indexing in NumVL Cell Matrix is as Follows: 
%{radfrac number, training, dimension - 1, compass point 
%number} 
%Within matrix: 
%B is located in Bias_plot(:,1) 
%bias is located in Bias_plot(:,2) 
%dimension is located in Bias_plot(:,3) 
%First 2 coordinates of compass point located in Bias_plot(:,4) and (:,5) 
%radfrac located in Bias_plot(:,6) 
%Training set size located in Bias_plot(:,7) 
%Set Axis Limits for All Graphs: 
graphlimits=[50,500,-40,40]; 
figure('Name','1,1,1 npa') 
r1_t50_d2_c01=[NumVL{1,1,1,1}] 
%x 100 to make a percent error 
r1_t50_d2_c01per=[r1_t50_d2_c01(:,:).*100] 
%x is out of original plot, y out of x 100 
plot (r1_t50_d2_c01(:,1),r1_t50_d2_c01per(:,2)); 
hold on 
r1_t50_d2_cneg01=[NumVL{1,1,1,5}] 
%x 100 to make a percent error 
r1_t50_d2_cneg01per=[r1_t50_d2_cneg01(:,:).*100] 
%x is out of original plot, y out of x 100 
plot (r1_t50_d2_cneg01(:,1),r1_t50_d2_cneg01per(:,2)); 
title({'Average Percent Error as Bootstrap Replicates Increase';'Radfrac=0.5 
Dimension=2 TNSPEC=50'}) 
xlabel('Bootstrap Replications') 
ylabel('Percent Error') 
legend('CP=(0,1)','CP=(0,-1)') 
axis(graphlimits) 
hold off 
    figure('Name','2,1,1 npa') 
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    r2_t50_d2_c01=[NumVL{2,1,1,1}]; 
    %x 100 to make a percent error 
    r2_t50_d2_c01per=[r2_t50_d2_c01(:,:).*100] 
    %x is out of original plot, y out of x 100 
    plot (r2_t50_d2_c01(:,1),r2_t50_d2_c01per(:,2)); 
       hold on 
    r2_t50_d2_cneg01=[NumVL{2,1,1,5}]; 
    %x 100 to make a percent error 
    r2_t50_d2_cneg01per=[r2_t50_d2_cneg01(:,:).*100] 
    %x is out of original plot, y out of x 100 
    plot (r2_t50_d2_cneg01(:,1),r2_t50_d2_cneg01per(:,2)); 
    title({'Average Percent Error as Bootstrap Replicates Increase';'Radfrac=0.6 
Dimension=2 TNSPEC=50'}) 
    xlabel('Bootstrap Replications') 
    ylabel('Percent Error') 
    legend('CP=(0,1)','CP=(0,-1)') 
    axis(graphlimits) 
    hold off 
 
figure('Name','3,1,1 npa') 
r3_t50_d2_c01=[NumVL{3,1,1,1}] 
%x 100 to make a percent error 
r3_t50_d2_c01per=[r3_t50_d2_c01(:,:).*100] 
%x is out of original plot, y out of x 100 
plot (r3_t50_d2_c01(:,1),r3_t50_d2_c01per(:,2)); 
 
hold on 
r3_t50_d2_cneg01=[NumVL{3,1,1,5}]; 
%x 100 to make a percent error 
r3_t50_d2_cneg01per=[r3_t50_d2_cneg01(:,:).*100]; 
%x is out of original plot, y out of x 100 
plot (r3_t50_d2_cneg01(:,1),r3_t50_d2_cneg01per(:,2)); 
title({'Average Percent Error as Bootstrap Replicates Increase';'Radfrac=0.7 
Dimension=2 TNSPEC=50'}) 
xlabel('Bootstrap Replications') 
ylabel('Percent Error') 
legend('CP=(0,1)','CP=(0,-1)') 
axis(graphlimits) 
hold off 
 
    figure('Name','4,1,1 npa') 
    r4_t50_d2_c01=[NumVL{4,1,1,1}] 
    %x 100 to make a percent error 
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    r4_t50_d2_c01per=[r4_t50_d2_c01(:,:).*100] 
    %x is out of original plot, y out of x 100 
    plot (r4_t50_d2_c01(:,1),r4_t50_d2_c01per(:,2)); 
    hold on 
    r4_t50_d2_cneg01=[NumVL{4,1,1,5}]; 
    %x 100 to make a percent error 
    r4_t50_d2_cneg01per=[r4_t50_d2_cneg01(:,:).*100] 
    %x is out of original plot, y out of x 100 
    plot (r4_t50_d2_cneg01(:,1),r4_t50_d2_cneg01per(:,2)); 
    title({'Average Percent Error as Bootstrap Replicates Increase';... 
        'Radfrac=0.8 Dimension=2 TNSPEC=50'}) 
    xlabel('Bootstrap Replications') 
    ylabel('Percent Error') 
    legend('CP=(0,1)','CP=(0,-1)') 
    axis(graphlimits) 
    hold off 
  
figure('Name','5,1,1 npa') 
r5_t50_d2_c01=[NumVL{5,1,1,1}] 
%x 100 to make a percent error 
r5_t50_d2_c01per=[r5_t50_d2_c01(:,:).*100] 
%x is out of original plot, y out of x 100 
plot (r5_t50_d2_c01(:,1),r5_t50_d2_c01per(:,2)); 
hold on 
r5_t50_d2_cneg01=[NumVL{5,1,1,5}] 
%x 100 to make a percent error 
r5_t50_d2_cneg01per=[r5_t50_d2_cneg01(:,:).*100]; 
%x is out of original plot, y out of x 100 
plot (r5_t50_d2_cneg01(:,1),r5_t50_d2_cneg01per(:,2)); 
title({'Average Percent Error as Bootstrap Replicates Increase';... 
'Radfrac=0.9 Dimension=2 TNSPEC=50'}) 
xlabel('Bootstrap Replications') 
ylabel('Percent Error') 
legend('CP=(0,1)','CP=(0,-1)') 
axis(graphlimits) 
hold off 
 
%Generate Last Figure 
    figure('Name','6,1,1 npa') 
    r6_t50_d2_c01=[NumVL{6,1,1,1}] 
     %Out of matrix variables to assign, so is being multiplied 
    %x 100 to make a percent error 
    %x 100 to make a percent error 
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    r6_t50_d2_c01per=[r6_t50_d2_c01(:,:).*100] 
    %x is out of original plot, y out of x 100 
    plot (r6_t50_d2_c01(:,1),r6_t50_d2_c01per(:,2)) 
    hold on 
    r6_t50_d2_cneg01=[NumVL{6,1,1,5}]; 
    %x 100 to make a percent error 
    r6_t50_d2_cneg01per=[r6_t50_d2_cneg01(:,:).*100]; 
    %x is out of original plot, y out of x 100 
    plot(r6_t50_d2_cneg01(:,1),r6_t50_d2_cneg01per(:,2)) 
    title({'Average Percent Error as Bootstrap Replicates Increase';... 
        'Radfrac=1.0 Dimension=2 TNSPEC=50'}) 
    xlabel('Bootstrap Replications') 
    ylabel('Percent Error') 
    legend('CP=(0,1)','CP=(0,-1)') 
    axis(graphlimits) 
    hold off 
 
  
 
164
Plotting_Code_Increase_TNSPEC_Dimension 
%This code plots tnspec vs. bias as dimension increases 
 
 
%Indexing in NumVL Cell Matrix is as Follows: 
%{radfrac number, training, dimension - 1, compass point 
%number} 
 
%Within matrix: 
%B is located in Bias_plot(:,1) 
%bias is located in Bias_plot(:,2) 
%dimension is located in Bias_plot(:,3) 
%First 2 coordinates of compass point located in Bias_plot(:,4) and (:,5) 
%radfrac located in Bias_plot(:,6) 
%Training set size located in Bias_plot(:,7) 
 
%Get all for (0,1) Compass Points 
r1_t50_d2_c01=[NumVL{1,1,1,1}]; 
r1_t100_d2_c01=[NumVL{1,2,1,1}]; 
r1_t150_d2_c01=[NumVL{1,3,1,1}]; 
r1_t200_d2_c01=[NumVL{1,4,1,1}]; 
r1_t250_d2_c01=[NumVL{1,5,1,1}]; 
r1_t300_d2_c01=[NumVL{1,6,1,1}]; 
r1_t350_d2_c01=[NumVL{1,7,1,1}]; 
r1_t400_d2_c01=[NumVL{1,8,1,1}]; 
r1_t450_d2_c01=[NumVL{1,9,1,1}]; 
r1_t500_d2_c01=[NumVL{1,10,1,1}]; 
 
Increasing_TNSPEC=[r1_t50_d2_c01(10,:);r1_t100_d2_c01(10,:);... 
    r1_t150_d2_c01(10,:);r1_t200_d2_c01(10,:);r1_t250_d2_c01(10,:);... 
    r1_t300_d2_c01(10,:);r1_t350_d2_c01(10,:);r1_t400_d2_c01(10,:);... 
    r1_t450_d2_c01(10,:);r1_t500_d2_c01(10,:)] 
 
%Get all (0,-1) Compass Points 
r1_t50_d2_cneg01=[NumVL{1,1,1,5}]; 
r1_t100_d2_cneg01=[NumVL{1,2,1,5}]; 
r1_t150_d2_cneg01=[NumVL{1,3,1,5}]; 
r1_t200_d2_cneg01=[NumVL{1,4,1,5}]; 
r1_t250_d2_cneg01=[NumVL{1,5,1,5}]; 
r1_t300_d2_cneg01=[NumVL{1,6,1,5}]; 
r1_t350_d2_cneg01=[NumVL{1,7,1,5}]; 
r1_t400_d2_cneg01=[NumVL{1,8,1,5}]; 
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r1_t450_d2_cneg01=[NumVL{1,9,1,5}]; 
r1_t500_d2_cneg01=[NumVL{1,10,1,5}]; 
 
Increasing_TNSPEC_neg=[r1_t50_d2_cneg01(10,:);r1_t100_d2_cneg01(10,:);... 
    r1_t150_d2_cneg01(10,:);r1_t200_d2_cneg01(10,:);r1_t250_d2_cneg01(10,:);... 
    r1_t300_d2_cneg01(10,:);r1_t350_d2_cneg01(10,:);r1_t400_d2_cneg01(10,:);... 
    r1_t450_d2_cneg01(10,:);r1_t500_d2_cneg01(10,:)] 
 
figure('Name','1,1,1 npa') 
plot (Increasing_TNSPEC(:,7),(Increasing_TNSPEC(:,2).*100)); 
%gives relative error b/c true value is 1.  Answer/1*100% = relative error 
 
hold on 
plot (Increasing_TNSPEC_neg(:,7),(Increasing_TNSPEC_neg(:,2).*100)); 
title({'Average Percent Error as Training Set Size Increases';'Dimension=2 Radfrac=0.5 
Bootstrap Replicates=500'}) 
xlabel('Training Set Size') 
ylabel('Percent Error') 
legend('CP=(0,1)','CP=(0,-1)') 
hold off 
 
 
    %Make second graph for dimension=3 
 
    r1_t50_d3_c01=[NumVL{1,1,2,1}] 
    r1_t100_d3_c01=[NumVL{1,2,2,1}] 
    r1_t150_d3_c01=[NumVL{1,3,2,1}]; 
    r1_t200_d3_c01=[NumVL{1,4,2,1}]; 
    r1_t250_d3_c01=[NumVL{1,5,2,1}]; 
    r1_t300_d3_c01=[NumVL{1,6,2,1}]; 
    r1_t350_d3_c01=[NumVL{1,7,2,1}]; 
    r1_t400_d3_c01=[NumVL{1,8,2,1}]; 
    r1_t450_d3_c01=[NumVL{1,9,2,1}]; 
    r1_t500_d3_c01=[NumVL{1,10,2,1}]; 
 
    Increasing_TNSPEC2=[r1_t50_d3_c01(10,:);r1_t100_d3_c01(10,:);... 
        r1_t150_d3_c01(10,:);r1_t200_d3_c01(10,:);r1_t250_d3_c01(10,:);... 
        r1_t300_d3_c01(10,:);r1_t350_d3_c01(10,:);r1_t400_d3_c01(10,:);... 
        r1_t450_d3_c01(10,:);r1_t500_d3_c01(10,:)] 
  
    r1_t50_d3_cneg01=[NumVL{1,1,2,5}] 
    r1_t100_d3_cneg01=[NumVL{1,2,2,5}] 
    r1_t150_d3_cneg01=[NumVL{1,3,2,5}]; 
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    r1_t200_d3_cneg01=[NumVL{1,4,2,5}]; 
    r1_t250_d3_cneg01=[NumVL{1,5,2,5}]; 
    r1_t300_d3_cneg01=[NumVL{1,6,2,5}]; 
    r1_t350_d3_cneg01=[NumVL{1,7,2,5}]; 
    r1_t400_d3_cneg01=[NumVL{1,8,2,5}]; 
    r1_t450_d3_cneg01=[NumVL{1,9,2,5}]; 
    r1_t500_d3_cneg01=[NumVL{1,10,2,5}]; 
 
    Increasing_TNSPEC2neg=[r1_t50_d3_cneg01(10,:);r1_t100_d3_cneg01(10,:);... 
        r1_t150_d3_cneg01(10,:);r1_t200_d3_cneg01(10,:);r1_t250_d3_cneg01(10,:);... 
        r1_t300_d3_cneg01(10,:);r1_t350_d3_cneg01(10,:);r1_t400_d3_cneg01(10,:);... 
        r1_t450_d3_cneg01(10,:);r1_t500_d3_cneg01(10,:)] 
 
    figure('Name','1,1,2 npa') 
    plot (Increasing_TNSPEC2(:,7),(Increasing_TNSPEC2(:,2).*100)); 
    hold on 
   plot (Increasing_TNSPEC2neg(:,7),(Increasing_TNSPEC2neg(:,2).*100)); 
    title({'Average Percent Error as Training Set Size Increases';... 
        'Dimension=3 Radfrac=0.5 Bootstrap Replicates=500'}) 
    xlabel('Training Set Size') 
    ylabel('Percent Error') 
    legend('CP=(0,1)','CP=(0,-1)') 
    hold off 
  
  
    %Make a third graph for 4 dimensions 
r1_t50_d4_c01=[NumVL{1,1,3,1}]; 
r1_t100_d4_c01=[NumVL{1,2,3,1}]; 
r1_t150_d4_c01=[NumVL{1,3,3,1}]; 
r1_t200_d4_c01=[NumVL{1,4,3,1}]; 
r1_t250_d4_c01=[NumVL{1,5,3,1}]; 
r1_t300_d4_c01=[NumVL{1,6,3,1}]; 
r1_t350_d4_c01=[NumVL{1,7,3,1}]; 
r1_t400_d4_c01=[NumVL{1,8,3,1}]; 
r1_t450_d4_c01=[NumVL{1,9,3,1}]; 
r1_t500_d4_c01=[NumVL{1,10,3,1}]; 
 
Increasing_TNSPEC3=[r1_t50_d4_c01(10,:);r1_t100_d4_c01(10,:);... 
    r1_t150_d4_c01(10,:);r1_t200_d4_c01(10,:);r1_t250_d4_c01(10,:);... 
    r1_t300_d4_c01(10,:);r1_t350_d4_c01(10,:);r1_t400_d4_c01(10,:);... 
    r1_t450_d4_c01(10,:);r1_t500_d4_c01(10,:)] 
 
r1_t50_d4_cneg01=[NumVL{1,1,3,5}]; 
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r1_t100_d4_cneg01=[NumVL{1,2,3,5}]; 
r1_t150_d4_cneg01=[NumVL{1,3,3,5}]; 
r1_t200_d4_cneg01=[NumVL{1,4,3,5}]; 
r1_t250_d4_cneg01=[NumVL{1,5,3,5}]; 
r1_t300_d4_cneg01=[NumVL{1,6,3,5}]; 
r1_t350_d4_cneg01=[NumVL{1,7,3,5}]; 
r1_t400_d4_cneg01=[NumVL{1,8,3,5}]; 
r1_t450_d4_cneg01=[NumVL{1,9,3,5}]; 
r1_t500_d4_cneg01=[NumVL{1,10,3,5}]; 
 
Increasing_TNSPEC3neg=[r1_t50_d4_cneg01(10,:);r1_t100_d4_cneg01(10,:);... 
    r1_t150_d4_cneg01(10,:);r1_t200_d4_cneg01(10,:);r1_t250_d4_cneg01(10,:);... 
    r1_t300_d4_cneg01(10,:);r1_t350_d4_cneg01(10,:);r1_t400_d4_cneg01(10,:);... 
    r1_t450_d4_cneg01(10,:);r1_t500_d4_cneg01(10,:)] 
 
figure('Name','1,1,3 npa') 
plot (Increasing_TNSPEC3neg(:,7),(Increasing_TNSPEC3(:,2).*100)); 
hold on 
plot (Increasing_TNSPEC_neg(:,7),(Increasing_TNSPEC_neg(:,2).*100)); 
title({'Average Percent Error as Training Set Size Increases';... 
    'Dimension=4 Radfrac=0.5 Bootstrap Replicates=500'}) 
xlabel('Training Set Size') 
ylabel('Percent Error') 
legend('CP=(0,1)','CP=(0,-1)') 
hold off 
 
 
%Make a graph for 11 dimensions 
r1_t50_d11_c01=[NumVL{1,1,10,1}]; 
r1_t100_d11_c01=[NumVL{1,2,10,1}]; 
r1_t150_d11_c01=[NumVL{1,3,10,1}]; 
r1_t200_d11_c01=[NumVL{1,4,10,1}]; 
r1_t250_d11_c01=[NumVL{1,5,10,1}]; 
r1_t300_d11_c01=[NumVL{1,6,10,1}]; 
r1_t350_d11_c01=[NumVL{1,7,10,1}]; 
r1_t400_d11_c01=[NumVL{1,8,10,1}]; 
r1_t450_d11_c01=[NumVL{1,9,10,1}]; 
r1_t500_d11_c01=[NumVL{1,10,10,1}]; 
 
Increasing_TNSPEC11=[r1_t50_d11_c01(10,:);r1_t100_d11_c01(10,:);... 
    r1_t150_d11_c01(10,:);r1_t200_d11_c01(10,:);r1_t250_d11_c01(10,:);... 
    r1_t300_d11_c01(10,:);r1_t350_d11_c01(10,:);r1_t400_d11_c01(10,:);... 
    r1_t450_d11_c01(10,:);r1_t500_d11_c01(10,:)] 
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r1_t50_d11_cneg01=[NumVL{1,1,10,5}]; 
r1_t100_d11_cneg01=[NumVL{1,2,10,5}]; 
r1_t150_d11_cneg01=[NumVL{1,3,10,5}]; 
r1_t200_d11_cneg01=[NumVL{1,4,10,5}]; 
r1_t250_d11_cneg01=[NumVL{1,5,10,5}]; 
r1_t300_d11_cneg01=[NumVL{1,6,10,5}]; 
r1_t350_d11_cneg01=[NumVL{1,7,10,5}]; 
r1_t400_d11_cneg01=[NumVL{1,8,10,5}]; 
r1_t450_d11_cneg01=[NumVL{1,9,10,5}]; 
r1_t500_d11_cneg01=[NumVL{1,10,10,5}]; 
 
Increasing_TNSPEC11neg=[r1_t50_d11_cneg01(10,:);r1_t100_d11_cneg01(10,:);... 
    r1_t150_d11_cneg01(10,:);r1_t200_d11_cneg01(10,:);r1_t250_d11_cneg01(10,:);... 
    r1_t300_d11_cneg01(10,:);r1_t350_d11_cneg01(10,:);r1_t400_d11_cneg01(10,:);... 
    r1_t450_d11_cneg01(10,:);r1_t500_d11_cneg01(10,:)] 
 
figure('Name','1,1,10 npa') 
plot (Increasing_TNSPEC11(:,7),(Increasing_TNSPEC11(:,2).*100)); 
hold on 
plot (Increasing_TNSPEC11neg(:,7),(Increasing_TNSPEC11neg(:,2).*100)); 
title({'Average Percent Error as Training Set Size Increases';'Dimension=11 Radfrac=0.5 
Bootstrap Replicates=500'}) 
xlabel('Training Set Size') 
ylabel('Percent Error') 
legend('CP=(0,1)','CP=(0,-1)') 
hold off  
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Plotting_Code_Increase_TNSPEC_Dimension 
 
%This code plots tnspec vs. bias as dimension increases 
 
 
%Indexing in NumVL Cell Matrix is as Follows: 
%{radfrac number, training, dimension - 1, compass point 
%number} 
 
%Within matrix: 
%B is located in Bias_plot(:,1) 
%bias is located in Bias_plot(:,2) 
%dimension is located in Bias_plot(:,3) 
%First 2 coordinates of compass point located in Bias_plot(:,4) and (:,5) 
%radfrac located in Bias_plot(:,6) 
%Training set size located in Bias_plot(:,7) 
 
%Get all for (0,1) Compass Points 
r1_t50_d2_c01=[NumVL{1,1,1,1}]; 
r1_t100_d2_c01=[NumVL{1,2,1,1}]; 
r1_t150_d2_c01=[NumVL{1,3,1,1}]; 
r1_t200_d2_c01=[NumVL{1,4,1,1}]; 
r1_t250_d2_c01=[NumVL{1,5,1,1}]; 
r1_t300_d2_c01=[NumVL{1,6,1,1}]; 
r1_t350_d2_c01=[NumVL{1,7,1,1}]; 
r1_t400_d2_c01=[NumVL{1,8,1,1}]; 
r1_t450_d2_c01=[NumVL{1,9,1,1}]; 
r1_t500_d2_c01=[NumVL{1,10,1,1}]; 
 
Increasing_TNSPEC=[r1_t50_d2_c01(10,:);r1_t100_d2_c01(10,:);... 
    r1_t150_d2_c01(10,:);r1_t200_d2_c01(10,:);r1_t250_d2_c01(10,:);... 
    r1_t300_d2_c01(10,:);r1_t350_d2_c01(10,:);r1_t400_d2_c01(10,:);... 
    r1_t450_d2_c01(10,:);r1_t500_d2_c01(10,:)] 
 
%Get all (0,-1) Compass Points 
r1_t50_d2_cneg01=[NumVL{1,1,1,5}]; 
r1_t100_d2_cneg01=[NumVL{1,2,1,5}]; 
r1_t150_d2_cneg01=[NumVL{1,3,1,5}]; 
r1_t200_d2_cneg01=[NumVL{1,4,1,5}]; 
r1_t250_d2_cneg01=[NumVL{1,5,1,5}]; 
r1_t300_d2_cneg01=[NumVL{1,6,1,5}]; 
r1_t350_d2_cneg01=[NumVL{1,7,1,5}]; 
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r1_t400_d2_cneg01=[NumVL{1,8,1,5}]; 
r1_t450_d2_cneg01=[NumVL{1,9,1,5}]; 
r1_t500_d2_cneg01=[NumVL{1,10,1,5}]; 
 
Increasing_TNSPEC_neg=[r1_t50_d2_cneg01(10,:);r1_t100_d2_cneg01(10,:);... 
    r1_t150_d2_cneg01(10,:);r1_t200_d2_cneg01(10,:);r1_t250_d2_cneg01(10,:);... 
    r1_t300_d2_cneg01(10,:);r1_t350_d2_cneg01(10,:);r1_t400_d2_cneg01(10,:);... 
    r1_t450_d2_cneg01(10,:);r1_t500_d2_cneg01(10,:)] 
 
figure('Name','1,1,1 npa') 
plot (Increasing_TNSPEC(:,7),(Increasing_TNSPEC(:,2).*100)); 
%gives relative error b/c true value is 1.  Answer/1*100% = relative error 
 
hold on 
plot (Increasing_TNSPEC_neg(:,7),(Increasing_TNSPEC_neg(:,2).*100)); 
title({'Average Percent Error as Training Set Size Increases';'Dimension=2 Radfrac=0.5 
Bootstrap Replicates=500'}) 
xlabel('Training Set Size') 
ylabel('Percent Error') 
legend('CP=(0,1)','CP=(0,-1)') 
hold off 
 
 
    %Make second graph for dimension=3 
 
    r1_t50_d3_c01=[NumVL{1,1,2,1}] 
    r1_t100_d3_c01=[NumVL{1,2,2,1}] 
    r1_t150_d3_c01=[NumVL{1,3,2,1}]; 
    r1_t200_d3_c01=[NumVL{1,4,2,1}]; 
    r1_t250_d3_c01=[NumVL{1,5,2,1}]; 
    r1_t300_d3_c01=[NumVL{1,6,2,1}]; 
    r1_t350_d3_c01=[NumVL{1,7,2,1}]; 
    r1_t400_d3_c01=[NumVL{1,8,2,1}]; 
    r1_t450_d3_c01=[NumVL{1,9,2,1}]; 
    r1_t500_d3_c01=[NumVL{1,10,2,1}]; 
 
    Increasing_TNSPEC2=[r1_t50_d3_c01(10,:);r1_t100_d3_c01(10,:);... 
        r1_t150_d3_c01(10,:);r1_t200_d3_c01(10,:);r1_t250_d3_c01(10,:);... 
        r1_t300_d3_c01(10,:);r1_t350_d3_c01(10,:);r1_t400_d3_c01(10,:);... 
        r1_t450_d3_c01(10,:);r1_t500_d3_c01(10,:)] 
  
    r1_t50_d3_cneg01=[NumVL{1,1,2,5}] 
    r1_t100_d3_cneg01=[NumVL{1,2,2,5}] 
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    r1_t150_d3_cneg01=[NumVL{1,3,2,5}]; 
    r1_t200_d3_cneg01=[NumVL{1,4,2,5}]; 
    r1_t250_d3_cneg01=[NumVL{1,5,2,5}]; 
    r1_t300_d3_cneg01=[NumVL{1,6,2,5}]; 
    r1_t350_d3_cneg01=[NumVL{1,7,2,5}]; 
    r1_t400_d3_cneg01=[NumVL{1,8,2,5}]; 
    r1_t450_d3_cneg01=[NumVL{1,9,2,5}]; 
    r1_t500_d3_cneg01=[NumVL{1,10,2,5}]; 
 
    Increasing_TNSPEC2neg=[r1_t50_d3_cneg01(10,:);r1_t100_d3_cneg01(10,:);... 
        r1_t150_d3_cneg01(10,:);r1_t200_d3_cneg01(10,:);r1_t250_d3_cneg01(10,:);... 
        r1_t300_d3_cneg01(10,:);r1_t350_d3_cneg01(10,:);r1_t400_d3_cneg01(10,:);... 
        r1_t450_d3_cneg01(10,:);r1_t500_d3_cneg01(10,:)] 
 
    figure('Name','1,1,2 npa') 
    plot (Increasing_TNSPEC2(:,7),(Increasing_TNSPEC2(:,2).*100)); 
    hold on 
   plot (Increasing_TNSPEC2neg(:,7),(Increasing_TNSPEC2neg(:,2).*100)); 
    title({'Average Percent Error as Training Set Size Increases';... 
        'Dimension=3 Radfrac=0.5 Bootstrap Replicates=500'}) 
    xlabel('Training Set Size') 
    ylabel('Percent Error') 
    legend('CP=(0,1)','CP=(0,-1)') 
    hold off 
  
  
    %Make a third graph for 4 dimensions 
r1_t50_d4_c01=[NumVL{1,1,3,1}]; 
r1_t100_d4_c01=[NumVL{1,2,3,1}]; 
r1_t150_d4_c01=[NumVL{1,3,3,1}]; 
r1_t200_d4_c01=[NumVL{1,4,3,1}]; 
r1_t250_d4_c01=[NumVL{1,5,3,1}]; 
r1_t300_d4_c01=[NumVL{1,6,3,1}]; 
r1_t350_d4_c01=[NumVL{1,7,3,1}]; 
r1_t400_d4_c01=[NumVL{1,8,3,1}]; 
r1_t450_d4_c01=[NumVL{1,9,3,1}]; 
r1_t500_d4_c01=[NumVL{1,10,3,1}]; 
 
Increasing_TNSPEC3=[r1_t50_d4_c01(10,:);r1_t100_d4_c01(10,:);... 
    r1_t150_d4_c01(10,:);r1_t200_d4_c01(10,:);r1_t250_d4_c01(10,:);... 
    r1_t300_d4_c01(10,:);r1_t350_d4_c01(10,:);r1_t400_d4_c01(10,:);... 
    r1_t450_d4_c01(10,:);r1_t500_d4_c01(10,:)] 
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r1_t50_d4_cneg01=[NumVL{1,1,3,5}]; 
r1_t100_d4_cneg01=[NumVL{1,2,3,5}]; 
r1_t150_d4_cneg01=[NumVL{1,3,3,5}]; 
r1_t200_d4_cneg01=[NumVL{1,4,3,5}]; 
r1_t250_d4_cneg01=[NumVL{1,5,3,5}]; 
r1_t300_d4_cneg01=[NumVL{1,6,3,5}]; 
r1_t350_d4_cneg01=[NumVL{1,7,3,5}]; 
r1_t400_d4_cneg01=[NumVL{1,8,3,5}]; 
r1_t450_d4_cneg01=[NumVL{1,9,3,5}]; 
r1_t500_d4_cneg01=[NumVL{1,10,3,5}]; 
 
Increasing_TNSPEC3neg=[r1_t50_d4_cneg01(10,:);r1_t100_d4_cneg01(10,:);... 
    r1_t150_d4_cneg01(10,:);r1_t200_d4_cneg01(10,:);r1_t250_d4_cneg01(10,:);... 
    r1_t300_d4_cneg01(10,:);r1_t350_d4_cneg01(10,:);r1_t400_d4_cneg01(10,:);... 
    r1_t450_d4_cneg01(10,:);r1_t500_d4_cneg01(10,:)] 
 
figure('Name','1,1,3 npa') 
plot (Increasing_TNSPEC3neg(:,7),(Increasing_TNSPEC3(:,2).*100)); 
hold on 
plot (Increasing_TNSPEC_neg(:,7),(Increasing_TNSPEC_neg(:,2).*100)); 
title({'Average Percent Error as Training Set Size Increases';... 
    'Dimension=4 Radfrac=0.5 Bootstrap Replicates=500'}) 
xlabel('Training Set Size') 
ylabel('Percent Error') 
legend('CP=(0,1)','CP=(0,-1)') 
hold off 
 
 
%Make a graph for 11 dimensions 
r1_t50_d11_c01=[NumVL{1,1,10,1}]; 
r1_t100_d11_c01=[NumVL{1,2,10,1}]; 
r1_t150_d11_c01=[NumVL{1,3,10,1}]; 
r1_t200_d11_c01=[NumVL{1,4,10,1}]; 
r1_t250_d11_c01=[NumVL{1,5,10,1}]; 
r1_t300_d11_c01=[NumVL{1,6,10,1}]; 
r1_t350_d11_c01=[NumVL{1,7,10,1}]; 
r1_t400_d11_c01=[NumVL{1,8,10,1}]; 
r1_t450_d11_c01=[NumVL{1,9,10,1}]; 
r1_t500_d11_c01=[NumVL{1,10,10,1}]; 
 
Increasing_TNSPEC11=[r1_t50_d11_c01(10,:);r1_t100_d11_c01(10,:);... 
    r1_t150_d11_c01(10,:);r1_t200_d11_c01(10,:);r1_t250_d11_c01(10,:);... 
    r1_t300_d11_c01(10,:);r1_t350_d11_c01(10,:);r1_t400_d11_c01(10,:);... 
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    r1_t450_d11_c01(10,:);r1_t500_d11_c01(10,:)] 
 
r1_t50_d11_cneg01=[NumVL{1,1,10,5}]; 
r1_t100_d11_cneg01=[NumVL{1,2,10,5}]; 
r1_t150_d11_cneg01=[NumVL{1,3,10,5}]; 
r1_t200_d11_cneg01=[NumVL{1,4,10,5}]; 
r1_t250_d11_cneg01=[NumVL{1,5,10,5}]; 
r1_t300_d11_cneg01=[NumVL{1,6,10,5}]; 
r1_t350_d11_cneg01=[NumVL{1,7,10,5}]; 
r1_t400_d11_cneg01=[NumVL{1,8,10,5}]; 
r1_t450_d11_cneg01=[NumVL{1,9,10,5}]; 
r1_t500_d11_cneg01=[NumVL{1,10,10,5}]; 
 
Increasing_TNSPEC11neg=[r1_t50_d11_cneg01(10,:);r1_t100_d11_cneg01(10,:);... 
    r1_t150_d11_cneg01(10,:);r1_t200_d11_cneg01(10,:);r1_t250_d11_cneg01(10,:);... 
    r1_t300_d11_cneg01(10,:);r1_t350_d11_cneg01(10,:);r1_t400_d11_cneg01(10,:);... 
    r1_t450_d11_cneg01(10,:);r1_t500_d11_cneg01(10,:)] 
 
figure('Name','1,1,10 npa') 
plot (Increasing_TNSPEC11(:,7),(Increasing_TNSPEC11(:,2).*100)); 
hold on 
plot (Increasing_TNSPEC11neg(:,7),(Increasing_TNSPEC11neg(:,2).*100)); 
title({'Average Percent Error as Training Set Size Increases';'Dimension=11 Radfrac=0.5 
Bootstrap Replicates=500'}) 
xlabel('Training Set Size') 
ylabel('Percent Error') 
legend('CP=(0,1)','CP=(0,-1)') 
hold off  
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RSD_as_Bootstrap_Radfrac_Increase 
 
%Plotting Relative Standard Deviation 
%as Bootstrapping and Radfrac Increase 
 
%This code plots bootstrapping vs. RSD as radfrac increases 
 
%Indexing in NumVL Cell Matrix is as Follows: 
%Indexing is {Radfrac Iteration Count (must separately count... 
%Radfrac value),Training Set Size,dimension,Compass Point,} 
%RSD_NumVL{radfrac_iteration_count,u,(v+1),j}=RSD; 
 
%Within matrix: 
%Store Relative Standard Deviation (average standard deviation/ 
%average) 
%RSD holds [1.compass point coordinate, 2.compass point coordinate,... 
%3.B, 4.RSD of returned standard deviation, ... 
%5.total number of dimensions (v+2), 6.radfrac,  
%7.Training Set Size] 
 
 
figure('Name','1,1,1 npa') 
r1_t50_d2_c01=[RSD_NumVL{1,1,1,1}]; 
plot (r1_t50_d2_c01(:,3),r1_t50_d2_c01(:,4)); 
hold on 
r1_t50_d2_cneg01=[RSD_NumVL{1,1,1,5}]; 
plot (r1_t50_d2_cneg01(:,3),r1_t50_d2_cneg01(:,4)); 
title({'Relative Standard Deviation as Bootstrap Replicates Increase';'Radfrac=0.5 
Dimension=2 TNSPEC=50'}) 
xlabel('Bootstrap Replications') 
ylabel('Relative Standard Deviation') 
legend('CP=(0,1)','CP=(0,-1)') 
%axis(graphlimits) 
hold off 
 
 
 
    figure('Name','2,1,1 npa') 
    r2_t50_d2_c01=[RSD_NumVL{2,1,1,1}]; 
    plot (r2_t50_d2_c01(:,3),r2_t50_d2_c01(:,4)); 
       hold on 
    r2_t50_d2_cneg01=[RSD_NumVL{2,1,1,5}]; 
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    plot (r2_t50_d2_cneg01(:,3),r2_t50_d2_cneg01(:,4)); 
    title({'Relative Standard Deviation as Bootstrap Replicates Increase';'Radfrac=0.6 
Dimension=2 TNSPEC=50'}) 
    xlabel('Bootstrap Replications') 
    ylabel('Relative Standard Deviation') 
    legend('CP=(0,1)','CP=(0,-1)') 
    hold off 
 
figure('Name','3,1,1 npa') 
r3_t50_d2_c01=[RSD_NumVL{3,1,1,1}]; 
plot (r3_t50_d2_c01(:,3),r3_t50_d2_c01(:,4)); 
 
hold on 
r3_t50_d2_cneg01=[RSD_NumVL{3,1,1,5}]; 
plot (r3_t50_d2_cneg01(:,3),r3_t50_d2_cneg01(:,4)); 
title({'Relative Standard Deviation as Bootstrap Replicates Increase';'Radfrac=0.7 
Dimension=2 TNSPEC=50'}) 
xlabel('Bootstrap Replications') 
ylabel('Relative Standard Deviation') 
legend('CP=(0,1)','CP=(0,-1)') 
hold off 
 
    figure('Name','4,1,1 npa') 
    r4_t50_d2_c01=[RSD_NumVL{4,1,1,1}]; 
    plot (r4_t50_d2_c01(:,3),r4_t50_d2_c01(:,4)); 
    hold on 
    r4_t50_d2_cneg01=[RSD_NumVL{4,1,1,5}]; 
    plot (r4_t50_d2_cneg01(:,3),r4_t50_d2_cneg01(:,4)); 
    title({'Relative Standard Deviation as Bootstrap Replicates Increase';... 
        'Radfrac=0.8 Dimension=2 TNSPEC=50'}) 
    xlabel('Bootstrap Replications') 
    ylabel('Relative Standard Deviation') 
    legend('CP=(0,1)','CP=(0,-1)') 
    hold off 
  
figure('Name','5,1,1 npa') 
r5_t50_d2_c01=[RSD_NumVL{5,1,1,1}]; 
plot (r5_t50_d2_c01(:,3),r5_t50_d2_c01(:,4)); 
hold on 
r5_t50_d2_cneg01=[RSD_NumVL{5,1,1,5}]; 
plot (r5_t50_d2_cneg01(:,3),r5_t50_d2_cneg01(:,4)); 
title({'Relative Standard Deviation as Bootstrap Replicates Increase';... 
'Radfrac=0.9 Dimension=2 TNSPEC=50'}) 
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xlabel('Bootstrap Replications') 
ylabel('Relative Standard Deviation') 
legend('CP=(0,1)','(0,-1)') 
hold off 
 
    figure('Name','6,1,1 npa') 
    r6_t50_d2_c01=[RSD_NumVL{6,1,1,1}]; 
    plot (r6_t50_d2_c01(:,3),r6_t50_d2_c01(:,4)); 
    hold on 
    r6_t50_d2_cneg01=[RSD_NumVL{6,1,1,5}]; 
    plot (r6_t50_d2_cneg01(:,3),r6_t50_d2_cneg01(:,4)); 
    title({'Relative Standard Deviation as Bootstrap Replicates Increase';... 
        'Radfrac=1.0 Dimension=2 TNSPEC=50'}) 
    xlabel('Bootstrap Replications') 
    ylabel('Relative Standard Deviation') 
    legend('CP=(0,1)','CP=(0,-1)') 
    hold off  
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RSD_as_TNSPEC_Dimension_Increase 
 
%Plotting Relative Standard Deviation 
%as TNSPEC and Dimension Increase 
 
 
%Indexing in NumVL Cell Matrix is as Follows: 
%Indexing is {Radfrac Iteration Count (must separately count... 
%Radfrac value),Training Set Size,dimension,Compass Point,} 
%RSD_NumVL{radfrac_iteration_count,u,(v+1),j}=RSD; 
 
%Within matrix: 
%Store Relative Standard Deviation (average standard deviation/ 
%average) 
%RSD holds [1.compass point coordinate, 2.compass point coordinate,... 
%3.B, 4.RSD of returned standard deviation, ... 
%5.total number of dimensions (v+2), 6.radfrac,  
%7.Training Set Size] 
 
%Set Axis Limits for Graphs 
%axis(limits) syntax is axis(xmin xmax ymin ymax) 
graphlimits=[50,500,0,0.1] 
 
%Get all for (0,1) Compass Points 
r1_t50_d2_c01=[RSD_NumVL{1,1,1,1}]; 
r1_t100_d2_c01=[RSD_NumVL{1,2,1,1}]; 
r1_t150_d2_c01=[RSD_NumVL{1,3,1,1}]; 
r1_t200_d2_c01=[RSD_NumVL{1,4,1,1}]; 
r1_t250_d2_c01=[RSD_NumVL{1,5,1,1}]; 
r1_t300_d2_c01=[RSD_NumVL{1,6,1,1}]; 
r1_t350_d2_c01=[RSD_NumVL{1,7,1,1}]; 
r1_t400_d2_c01=[RSD_NumVL{1,8,1,1}]; 
r1_t450_d2_c01=[RSD_NumVL{1,9,1,1}]; 
r1_t500_d2_c01=[RSD_NumVL{1,10,1,1}]; 
 
Increasing_TNSPEC=[r1_t50_d2_c01(10,:);r1_t100_d2_c01(10,:);... 
    r1_t150_d2_c01(10,:);r1_t200_d2_c01(10,:);r1_t250_d2_c01(10,:);... 
    r1_t300_d2_c01(10,:);r1_t350_d2_c01(10,:);r1_t400_d2_c01(10,:);... 
    r1_t450_d2_c01(10,:);r1_t500_d2_c01(10,:)]; 
 
%Get all (0,-1) Compass Points 
r1_t50_d2_cneg01=[RSD_NumVL{1,1,1,5}]; 
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r1_t100_d2_cneg01=[RSD_NumVL{1,2,1,5}]; 
r1_t150_d2_cneg01=[RSD_NumVL{1,3,1,5}]; 
r1_t200_d2_cneg01=[RSD_NumVL{1,4,1,5}]; 
r1_t250_d2_cneg01=[RSD_NumVL{1,5,1,5}]; 
r1_t300_d2_cneg01=[RSD_NumVL{1,6,1,5}]; 
r1_t350_d2_cneg01=[RSD_NumVL{1,7,1,5}]; 
r1_t400_d2_cneg01=[RSD_NumVL{1,8,1,5}]; 
r1_t450_d2_cneg01=[RSD_NumVL{1,9,1,5}]; 
r1_t500_d2_cneg01=[RSD_NumVL{1,10,1,5}]; 
 
Increasing_TNSPEC_neg=[r1_t50_d2_cneg01(10,:);r1_t100_d2_cneg01(10,:);... 
    r1_t150_d2_cneg01(10,:);r1_t200_d2_cneg01(10,:);r1_t250_d2_cneg01(10,:);... 
    r1_t300_d2_cneg01(10,:);r1_t350_d2_cneg01(10,:);r1_t400_d2_cneg01(10,:);... 
    r1_t450_d2_cneg01(10,:);r1_t500_d2_cneg01(10,:)]; 
 
figure('Name','1,1,1 npa') 
plot (Increasing_TNSPEC(:,7),Increasing_TNSPEC(:,4)); 
 
hold on 
plot (Increasing_TNSPEC_neg(:,7),Increasing_TNSPEC_neg(:,4)); 
title({'Relative Standard Deviation as Training Set Size Increases';'Dimension=2 
Radfrac=0.5 Bootstrap Replicates=500'}) 
xlabel('Training Set Size') 
ylabel('Absolute Error') 
legend('CP=(0,1)','CP=(0,-1)') 
axis(graphlimits) 
hold off 
 
 
    %Make second graph for dimension=3 
 
    r1_t50_d3_c01=[RSD_NumVL{1,1,2,1}]; 
    r1_t100_d3_c01=[RSD_NumVL{1,2,2,1}]; 
    r1_t150_d3_c01=[RSD_NumVL{1,3,2,1}]; 
    r1_t200_d3_c01=[RSD_NumVL{1,4,2,1}]; 
    r1_t250_d3_c01=[RSD_NumVL{1,5,2,1}]; 
    r1_t300_d3_c01=[RSD_NumVL{1,6,2,1}]; 
    r1_t350_d3_c01=[RSD_NumVL{1,7,2,1}]; 
    r1_t400_d3_c01=[RSD_NumVL{1,8,2,1}]; 
    r1_t450_d3_c01=[RSD_NumVL{1,9,2,1}]; 
    r1_t500_d3_c01=[RSD_NumVL{1,10,2,1}]; 
 
    Increasing_TNSPEC2=[r1_t50_d3_c01(10,:);r1_t100_d3_c01(10,:);... 
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        r1_t150_d3_c01(10,:);r1_t200_d3_c01(10,:);r1_t250_d3_c01(10,:);... 
        r1_t300_d3_c01(10,:);r1_t350_d3_c01(10,:);r1_t400_d3_c01(10,:);... 
        r1_t450_d3_c01(10,:);r1_t500_d3_c01(10,:)]; 
  
    r1_t50_d3_cneg01=[RSD_NumVL{1,1,2,5}]; 
    r1_t100_d3_cneg01=[RSD_NumVL{1,2,2,5}]; 
    r1_t150_d3_cneg01=[RSD_NumVL{1,3,2,5}]; 
    r1_t200_d3_cneg01=[RSD_NumVL{1,4,2,5}]; 
    r1_t250_d3_cneg01=[RSD_NumVL{1,5,2,5}]; 
    r1_t300_d3_cneg01=[RSD_NumVL{1,6,2,5}]; 
    r1_t350_d3_cneg01=[RSD_NumVL{1,7,2,5}]; 
    r1_t400_d3_cneg01=[RSD_NumVL{1,8,2,5}]; 
    r1_t450_d3_cneg01=[RSD_NumVL{1,9,2,5}]; 
    r1_t500_d3_cneg01=[RSD_NumVL{1,10,2,5}]; 
 
    Increasing_TNSPEC2neg=[r1_t50_d3_cneg01(10,:);r1_t100_d3_cneg01(10,:);... 
        r1_t150_d3_cneg01(10,:);r1_t200_d3_cneg01(10,:);r1_t250_d3_cneg01(10,:);... 
        r1_t300_d3_cneg01(10,:);r1_t350_d3_cneg01(10,:);r1_t400_d3_cneg01(10,:);... 
        r1_t450_d3_cneg01(10,:);r1_t500_d3_cneg01(10,:)]; 
 
    figure('Name','1,1,2 npa') 
    plot (Increasing_TNSPEC2(:,7),Increasing_TNSPEC2(:,4)); 
    hold on 
   plot (Increasing_TNSPEC2neg(:,7),Increasing_TNSPEC2neg(:,4)); 
    title({'Relative Standard Deviation as Training Set Size Increases';... 
        'Dimension=3 Radfrac=0.5 Bootstrap Replicates=500'}) 
    xlabel('Training Set Size') 
    ylabel('Absolute Error') 
    legend('CP=(0,1)','CP=(0,-1)') 
    axis(graphlimits) 
    hold off 
  
  
    %Make a third graph for 4 dimensions 
r1_t50_d4_c01=[RSD_NumVL{1,1,3,1}]; 
r1_t100_d4_c01=[RSD_NumVL{1,2,3,1}]; 
r1_t150_d4_c01=[RSD_NumVL{1,3,3,1}]; 
r1_t200_d4_c01=[RSD_NumVL{1,4,3,1}]; 
r1_t250_d4_c01=[RSD_NumVL{1,5,3,1}]; 
r1_t300_d4_c01=[RSD_NumVL{1,6,3,1}]; 
r1_t350_d4_c01=[RSD_NumVL{1,7,3,1}]; 
r1_t400_d4_c01=[RSD_NumVL{1,8,3,1}]; 
r1_t450_d4_c01=[RSD_NumVL{1,9,3,1}]; 
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r1_t500_d4_c01=[RSD_NumVL{1,10,3,1}]; 
 
Increasing_TNSPEC3=[r1_t50_d4_c01(10,:);r1_t100_d4_c01(10,:);... 
    r1_t150_d4_c01(10,:);r1_t200_d4_c01(10,:);r1_t250_d4_c01(10,:);... 
    r1_t300_d4_c01(10,:);r1_t350_d4_c01(10,:);r1_t400_d4_c01(10,:);... 
    r1_t450_d4_c01(10,:);r1_t500_d4_c01(10,:)]; 
 
r1_t50_d4_cneg01=[RSD_NumVL{1,1,3,5}]; 
r1_t100_d4_cneg01=[RSD_NumVL{1,2,3,5}]; 
r1_t150_d4_cneg01=[RSD_NumVL{1,3,3,5}]; 
r1_t200_d4_cneg01=[RSD_NumVL{1,4,3,5}]; 
r1_t250_d4_cneg01=[RSD_NumVL{1,5,3,5}]; 
r1_t300_d4_cneg01=[RSD_NumVL{1,6,3,5}]; 
r1_t350_d4_cneg01=[RSD_NumVL{1,7,3,5}]; 
r1_t400_d4_cneg01=[RSD_NumVL{1,8,3,5}]; 
r1_t450_d4_cneg01=[RSD_NumVL{1,9,3,5}]; 
r1_t500_d4_cneg01=[RSD_NumVL{1,10,3,5}]; 
 
Increasing_TNSPEC3neg=[r1_t50_d4_cneg01(10,:);r1_t100_d4_cneg01(10,:);... 
    r1_t150_d4_cneg01(10,:);r1_t200_d4_cneg01(10,:);r1_t250_d4_cneg01(10,:);... 
    r1_t300_d4_cneg01(10,:);r1_t350_d4_cneg01(10,:);r1_t400_d4_cneg01(10,:);... 
    r1_t450_d4_cneg01(10,:);r1_t500_d4_cneg01(10,:)]; 
 
figure('Name','1,1,3 npa') 
plot (Increasing_TNSPEC3neg(:,7),Increasing_TNSPEC3(:,4)); 
hold on 
plot (Increasing_TNSPEC_neg(:,7),Increasing_TNSPEC_neg(:,4)); 
title({'Relative Standard Deviation as Training Set Size Increases';... 
    'Dimension=4 Radfrac=0.5 Bootstrap Replicates=500'}) 
xlabel('Training Set Size') 
ylabel('Absolute Error') 
legend('CP=(0,1)','CP=(0,-1)') 
axis(graphlimits) 
hold off 
 
 
%Make a graph for 11 dimensions 
r1_t50_d11_c01=[RSD_NumVL{1,1,10,1}]; 
r1_t100_d11_c01=[RSD_NumVL{1,2,10,1}]; 
r1_t150_d11_c01=[RSD_NumVL{1,3,10,1}]; 
r1_t200_d11_c01=[RSD_NumVL{1,4,10,1}]; 
r1_t250_d11_c01=[RSD_NumVL{1,5,10,1}]; 
r1_t300_d11_c01=[RSD_NumVL{1,6,10,1}]; 
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r1_t350_d11_c01=[RSD_NumVL{1,7,10,1}]; 
r1_t400_d11_c01=[RSD_NumVL{1,8,10,1}]; 
r1_t450_d11_c01=[RSD_NumVL{1,9,10,1}]; 
r1_t500_d11_c01=[RSD_NumVL{1,10,10,1}]; 
 
Increasing_TNSPEC11=[r1_t50_d11_c01(10,:);r1_t100_d11_c01(10,:);... 
    r1_t150_d11_c01(10,:);r1_t200_d11_c01(10,:);r1_t250_d11_c01(10,:);... 
    r1_t300_d11_c01(10,:);r1_t350_d11_c01(10,:);r1_t400_d11_c01(10,:);... 
    r1_t450_d11_c01(10,:);r1_t500_d11_c01(10,:)]; 
 
r1_t50_d11_cneg01=[RSD_NumVL{1,1,10,5}]; 
r1_t100_d11_cneg01=[RSD_NumVL{1,2,10,5}]; 
r1_t150_d11_cneg01=[RSD_NumVL{1,3,10,5}]; 
r1_t200_d11_cneg01=[RSD_NumVL{1,4,10,5}]; 
r1_t250_d11_cneg01=[RSD_NumVL{1,5,10,5}]; 
r1_t300_d11_cneg01=[RSD_NumVL{1,6,10,5}]; 
r1_t350_d11_cneg01=[RSD_NumVL{1,7,10,5}]; 
r1_t400_d11_cneg01=[RSD_NumVL{1,8,10,5}]; 
r1_t450_d11_cneg01=[RSD_NumVL{1,9,10,5}]; 
r1_t500_d11_cneg01=[RSD_NumVL{1,10,10,5}]; 
 
Increasing_TNSPEC11neg=[r1_t50_d11_cneg01(10,:);r1_t100_d11_cneg01(10,:);... 
    r1_t150_d11_cneg01(10,:);r1_t200_d11_cneg01(10,:);r1_t250_d11_cneg01(10,:);... 
    r1_t300_d11_cneg01(10,:);r1_t350_d11_cneg01(10,:);r1_t400_d11_cneg01(10,:);... 
    r1_t450_d11_cneg01(10,:);r1_t500_d11_cneg01(10,:)]; 
 
figure('Name','1,1,10 npa') 
plot (Increasing_TNSPEC11(:,7),Increasing_TNSPEC11(:,4)); 
hold on 
plot (Increasing_TNSPEC11neg(:,7),Increasing_TNSPEC11neg(:,4)); 
title({'Relative Standard Deviation as Training Set Size Increases';'Dimension=11 
Radfrac=0.5 Bootstrap Replicates=500'}) 
xlabel('Training Set Size') 
ylabel('Absolute Error') 
legend('CP=(0,1)','CP=(0,-1)') 
axis(graphlimits) 
hold off  
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Figures_Code 
 
figure 
mu=[0,0]; 
 sigma=[2,1]; 
TNSPEC=mvnrnd(mu,sigma,100); 
scatter(TNSPEC(:,1), TNSPEC(:,2)) 
hold on 
%equation of an ellipse 
 
 
%Graph Compass Points 
compass_points=[0,1;(-2/(sqrt(5))),(2/(sqrt(5))); -2,0;(-2/(sqrt(5))),(-2/(sqrt(5)));  
    0,-1;(2/(sqrt(5))),(-2/(sqrt(5))); 2,0; (2/(sqrt(5))),(2/(sqrt(5)))]; 
scatter(compass_points(:,1),compass_points(:,2),50,'r','filled') 
 
%Graph Center 
scatter(0,0,50,'r','filled') 
 
%Graph Ellipse 
a=2; % horizontal radius 
b=1; % vertical radius 
x0=0; % x0,y0 ellipse centre coordinates 
y0=0; 
t=-pi:0.01:pi; 
x=x0+a*cos(t); 
y=y0+b*sin(t); 
plot(x,y) 
 
hold off 
 
figure 
mu=[0,0]; 
 sigma=[1,1]; 
TNSPEC=mvnrnd(mu,sigma,100); 
scatter(TNSPEC(:,1), TNSPEC(:,2)) 
hold on 
 
%Graph center 
scatter(0,0,'filled') 
%Graph circle for 1 standard deviation 
centers=[0,0]; 
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radii=[1]; 
viscircles(centers,radii) 
 
%Graph second standard deviation 
radii=[2]; 
viscircles(centers,radii,'Color','b') 
hold off  
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Graphing_Code_2 
%Requires workspace variables NumVL and RSD_NumVL, Max_training,  
 
%Make sure these exist. 
NumVL; 
RSD_NumVL; 
 
out=[cat(1,NumVL{:})]; 
x=size(out); 
w=x(:,1); 
y=zeros(x(:,1),1); 
 
%Designate compass points - work in progress 
newmatrix=[out,y]; 
 
%nonprincipal axis points 
    npa=newmatrix(:,4)==0; 
  
%principal axis points 
    pa=newmatrix(:,4)==2; 
    opa=newmatrix(:,4)==-2; 
  
 %since diagonals have a calculation that determines the value 
 %it is hard to tell how many digits of precision  
 %therefore, diagonals are not equal to 0, 2, or -2. 
  
    %First find indices ~=0 
    dp=newmatrix(:,4)~=0; 
    dp2=newmatrix(dp,:); 
    %Now find indices in the ~=0 subset also ~= 2 
    fdp=dp2(:,4)~=2; 
    dp3=dp2(fdp,:); 
    %Last, find indices in that subset also ~= to -2 
    ffdp=dp3(:,4)~=-2; 
  
    nonprincipalaxis=[newmatrix(npa,:)]; 
    principalaxis=[newmatrix(pa,:);newmatrix(opa,:)]; 
    diagonalpoints=[dp3(ffdp,:)]; 
  
    %Regress Non-Principal 
    %B is located in Bias_plot(:,1) 
    %bias is located in Bias_plot(:,2) 
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    %dimension is located in Bias_plot(:,3) 
    %First 2 coordinates of compass point located in Bias_plot(:,4) and (:,5) 
    %radfrac located in Bias_plot(:,6) 
    %Training set size located in Bias_plot(:,7) 
    %Columns are 
    %(bootstrap,bias,dimension,compass,compass,radfrac,training) 
    npa_output=[nonprincipalaxis(:,2)]; 
 
npa_input=[nonprincipalaxis(:,1),nonprincipalaxis(:,3),nonprincipalaxis(:,6),nonprincipala
xis(:,7)]; 
    reg = MultiPolyRegress(npa_input,npa_output,5) 
  
  
    %Regress Principal 
    %B is located in Bias_plot(:,1) 
    %bias is located in Bias_plot(:,2) 
    %dimension is located in Bias_plot(:,3) 
    %First 2 coordinates of compass point located in Bias_plot(:,4) and (:,5) 
    %radfrac located in Bias_plot(:,6) 
    %Training set size located in Bias_plot(:,7) 
    %Columns are 
    %(bootstrap,bias,dimension,compass,compass,radfrac,training) 
    pa_output=[principalaxis(:,2)]; 
    pa_input=[principalaxis(:,1),principalaxis(:,3),principalaxis(:,6),principalaxis(:,7)]; 
    reg = MultiPolyRegress(pa_input,pa_output,5) 
  
  
    %Regress Diagonal 
    %B is located in Bias_plot(:,1) 
    %bias is located in Bias_plot(:,2) 
    %dimension is located in Bias_plot(:,3) 
    %First 2 coordinates of compass point located in Bias_plot(:,4) and (:,5) 
    %radfrac located in Bias_plot(:,6) 
    %Training set size located in Bias_plot(:,7) 
    %Columns are 
    %(bootstrap,bias,dimension,compass,compass,radfrac,training) 
    d_output=[diagonalpoints(:,2)]; 
 
d_input=[diagonalpoints(:,1),diagonalpoints(:,3),diagonalpoints(:,6),diagonalpoints(:,7)]; 
    reg = MultiPolyRegress(d_input,d_output,5)  
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RTCR_Point_Bias2 
%RTCR_Point_Bias2.m 
 %This program calculates the average percent error of RTCR outputs and graphs  
 %the average percent error for each compass point at increasing numbers of 
 %bootstrap replications. 
 
 
%TNSPEC=mvnrnd(mu,sigma,50*u);compass_points=[0,1;... 
  %(-2/(sqrt(5))),(2/(sqrt(5)));... 
  %-2,0;... 
  %(-2/(sqrt(5))),(-2/(sqrt(5)));...  
  %  0,-1;... 
  %(2/(sqrt(5))),(-2/(sqrt(5)));... 
  %2,0;... 
  %(2/(sqrt(5))),(2/(sqrt(5)))]; 
 
A=NumVL{1,1,1,1} 
    point_0_1=A; 
 point_0_1(:,2)=( point_0_1(:,2)/(expected_standard_deviation(1))*100) 
  
 figure 
plot(point_0_1(:,1),point_0_1(:,2),'-*r') 
 hold on 
  
 A=NumVL{1,1,1,2} 
    point2=A; 
point2(:,2)=( point2(:,2)/(expected_standard_deviation(1))*100) 
plot(point2(:,1),point2(:,2),'-*b') 
 hold on 
  
  A=NumVL{1,1,1,3}; 
    point3=A; 
point3(:,2)=( point3(:,2)/(expected_standard_deviation(1))*100) 
plot(point3(:,1),point3(:,2),'-*k') 
 hold on 
  
 A=NumVL{1,1,1,4} 
    point4=A; 
point4(:,2)=( point4(:,2)/(expected_standard_deviation(1))*100) 
plot(point4(:,1),point4(:,2),'-ob') 
 hold on 
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  A=NumVL{1,1,1,5} 
    point5=A; 
point5(:,2)=( point5(:,2)/(expected_standard_deviation(1))*100) 
plot(point5(:,1),point5(:,2),'-or') 
 hold on 
  
 A=NumVL{1,1,1,6} 
    point6=A; 
point6(:,2)=( point6(:,2)/(expected_standard_deviation(1))*100) 
plot(point6(:,1),point6(:,2),'-sb') 
 hold on 
  
   A=NumVL{1,1,1,7} 
    point7=A; 
point7(:,2)=( point7(:,2)/(expected_standard_deviation(1))*100) 
plot(point7(:,1),point7(:,2),'-ok') 
 hold on 
  
 A=NumVL{1,1,1,8} 
    point8=A; 
point8(:,2)=( point8(:,2)/(expected_standard_deviation(1))*100) 
plot(point8(:,1),point8(:,2),'-pb') 
 hold off 
 legend('(0,1)','(-2/(sqrt(5))),(2/(sqrt(5)))', '(-2,0),',... 
     '(-2/(sqrt(5))),(-2/(sqrt(5)))', '(0,-1)', '(2/(sqrt(5))),(-2/(sqrt(5)))',... 
     '(2,0)','(2/(sqrt(5))),(2/(sqrt(5))','Location','southoutside') 
 title({'Average Percent Error as Bootstrap Replicates Increase';'Radfrac=0.5 
Dimension=2 TNSPEC=50'}) 
 xlabel('Bootstrap Replicates') 
 ylabel('Average Percent Error of Six Runs') 
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